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Oral cancer is the sixth most common cancer worldwide and has been marked by 
high morbidity and poor survival rates that have changed little over the past few decades. 
Beyond prevention, early detection is the most crucial determinant for successful 
treatment and survival of cancer. Yet current methodologies for cancer diagnosis based 
upon pathological examination alone are insufficient for detecting early tumor 
progression and molecular transformation. Development of new diagnostic tools 
incorporating tumor biomarkers could enhance early detection by providing molecular-
level insight into the biochemical and cellular changes associated with oral 
carcinogenesis.  
The work presented in this doctoral dissertation aims to address this clinical need 
through the development of new automated cellular analysis methods, incorporating lab-
on-a-chip sensor techniques, for examination of molecular and morphological biomarkers 
associated with oral carcinogenesis. Using the epidermal growth factor receptor (EGFR) 
 viii
as a proof-of-principle biomarker, the sensor system demonstrated capacity to support 
rapid biomarker analysis in less than one-tenth the time of traditional methods and 
effectively characterized EGFR biomarker over-expression in oral tumor-derived cell 
lines. Successful extension from in vitro tumor cell lines to clinically relevant exfoliative 
brush cytology was demonstrated, providing a non-invasive method for sampling 
abnormal oral epithelium. Incorporation of exfoliative cytology further helped to define 
the important assay and imaging parameters necessary for dual molecular and 
morphological analysis in adherent epithelium. Next, this new sensor assay and method 
was applied in a small pilot study in order to secure an initial understanding of the 
diagnostic utility of such biosensor systems in clinical settings. Four cellular features 
were identified as useful indicators of cancerous or pre-cancerous conditions including, 
the nuclear area and diameter, nuclear-to-cytoplasm ratio, and EGFR biomarker 
expression. Further examination using linear regression and ROC curve analysis 
identified the morphological features as the best predictors of disease while a 
combination of all features may be ideal for classification of OSCC and pre-malignancy 
with high sensitivity and specificity. Further testing in a larger sample size is necessary to 
validate this regression model and the LOC sensor technique, but shows strong promise 
as a new diagnostic tool for early detection of oral cancer.  
 ix
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Chapter 1:  Oral Cancer Pathology, Detection, and the use of 
Adjunctive Diagnostic Techniques 
1.1 OVERVIEW 
The following dissertation details the development of a cellular sensor for 
detection of biomarkers associated with oral cancer and pre-cancerous lesions using a 
membrane-based lab-on-a-chip (LOC) platform. This general LOC approach has been 
developed over the past decade and serves as a miniaturized diagnostic platform suitable 
for whole cell immunoassays as described previously for CD3+/CD4+ immune 
monitoring in HIV patients.1 The LOC sensor system utilizes a size-selective membrane 
that functions as a microsieve to capture and screen cells from bodily fluids, such as 
whole blood and saliva, or biopsy suspensions. Once captured, a series of 
immunofluorescent reagents are passed over the sensor membrane revealing the number 
and phenotype of cells present via automated imaging and microscopy.   
In the following section, the motivation for this research is provided emphasizing 
the U.S. and global significance of oral cancer. In addition, a brief synopsis of oral cancer 
biology and clinical pathology is discussed. Particular attention is paid to the detection of 
pre-malignant lesions and the value of histological diagnosis for prediction of malignant 
development in order to provide perspective on existing procedures and the need for new 
diagnostic techniques targeting early tumorigenesis. Various adjunctive devices to aid 
diagnosis are summarized followed by a description of the LOC approach for 
characterization of oral cancer and pre-cancerous risk using molecular and morphological 
biomarkers. A short description of the chapter contents to follow in the dissertation is 
outlined at the end of this section. 
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1.2 MOTIVATION  
Oral cancer accounts for 3-5 % of all cancers in the United States with an 
estimated 34,000 new cases and nearly 8,000 deaths in 2007 alone.2 Worldwide the 
problem is more pronounced afflicting over 300,000 people per year, particularly in 
western Europe and developing countries where high incidence rates reflect the 
prevalence of specific risk factors such as tobacco and alcohol use.3 The long-term 
prognosis for patients with oral cancer is poor, with 5-year and 10-year survival rates at 
60% and 48%, respectively.2  These survival rates are among the lowest for all major 
cancers and have increased only moderately in the past few decades, despite significant 
advancements in surgical procedures and treatment for oral cancer.2, 4  
Beyond prevention, early detection is the most crucial determinant for successful 
treatment and survival of oral cancer. In addition, management of early stage oral cancer 
is often accomplished with less aggressive methods which can preserve vital organ 
function and physical appearance, resulting in a better quality of life for patients. 
Unfortunately, the majority of oral cancers exhibit advanced stage disease with spread to 
regional lymph nodes and/or distant metastases at the time of initial diagnosis suggesting 
that current detection methods, based upon visual examination alone, are insufficient for 
early tumor progression and molecular transformation.4, 5 
 Development of new diagnostic methods incorporating tumor biomarkers could 
enhance early detection by providing molecular-level insight into the biochemical and 
cellular changes associated with oral carcinogenesis.6 A number of biomarkers (DNA, 
RNA and protein) demonstrating significant diagnostic, prognostic, and therapeutic 
potential have been characterized in oral cancer, including cyclins involved in cell cycle 
regulation; growth factors and their receptors; matrix metalloproteinases (MMPs) 
involved in cell attachment and migration; angiogenic factors; inflammatory mediators; 
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and apoptotic signaling molecules.6-8 Given that molecular changes in these key cellular 
processes often occur prior to the histological changes associated with the clinical 
appearance of cancer, diagnostic tools for biomarker characterization offer new 
opportunities for oral cancer detection at early stages where treatment is most effective 
and survival is up to 85%.6, 8, 9  
1.3 ORAL CAVITY ANATOMY AND STRUCTURE OF EPITHELIAL MUCOSA 
Oral cancer encompasses all cancers developing in the oral cavity and pharynx.10 
The oral cavity includes the lips, tongue, minor salivary glands, gingiva, hard palate, 
buccal mucosa, and floor of the mouth. The oropharynx, located in the throat just behind 
the oral cavity, includes the base of the tongue, soft palate, tonsils, and throat walls. 
Approximately 90% of all oral malignancies are squamous cell carcinomas that originate 
in the epithelial mucosa lining the oral cavity and its tissues.10  Oral squamous cell 
carcinoma (OSCC) is frequently the cancer-type referred to with the general term “oral 
cancer” and hereafter may be used interchangeably. Malignancies arising in the lymphoid 
tissue (lymphoma), salivary glands (adenocarcinoma), soft-tissues (melanoma), and 
skeletal tissues (sarcoma) account for the remaining 10% of oral tumors.  
The oral mucosa is composed of two layers, an outer layer of epithelium and an 
underlying connective tissue layer (Figure 1-1). The epithelial layer is a stratified 
squamous epithelium that is either keratinized or nonkeratinized and functions as a 
protective barrier against mechanical, microbial, and chemical damage.11 The underlying 
layer of dense connective tissue is known as the lamina propria and functions to provide 
mechanical support and nutrients for the epithelium.11, 12 Beneath the lamina propria, a 
submucosa containing blood vessels, fat, and secretion glands may be present.12 At 
various sites within the oral cavity, structural modifications in both the epithelial and 
connective tissue layers arise based upon the functional demands of each region.12 The 
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three distinct histological types of oral mucosa which correspond to tissue function 
include: (i) the masticatory mucosa found on the gingiva and hard palate which possesses 
a mechanically tough, keratinized epithelium for protection against shear forces during 
mastication; (ii) the lining mucosa, with a nonkeratinized, flexible epithelium located on 
the lips, buccal regions, soft palate, floor of the mouth, and ventral surface of the tongue; 
and (iii) the specialized mucosa which is a mosaic of keratinized and nonkeratinized 
epithelia with specialized papillae located on the dorsal surface of the tongue.11-13   
Similar to skin, the oral epithelium is arranged in multiple strata of densely 
packed epithelial cells that exhibit various patterns of differentiation.11  The deepest layer 
is the basal epithelium consisting of undifferentiated mitotically active cells, often 
cuboidal or columnar in shape, which are responsible for cell production and division 
(Figure 1-1).12 These basal cells are located directly above the basement membrane 
which anchors the epithelium to the underlying connective tissue. Upon cell division, 
basal cells migrate superficially into the spinous layer where they increase in cell size and 
volume, express differentiation-specific cytokeratins and take on a polyhedral 
appearance.11, 12 As cells enter the granular (keratinized) or intermediate (nonkeratinized) 
layer, cells become flattened and densely packed with keratin filaments. In the surface 
layer of keratinized epithelium cells have thickened plasma membranes, compact arrays 
of condensed keratin filaments, no organelles and are surrounded by an external lipid 
matrix forming a permeability barrier.11, 12 A similar progression occurs in nonkeratinized 
epithelium of lining mucosa, although organelles and nuclei persist in the outermost 
layer, here the superficial layer, and the permeability barrier formed is less effective than 
keratinized oral epithelium.11, 12 Ultimately, the surface epithelial cells are sloughed off 
into the oral cavity and replenished from basal cell mitosis.  
Cell production and turnover rates in oral mucosa differ at various anatomical 
sites, but typically occur rapidly (1 to 3 weeks) when compared to the epidermis of the 
skin (4 to 10 weeks depending upon site).12 Thickness of the oral epithelium is also site-
specific and ranges from 190 ± 40 µm in the floor of the mouth to 580 ± 90 µm in the 
buccal mucosa lining the cheek.12 Additional non-epithelial cell types present in the oral 
mucosa include pigment producing melanocytes, Langerhans’ cells, Merkel cells, and 
inflammatory cells such as lymphocytes, leukocytes, and mast cells. 11, 12 Together these 
cells can account for as much as 10% of the total cell population in the oral epithelium.11  
 
Figure 1-1.  (a) Schematic drawing of the oral mucosa exhibiting the layers of stratified 
squamous epithelia; (b) Tissue section from the oral mucosa stained with hematoxylin 
and eosin. Figure reprinted with permission from Macmillan Publishers Ltd, Nature 
Reviews Cancer 14, copyright 2005. 
1.4 ORAL CANCER BIOLOGY AND BACKGROUND 
1.4.1 Epidemiology and Etiology 
Oral cancer occurs predominately in adult males, aged 50 years and older with a 
history of tobacco and alcohol use, the primary risk factors for oral cancer. These risk 
factors account for the high incidence rates found in populations where cultural and 
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social use of tobacco and/or alcohol are common, such as Western Europe, Southeast 
Asia, and Melanesia (Table 1-1). In many regions, men exhibit greater prevalence than 
women, with incidence rates of 7.9 per 100,000 males versus 3.3 per 100,000 females in 
the US (Table1-1), due to higher proportion of smoking and drinking habits in men.15-17 
Interestingly, these factors appear to act individually or synergistically, with up to 100 
times higher risk in heavy smokers and heavy drinkers.10 Tobacco in all forms, including 
cigarettes, cigars, pipe tobacco, or smokeless tobacco such as chewing tobacco, snuff, 
and betel quid, increases the risk of oral cancer. Betel quid, common in India, Southeast 
Asia and the South Pacific islands, consists of a betel leaf that is wrapped around a 
mixture of areca nut and slaked lime with tobacco and sweeteners. In the past decade, 
there has been an alarming increase in the popularity of cheap, ready-packaged chewing 
tobacco that is often chocolate or mint candy flavored, among children in India over 
traditional betel quid. This trend has lead to an increase in malignant and pre-malignant 
lesions of the buccal mucosa in younger Indian populations, <50 years old.16, 18, 19  
In addition, recent studies have linked high-risk HPVs (human papiloma virus-16 
and 18) to oral cancer development in up to 25 % of all OSCC cases.20, 21 HPV, one of the 
most common sexually transmitted diseases worldwide, may partially account for the 
increase in oral cancer among young adults 20-45, particularly those located on the 
tongue and tonsil.22 HPV-associated OSCC may display distinct molecular, clinical, and 
pathological characteristics along with significantly improved prognosis (59% reduction 
in risk of death) versus non-HPV OSCC.20, 21 Additional factors which may play a role in 





Table 1-1.   Oral cancer incidences for men and women according to geographic regions 
as reported in GLOBOCAN 2002 statistics.3, 15 Patterns of cancer distribution can be 
traced to social and cultural use of tobacco and/or alcohol in specific geographic regions, 
including Melanesia, India, and Western Europe. 
Age-Standardized Incidence Rate  
of Oral Cancer (per 100,000)15 Region/Country 
Male Female 
North America 7.8 3.3 
United States 7.9 3.3 
Canada 6.9 2.9 
Southern Africa 11.1 3.1 
Botswana 23.1 9.5 
Namibia 16.1 7.2 
Lesotho 2.9 1.6 
South African Republic 11.2 2.9 
Swaziland 2.4 1.4 
South Central Asia 12.7 8.3 
Afghanistan 6.8 5.9 
Bangladesh 13.4 16.8 
Bhutan 12.8 8.4 
India 12.8 7.5 
Iran 2.9 1.7 
Kazakhstan 14.9 2.7 
Kyrgyzstan 8.1 1.7 
Nepal 12.8 8.4 
Pakistan 14.7 14.7 
Sri Lanka 24.5 9.2 
Tajikistan 2.6 1.3 
Turkmenistan 12.9 3.3 
Uzbekistan 9.3 2.3 
Western Europe 11.3 2.7 
Austria 11.3 1.7 
Belgium 7.7 2.5 
France  14.8 2.7 
Germany  11.1 2.8 
Luxembourg 9.0 2.7 
The Netherlands 5.6 3.3 
Switzerland 9.0 2.5 
Australia/New Zealand 10.2 4.5 
Melanesia 31.5 20.2 
Fiji 1.9 1.4 
Papua New Guinea 40.9 26.3 
Solomon Islands 34.1 21.7 
Vanuatu 3.7 2.0 
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1.4.2 Clinical, Histological, and Molecular Progression of Oral Cancer 
1.4.2.1 Pre-malignant Lesions  
Oral squamous cell carcinoma is often preceded by the emergence of clinically 
visible premalignant changes in the epithelial mucosa.  These oral pre-malignant lesions 
(OPL) typically appear as white or red plaques know as leukoplakia and erythroplakia, 
respectively.24, 25 Leukoplakia is by far the most common form of oral precancer, 
representing approximately 85% of all pre-malignancies.24 Leukoplakia frequently occurs 
in the buccal mucosa, alveolar mucosa and lower lip with the majority of lesions 
exhibiting benign hyperkeratosis occurring in response to chronic irritation (eg, from 
dentures, lichen planus, tobacco, or cheek biting).10, 26 However, a fraction of 
leukoplakias exhibit increased risk of malignant transformation at rates varying from 3% 
to 17.5%. 10, 25-28 While erythroplakia is less common than leukoplakia, there is a near 
total association of erythroplakia (90-100%) with either dysplasia or outright carcinoma 
at initial identification, reflecting significantly greater malignant potential.10, 24, 25  
Since only a fraction of all OPLs actually progress to carcinoma, the clinical 
challenge is to identify which lesions possess a high-risk of malignant transformation and 
treat them accordingly. Assessment of malignant potential is influenced by factors such 
as clinical appearance (e.g. homogeneous versus non-homogeneous leukoplakias), 
etiology, and location, as well as the presence and degree of dysplasia. For example, non-
homogeneous or “speckled” leukoplakias possess four- to five-times greater risk of 
malignant development than homogeneous ones.26, 28, 29 In addition, several high-risk 
lesion sites have been identified that are more likely to harbor dysplastic or malignant 
changes, including the floor of the mouth and ventral/lateral surface of the tongue.10 
However, the most widely accepted predictor of cancer development is currently the 
presence and degree of dysplasia found upon surgical biopsy of the lesion tissue.  
 
Table 1-2.    Histological characteristics of epithelial dysplasia  29, 30 
Loss of polarity of the basal cells 
The presence of more than one layer having a basaloid appearance 
Increased nuclear-cytoplasmic ratio 
Drop-shaped rete-ridges 
Irregular epithelial stratification and differentiation 
Increased number of mitotic figures, particularly in upper layers 
Presence of abnormal mitoses 
Cellular and nuclear pleomorphism 
Nuclear hyperchramatism 
Enlarged nuclei and prominent nucleoli 





Dysplasia is a histologic term to describe the occurrence and extent of epithelial 
abnormality, often sub-divided into mild, moderate, or severe cases. Histological changes 
which may contribute to a diagnosis of epithelial dysplasia are listed in Table 1-2.30 
These include features of tissue architecture as well as individual cyto-morphological 
features, such as increased nuclear/cytoplasmic ratio, an increase in number of mitotic 
figures, and cellular and nuclear pleomorphism. Not all of these changes are necessarily 
seen in any one case and recognition/interpretation of their significance in various 
combinations is associated with considerable subjectivity.30, 31 It should also be noted that 
some minor cellular atypia may be seen in epithelium due to inflammation and/or wound 
healing.30   
In general, the risk of cancer development increases with the degree of dysplasia 
(Figure 1-2).29 However, there are several major problems associated with the importance 
of epithelial dysplasia in predicting malignant development. First, the diagnosis and 
grading of dysplasia is ultimately a subjective process with high inter-observer 
variability.32 Much of this variability is attributed to the lack of a well defined and 
universally accepted criterion for sub-dividing and grading of epithelial dysplasia.31 In 
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addition, not all dysplastic OPLs will fully develop into carcinoma.26, 29 Pindborg et al. 
reported spontaneous regression in nearly 15% of OPLs previously exhibiting dysplasia, 
often when tobacco use was reduced or eliminated.27 Further, it appears that cancer 
development may occur from lesions diagnosed as non-dysplastic in previous biopsies.26, 
28 In order to overcome these limitations, novel strategies using clinical and 
histopathological data combined with molecular biomarker analysis, may be needed to 
improve prediction of cancer development from pre-malignant lesions.29, 33   
 
 
Figure 1-2.  Schematic diagram of cellular and histological changes associated with oral 
cancer progression from mild, moderate and severe dysplasia to carcinoma in situ and 
ultimately invasive carcinoma. Figure reprinted with permission from Macmillan 
Publishers Ltd, Nature Reviews Cancer. 34 
1.4.2.2 Squamous Cell Carcinoma 
Histologically, OSCC development may be viewed as an extension of the 
epithelial irregularity found in pre-malignancies through increasing degrees of dysplasia 
(mild → moderate → severe). When severe dysplasia is apparent throughout the entire 
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thickness of the epithelium, it is termed carcinoma in situ. Ultimately, the tumor cells 
breach the basement membrane and invade the underlying submucosa marking the 
defining transition into invasive squamous cell carcinoma (Figure 1-2).  
OSCC is found most frequently in the lateral tongue, representing approximately 
40% of all cases, and the floor of the mouth.2, 10 The high-risk of malignancy at these 
sites is attributed to the pooling of saliva containing carcinogens in these areas, as well as 
the lack of protection afforded by the thin, non-keratinized epithelium present.10, 29 A 
large number of squamous cell carcinomas also develop in the lower lip vermilion border 
due to excessive sun exposure, but typically possess low risk of metastasis.10 Advanced 
metastatic spread of OSCC regularly encompasses multiple oral sites and/or cervical 
lymph nodes with greater than 50% of all OSCC cases showing regional lymph node 
involvement at initial diagnosis.4, 16 Distant metastases can occur in any part of the body, 
but are seen most frequently in the lungs, bones, and liver.10  
Approximately 9-14% of patients who have been diagnosed with oral cancer 
possess a second primary tumor in the upper aerodigestive tract at diagnosis.35 Following 
treatment, oral cancer patients continue to exhibit significantly higher risk for 
development of second primary tumors at a rate of 3-7% per year, higher than any other 
malignancy.36 This independent development of multiple primary tumors is attributed to 
widespread, chronic exposure of the mucosal epithelium to carcinogens such as tobacco 
and alcohol, through a process known as “field cancerization.”37 Originally proposed by 
Slaughter et. al. in 1953, the theory of field cancerization suggests that the exposed 
epithelium has been preconditioned for cancer development and may harbour sub-clinical 
changes related to carcinogenesis.37 This theory has been supported by various clinical, 
histopathological38 and molecular39 evidence where normal appearing mucosa at the 
margin of an oral lesion or in a “mirror-image” biopsy exhibited distinct alterations 
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associated with cancer progression. Alternatively, it has been proposed that clonal 
expansion of initially transformed cells followed by micrometastasis may give rise to 
multiple primary oral tumors.38  
1.4.2.3 Molecular Progression Model 
Molecular development of OSCC occurs through a multi-step process of 
accumulated genetic, epigenetic, and biochemical alterations in tumor suppressor genes 
and proto-oncogenes.40 These alterations manifest in the outward phenotypic changes in 
cellular and tissue morphology seen clinically or histologically. The presence of genetic 
changes in clinically normal or dysplastic tissue, particularly at the margin of OSCC 
tumors, suggests that molecular events occur early during tumorigenesis and may be used 
as indicators of disease and/or measurement of disease progression.39, 41, 42  
Examination of the genetic changes associated with each histopathological stage, 
from pre-neoplastic lesions to invasive cancer, has helped to outline a model for the 
molecular progression of oral cancer, similar to colorectal cancer (Figure 1-3).41 Here, 
loss of heterozygosity (LOH) in chromosomal region 9p21 is the most frequently 
observed genetic alteration and occurs early during tumorigenesis.41, 42 As a consequence 
of this event, the p16 gene which encodes a cyclin-dependent kinase inhibitor involved in 
cell cycle regulation, is inactivated.41, 42 Subsequent events include LOH at the p53 gene 
locus (17p13), cyclin D1 (11q13), and retinoblastoma (13q) whose gene products are key 
regulators of cell cycle progression, DNA repair, and apoptosis.41, 42 Importantly, it is the 
accumulation rather than the order of genetic events that influences malignant 
progression. In a study by Rosin et al. risk of cancer development from OPLs was low in 
the absence of genetic alterations, increased moderately in the presence of genetic 
mutations on chromosomes 3p and 9p, and high when 3p and 9p mutations were 
accompanied by additional loss in one or more chromosomal regions (including 4q, 8p, 
11q, 13q and 17p).43 The continued accumulation in genetic mutations as a result of 
exposure to carcinogens, such as tobacco and alcohol, ultimately leads to wide-spread 
genomic instability associated with advanced cancer progression and metastasis. 
 
 
Figure 1-3. The molecular progression model for oral tumorigenesis proposed by 
Califano et al. demonstrates genetic events, such as the loss of heterozygosity in 
chromosomal regions encoding tumor suppressor genes and oncogenes, which are 
associated with histologically distinct stages of eary OSCC development. Figure 
modified from 41, 42. 
Although this model provides a nice framework for understanding the genetic 
events associated with early development of oral cancer, it is far from complete and 
expresses a somewhat narrow view of tumorigenesis. Mechanisms involved in cancer 
development are not limited to genetic mutation only, but may include a variety of other 
epi-genetic and biochemical means to transform cellular function, including promoter 
hypermethylation and post-translational protein modifications effecting structure, 
function, enzymatic activity, localization, and expression.44, 45  
1.4.3 Current Detection of Oral Cancer and Pre-malignant Lesions 
Currently, detection of oral cancer and pre-malignant lesions relies upon visual 
inspection of the oral cavity for mucosal abnormalities in a process known as 
conventional oral examination (COE). Dental professionals and primary care physicians 
who see patients regularly are more likely to identify early-stage lesions through yearly 
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cancer related check-ups, as recommended by the American Cancer Society. However, 
only 13% of Americans report receiving an oral cancer examination in the past year and 
knowledge of the COE process among these clinicians may be inadequate.46  
In a recent systematic review of seven studies evaluating COE as a method for 
detecting early cancerous lesions, sensitivity ranging from 60% - 97% and specificity 
ranging from 75% - 99% were reported, which are comparable to rates found in other 
cancer screening programs.47 This suggests that COE may be an adequate screening 
method to identify oral lesions. Shortcomings of this method include the inability to 
detect sub-clinical abnormalities or discriminate between benign lesions and those with a 
high-risk of malignancy which may require the use of adjunctive diagnostic techniques.48 
Further, the effectiveness of COE screening to reduce disease-related mortality remains 
to be determined.49, 50  
1.4.4 Clinical Diagnosis and Staging 
Upon initial identification of a suspected pre-malignant lesion using visual 
examination, with or without adjunctive tests, clinicians typically pursue a two week 
follow-up approach for monitoring.51 If the lesion persists in the absense of identifiable 
causes of local inflammation, a surgical biopsy is performed for definitive 
histopathological diagnosis. The decision to perform a surgical biopsy may be accelerated 
based upon clinical appearance of the lesion (e.g. presence of induration, erythematous 
component, and ulceration), location (e.g. floor of the mouth or tongue), size, patient 
history (e.g. past malignancy, smoking and alcohol use), and symptoms, such as 
numbness or pain.51 In general, it is recommended that OPLs exhibiting moderate 
dysplasia or worse be removed by surgical excision, laser, or cryosurgery and monitored 
through follow-up every six months to one year.10, 51, 52 Interestingly, surgical 
intervention does not appear to completely prevent malignant transformation in OPLs and 
recurrence rates up to 35% have been reported.52, 53 This relatively poor treatment success 
may be due in part to inadequately defined lesion margins during excision and/or the 
persistence of cancer stigmatized cells beyond the excision site as suggested by the field 
cancerization model.53 
For patients with histologically confirmed invasive OSCC, further diagnostic tests 
such as physical examination, endoscopy, x-ray, CT, MRI, PET, and/or radionuclide 
scans are needed to assess the extent of tumor spread and presence of additional primary 
tumors. These test are utilized for staging in order to establish appropriate treatment and 
evaluate prognosis.54 Tumors are most often classified according to the TNM, tumor-
node-metastasis system updated by the American Joint Committee on Cancer in 2002, 
where (T) represents the primary tumor size, (N) indicates the status and extent of 
regional lymph node involvement, and (M) denotes the presence or absence of distant 
metastasis.54, 55 The TNM stage grouping establishes an overall clinical stage (I-IV) that 
is closely related to survival (Table 1-3) according to an inverse relationship where the 
five-year survival rate for advanced stage disease (stage III-IV) is at or below 41%, 
whereas in early stage disease (stage I-II) five-year survival approaches 85%.24, 54  
 
Table 1-3.  Five-year survival rates of oral cancer according to tumor stage. 4, 24, 54 
Clinical 
Stage TNM Classification 
Five-year 
survival rate Disease Status 
 % Cases at 
Diagnosis 
0 Tis N0 M0 NA Localized in situ  
I T1 N0 M0 68-85% 30-40% 
II T2 N0 M0 53-66% 
Localized 
 
III T1-3 N0-1 M0 41% 
IV A/B Any T4,or T1-3 N2-3 M0 9-27% 
Advanced 
Regional Lymph Nodes >50% 




1.4.5 Treatment and Prognosis  
Extensive review of OSCC treatment and prognosis is beyond the scope of this 
dissertation and have been published elsewhere.4, 56-59 Briefly, surgery and/or radiation 
therapy is the mainstay of treatment for early stage OSCC (stage I-II), where the tumor 
remains ≤ 4 cm in size and localized within the oral cavity.23, 56 Treatment of locally 
advanced disease (stage III-IVA/B) requires a more extensive multidisciplinary approach 
using surgery, radiation, chemotherapy, or a combination of treatment modalities.4, 56  
The most widely used treatment approach includes surgery followed by adjuvant 
chemoradiotherapy or radiation to reduce locoregional failure, the most common cause of 
death among OSCC patients.4 Alternatively, neoadjuvant chemoradiotherapy, with or 
without surgery as a salvage treatment, has become the dominant treatment strategy in 
some cancer centers due to improved organ preservation.4 The emergence of molecular 
targeted therapeutics, such as the EGFR monoclonal antibody cetuximab (Erbitux®, 
Bristol Myers Squibb) may further enhance efficacy of current treatments with reduced 
treatment-related cytotoxicity.4 
Lymph node status appears to be the most significant prognostic factor for OSCC 
with survival approximately cut in half when metastases are found in local or regional 
lymph nodes.59 In these patients, the number of positive nodes and the presence of 
extracapsular spread contribute to a negative prognosis.59 Other classic 
clinicopathological features including anatomical site, tumor size, grade, and maximal 
thickness have been shown to possess limited predictive value for the identification of 
patients with a high risk of disease relapse and death.59  
1.5 ORAL CANCER BIOMARKERS 
Recent advances in high-throughput “-omic” technologies has helped to unravel 
complex cellular mechanisms associated with tumorigenesis revealing a number of 
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molecular markers, or biomarkers, related to oral cancer initiation and progression.14, 60-64 
In the context of cancer research, biomarkers may be defined as “any substance or 
process that is indicative of the presence of cancer in the body.”65 However, the clinical 
role for biomarkers is not limited to detection. Biomarkers have been utilized in a range 
of clinical settings including screening, diagnosis, staging, prediction of treatment 
response, and monitoring of treatment and recurrence.65, 66 Biomarkers directly involved 
in tumorigenesis and originating from the tumor itself, known as tumor-derived markers, 
have further served as targets for therapeutic intervention in an effort to reverse or inhibit 
disease development.67   
The performance of a biomarker is measured by its sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV) (Table 1-4). 
Sensitivity refers to the proportion of diseased individuals (confirmed using a diagnostic 
“gold standard” technique) whom test positive using the biomarker assay, whereas 
specificity refers to the proportion of non-diseased individuals with a negative biomarker 
result.65 An ideal biomarker would exhibit 100% sensitivity and 100% specificity, i.e. 
everyone with cancer would test positive and everyone without cancer would test 
negative. In reality, acceptable sensitivity and specificity rates are dependent upon the 
intended use, for example diagnostic/monitoring tests place higher requirements on 
sensitivity while screening tests require higher specificity.65 Biomarker performance may 
be measured further using predictive values which estimate the probability of disease 
according to a biomarker test result. Here, PPV indicates the percentage of individuals 
with a positive test that actually have the disease, while NPV is the percentage of 




  Confirmed Clinical Diagnosis 
  Diseased Non-Diseased
Positive True Positive False PositiveBiomarker Test 
Result 
Negative False Negative True Negative
Sensitivity = TP/(TP+FN)     Specificity = TN/(TN+FP) 
PPV = TP/(TP + FP)      NPV = TN/(TN + FN) 
Table 1-4. Biomarker performance calculations of sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV). 
A number of biomarkers demonstrating significant diagnostic, prognostic, and 
therapeutic potential have been characterized in oral cancer. These biomarkers can be 
broadly classified according to their normal function in cell proliferation, differentiation, 
growth and signaling pathways, apoptosis, angiogenesis, and extracellular matrix 
degradation and migration.6-8 Additional genomic markers include genetic alterations in 
tumor suppressor genes and oncogenes, which often result in dysregulation of the cell 
cycle, and markers of genetic/chromosomal instability, such as changes in DNA content 
(aneuploidy), micronuclei, microsatellite repeats, and allelic imbalance (LOH). 7, 8, 23, 67, 68  
As will be discussed later in the dissertation, the epidermal growth factor receptor 
biomarker was selected as a proof-of-concept biomarker for initial development of LOC 
sensor assays due to its overexpression in up to 90% of all OSCC and association with 
early tumorigenesis and aggressive cancer phenotypes.69-71 Obviously, cancer 
development is a complex process disrupting a number of diverse cellular functions, 
therefore, it is unlikely that a single biomarker alone will provide sufficient sensitivity 
and specificity for conclusive cancer diagnosis. Instead a combination, or panel, of 
multiple biomarkers may be necessary for early detection and screening.33 Nevertheless, 
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when utilized as an adjunct to current diagnostic methods, even a single biomarker has 
the potential to enhance early detection of oral cancer by reducing subjectivity associated 
with histopathological diagnosis and providing a molecular-level basis for risk 
assessment in primary or recurrent lesions.  
Many OSCC biomarkers (DNA, RNA, and protein) have been identified in 
cancerous oral tissue or cells, as well as in extracellular fluids that drain from the oral 
cavity such as blood or saliva.60, 62, 72-75 Particularly in the case of oral cancer, saliva 
presents an ideal fluid for biomarker identification due to the close proximity to the 
primary tumor site, availability of exfoliated cytology samples, and accessibility to the 
oral cavity.  Li et al. examined the salivary mRNA transcript profile revealing seven 
putative biomarkers, including several inflammatory proteins and cellular enzymes, 
which could distinguish OSCC from healthy controls with high sensitivity and 
specificity.72 Unfortunately, the absense of pre-malignant lesions and diseased controls 
(e.g. periodontitis or lichen planus) in this study leaves the role for such techniques in 
clinical diagnostics unclear.  
Other approaches for cancer biomarker detection have directly examined oral 
epithelial cells, which can be found in whole saliva due to natural exfoliation of surface 
cells, oral rinses, or in brushings to selectively sample regions of the epithelium. 
Epithelial brushings or scrapings have been utilized for decades to screen for cervical 
cancer, but have traditionally provided inconsistent results in oral cancer detection due 
limited sampling of basal cells. Most dysplastic changes are visible first in the basal cells 
and may be lost in more mature keratinized cells located near the surface; therefore, full 
thickness sampling is essential to yield representative findings for diagnostic purposes.6 
Use of a cytobrush reportedly provides full trans-epithelial sampling for 
cytomorphological analysis as described below for OralCDx® testing.6, 76  Exfoliative 
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cytology samples have also been subjected to molecular analysis, including LOH, 
microsatellite analysis, gene expression via RT-PCR, fluorescent in situ hybridization, 
DNA aneuploidy, and immunohistochemistry in an effort to improve OSCC detection 
and characterization.73, 74, 77, 78 Alternatively, use of epithelial cells naturally exfoliated in 
saliva may also provide diagnostic information as reported by Xie et al. who catalogued 
over 1000 proteins and 30 bacterial species from whole cells in saliva of OSCC 
patients.75 Many of the markers identified have been previously characterized in cell 
signaling and tumorigenesis pathways suggesting that whole cells in saliva may serve as 
a useful diagnostic medium, although the utility of this technique for early detection 
remains to be determined.75 
Despite the availability of OSCC biomarkers with diagnostic and prognostic 
potential, none have successfully been translated into clinical practice. Barriers to the 
application of biomarkers include the high complexity of many biomarker assay 
formats.79 For example, genomic and proteomic techniques require large instrumentation, 
extensive quality control, and highly skilled technicians that are often beyond the 
resources of many hospitals and smaller clinics. In addition, the majority of biomarker 
research has focused upon OSCC rather than pre-malignancies, possibly due to a lack of 
availability or access to these patients and samples, which limits the development and 
application of biomarkers for early detection. Further, there is an immense cost associated 
with the development, validation, and FDA regulatory approval process for either single 
or multi-biomarker assays.79 Such issues should be considered in light of the fact that the 
final test must remain cost-effective for both the patients and insurance companies in 
order to be accessible to the general public.  
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1.6 ADJUNCTIVE TECHNIQUES FOR ORAL CANCER DETECTION AND DIAGNOSIS 
The limitations of conventional oral examination and histopathology of OPLs has 
spurred the development of diagnostic aids and adjunctive techniques to enhance early 
detection of oral cancer. The clinical role for these adjuncts includes screening for 
evidence of occult disease or abnormal changes and assessment of the biologic potential 
in clinically apparent lesions.48 The easy accessibility to the oral cavity permits the use of 
relatively non-invasive procedures, such as in vivo light-based methods to enhance 
visualization of abnormal mucosa or exfoliative cytology. In the following section, 
particular attention is paid to techniques that are currently in clinical use and a summary 
of clinical studies to define the sensitivity and specificity for each method is provided in 
Table 1-5. 
1.6.1 OralCDx® Brush Biopsy  
The OralCDx® brush biopsy with computer-assisted analysis (OralScan 
Laboratories Inc., Suffern, NY) is an exfoliative cytology technique which utilizes a 
cytobrush to obtain a trans-epithelial sampling of cells from an oral lesion for 
morphological analysis of atypia, similar in theory to a cervical Pap test.76 The slide-
based specimens are analyzed at a central laboratory facility in New York for abnormal 
cellular morphology, keratinization, and relative DNA ploidy.76 Samples are classified 
into four categories: (i) positive, with definitive evidence of epithelial dysplasia or 
carcinoma; (ii) atypical, exhibiting abnormal epithelial changes of uncertain diagnostic 
significance; (iii) negative, where no epithelial abnormality is detected; or (iv) 
inadequate, due to insufficient specimen collection.76 The OralCDx® procedure is not 
intended as a  replacement to surgical biopsy, rather targets examination of innocuous 
appearing lesions that do not warrant surgical biopsy but may harbour high-risk of 
malignant transformation, such as leukoplakias of unknown clinical significance.76, 80, 81  
 22
In a large multi-centre study, the OralCDx®  brush test demonstrated high 
sensitivity and specificity (100% and 93% respectively), with approximately 7% 
inadequate specimens, for detection of atypical epithelia as confirmed by scalpel 
biopsy.76 Unfortunately, in this study scalpel biopsy was not performed for all, or even 
the majority, of OralCDx® “negative” or “atypical” specimens possibly resulting in over-
estimation of the sensitivity/specificity for this test.48, 76 In another study by Scheifele et 
al., in which brush and surgical biopsies were performed on all subjects, 92% sensitivity 
and 94% specificity for detection of dysplasia and OSCC was reported.81 However, both 
of these studies included a combination of both suspicious and non-suspicious lesions 
which may not accurately reflect the sensitivity and specificity in strictly non-suspicious 
or innocuous lesions for which the test is designed.48, 76 As such, these studies focus on 
the ability of the OralCDx® methodology to confirm the presence of oral cancer in 
patients which exhibit overt signs of carcinoma or are known to be SCC positive bringing 
into question the weight that should be associated with the diagnostic performance values 
mentioned above. Potter et al. further underscore the importance of the selection of 
epithelial lesions appropriate for OralCDx® testing as false negative results in suspicious 
“speckled” lesions have been reported.82, 83   
Despite promising results of the OralCDx® test and initial interest in this new 
technique, widespread clinical use by dental practitioners is waning due to high rates of 
false positive test results (personal communication). This trend is supported by Poate et 
al. reporting a 71% sensitivity and 32% specificity using the OralCDx® system.82 Here, 
the low specificity may be due to flaws in the retrospective study design or the high 
occurrence of false positive results associated with benign inflammatory conditions, such 
as lichen planus.76, 81 The latter suggests the need for additional disease-specific 
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biomarkers which may be used in conjunction with brush cytology to improve molecular-
level characterization of oral lesions.81, 82  
1.6.2 OraTest® - Toluidine Blue Staining 
Vital tissue staining via topical application of toluidine blue (tolonium chloride), a 
metachromatic dye that preferentially stains cells with elevated DNA content, has been 
utilized for decades to assist in identifying oral cancer sites and/or delineating margins 
for excisional biopsy. The literature on toluidine blue is extensive and reviewed 
elsewhere.48 In one study, examination of OSCC lesions using OraTest® (formerly 
OraScan®, Zila Pharmaceuticals, Phoenix, AZ), a ready-to-use tolunium blue kit, yielded 
a high sensitivity (100%) but low specificity (62%).84 Interestingly, sensitivity decreased 
dramatically (80%) for the identification of lesions exhibiting epithelial dysplasia only.84 
Similar results have been reported elsewhere using generic toluidine blue85, 86 and 
suggests that although toluidine blue staining yields high sensitivity in detecting SCC 
malignancies, its usefulness may be limited in characterizing mild-moderate epithelial 
dysplasia found in oral pre-malignant lesions.6, 84, 87  
1.6.3 ViziLite® - Chemiluminescent Device 
The ViziLite® device (Zila Pharmaceuticals, Phoenix, AZ) is an oral lesion 
identification system that involves an oral rinse with 1% acetic acid for 1 minute 
followed by visual examination under chemiluminescent light. In theory, acetic acid 
removes the glycoprotein barrier and slightly dehydrates the oral mucosa such that 
neoplastic cells with an increased nuclear/cytoplasmic ratio and density reflect more light 
than normal mucosa and appear “acetowhite.” This effect is enhanced when visualized 
under chemiluminescent light at 490-510 nm wavelengths; although, glare from the light 
has been reported to hinder visualization as well.88, 89 Literature reporting the efficacy of 
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ViziLite® in detecting oral malignant and pre-malignant lesions and the benefit of this 
method over current techniques is somewhat limited.88-91 One study suggests that 
ViziLite® is superior to toluidine blue for detection of OSCC and epithelial dysplasia 
with a reported sensitivity of 100%.90 However, ViziLite® failed to differentially identify 
benign conditions showing excessive keratinization and/or inflammation, generating a 
high false-positive rate and low specificity of 14%, which is likely to result in numerous 
unnecessary biopsies during follow-up.90 Interestingly, Huber et al. reported the 
identification of one subclinical lesion with ViziLite® “acetowhite” positive results, 
verified as atypical using the OralCDx system, suggesting possible utility in detection of 
occult epithelial abnormalities.88 The clinical value and widespread acceptance of the 
ViziLite® system to enhance standard visual examination remains to be determined.  
1.6.4 VELscope® - Autofluorescence Visualization  
The VELscope® (LED Dental Inc. Vancouver, British Columbia, Canada) is an 
FDA cleared hand-held device for the direct visualization of tissue fluorescence in the 
oral cavity. Tissue autofluorescence is produced by naturally occurring fluorophores 
present in epithelial cells or tissue matrix after excitation at suitable wavelengths of light, 
typically in the ultra violet to blue light range (<450 nm).92 Cell or matrix constituents 
contributing to autofluorescence include collagen, elastin, keratin, reduced nicotinamide 
adenine dinucleotide (NADH), flavins (FAD+, FMN, and riboflavin) and aromatic amino 
acids (tryptophan, tyrosine, and phenylalanine). Autofluorescence emitted by these 
endogenous fluorophores is subjected to absorption and scattering events in the tissue 
prior to detection or visualization, which alters the measurable autofluorescence profile.92 
Under diseased conditions, fluorophore concentrations as well as the light scattering and 
absorption properties of the tissue are altered due to a variety of changes in cell 
metabolism, blood supply, and tissue architecture (e.g. nuclear size distribution, collagen 
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content, and thickness of the epithelium).92 Analysis of tissue autofluorescence has been 
utilized to detect cancers of the lung, bladder, gastrointestinal tract, colon, cervix, and 
head and neck.92-95  
The VELscope® utilizes blue excitation light (400-460 nm) to excite endogenous 
green-red fluorophores present in oral epithelium whose emission in the visible range 
(>475 nm) can be detected by the unaided human eye. Fluorescence visualization loss 
(FVL), or a decrease in visible autofluorescence in this wavelength range, is found in 
high-risk oral premalignant lesions and SCC.93 In a clinical study examining 50 oral 
lesions, using histology as the diagnostic standard, the device exhibited a sensitivity of 
98% and specificity of 100% when discriminating normal mucosa from high-risk 
premalignancy (severe dysplasia/CIS) or invasive carcinoma.93 In addition, the 
VELscope® optical device has demonstrated potential for detection of occult oral lesions 
in pateints previously treated for OSCC to identify second primary and recurrent tumors, 
as well as  assessment of tumor margins to aid surgical excision.96, 97 Although the 
VELscope® shows significant promise, independent studies are lacking and the results of 
an eight-year longitudinal study are awaited to more accurately determine device 









Table 1-5. Summary of FDA cleared oral cancer detection devices with representative 
studies reporting sensitivity and specificity of each technique. 
Device 
FDA 
Clearance Detection Method Sensitivity Specificity # Patients Reference 
OralCDx No  100% 93% n = 945 Sciubba et al.76 




Brush biopsy with 
computer assisted 
analysis 
71% 32% n = 112 Poate et al.82 
VELscope® July 2006 Direct visualization of 
tissue autofluorescence 
98% 100% n = 50; only 
SCC 
Lane et al. 2006 
93 
ViziLite Nov 2001 Acetic acid wash and 
chemiluminescence 
100% 14% n = 46; only 
SCC 
Ram and Siar 
200590 
OraTest® Phase III Toluidine blue 80% dysplasia 
100% carcinoma 
62% n = 102 Warnakulsauriy
a et al.84 
   92.5% 63% n = 59 Epstein et al.85* 
   77% 67% n = 50 Onofre et al.86* 
*study used generic toluidine blue 
 
1.7 LAB-ON-A-CHIP SENSOR BACKGROUND  
Over the past decade, research efforts in the McDevitt laboratory have led to the 
creation of a series of powerful microchip sensor systems that have the capacity to 
quantitate cellular antigens and diverse analytes within complex fluids, such as whole 
blood, saliva, and biopsy suspensions. These miniaturized lab-on-a-chip (LOC) systems 
could enable rapid, highly sensitive and cost-effective in vitro diagnostic tests to be 
completed at the point-of-care where patient care is most effective. Such systems hold 
strong promise for a variety of important diagnostic tests including HIV immune function 
monitoring, and cardiac risk assessment.1, 98  
The lab-on-a-chip sensor system employs two basic methodologies for 
widespread application in clinical diagnostics; the membrane-based system which is 
optimized for cellular analysis1, 99-101 and the bead-based sensor designed for biochemical 
detection of circulating analytes.98, 102, 103 Developed initially as an “electronic taste chip”, 
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the LOC bead-based platform mimics the general structure and function of the human 
taste bud with chemically derivatized polymer microspheres as sensing elements. The 
microspheres, typically ~280µm porous agarose beads, serve as three dimensional 
substrates for sandwich type immunoassays designed for detection and quantitation of 
circulating disease biomarkers, such as C-reactive protein (CRP) for cardiac risk 
assessment.104 In LOC bead-based immunoassays, sensitized beads are spatially 
positioned in a micro-etched array of wells on a silicon wafer/chip platform such that 
each bead within the array is a self-contained microreactor system, with its selectivity 
determined by the specificity of the antibody immobilized on the bead surface. The bead-
filled microchip is placed between two optically transparent polymethyl-methacrylate 
(PMMA) inserts, with machined fluid inlet and outlet ports, and fitted within a custom 
metal housing or “flow cell”. The trans-wafer openings allow for reagent and sample 
solutions to be delivered to each chamber as well as provide optical access to the 
chemically sensitive microspheres for fluorescent or colorimetric detection. Such bead-
based sensor systems have been characterized for assessment of cardiac risk, acute 
myocardial infarction (AMI), and periodontitis using single or multiple biomarker panels 
with significant implications toward clinical diagnostics.98, 104, 105 In addition, bead-based 
immunoassays are currently being explored for their capacity to detect and quantitate 
cancer biomarkers such as carcinoembryonic antigen (CEA) and cancer antigen-125 (CA-
125) from serum and/or saliva as a non-invasive method for cancer detection and 
screening.  
Along with the bead-based sensor arrays, a membrane-based sensor platform has 
been developed for analysis of whole cells. In this system, the microspheres and silicon 
microchip are replaced with a size-selective membrane, which functions as a micro-sieve 
to capture and screen cells from biological fluids or biopsy suspensions. Once captured, 
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cells are analyzed for protein and/or nucleic acids using assay-specific fluorescent 
labeling techniques. This novel mechanical entrapment approach has been employed in 
the context of online detection of bacillus spores in mail-handling facilities as well as for 
the enumeration of human CD4+ lymphocytes from whole blood samples.1, 99  
Building upon the established tool-kit of diagnostic sensors, this dissertation 
outlines the development and application of membrane-based LOC sensor methodologies 
for single-cell analysis of OSCC biomarkers in exfoliative cytology specimens. This 
biological system presents unique challenges not previously encountered, particularly in 
the analysis of adherent epithelial cells which are irregularly shaped (non-spherical) and 
may remain in adherent clusters following collection. Although oral cancer is targeted, 
the techniques and methods developed here may be applicable toward screening other 
epithelial malignancies where exfoliative cytology or fine-needle aspiration specimens 
are available such as lung, breast, ovarian, and prostate cancer.  
1.8 SUMMARY AND DISSERTATION OVERVIEW 
The preceeding sections detail the clinical need and challenges associated with 
early detection of oral cancer and characterization of high-risk premalignant oral lesions, 
particularly leukoplakia. Ironically, oral cancer is well suited for early detection and 
advanced screening techniques due to the presence of pre-malignant changes that are 
visible in the oral epithelium and the easy accessibility to the oral cavity. Yet, visual 
examination alone is insufficient for early detection and while several adjunctive devices 
are currently available, they have demonstrated restricted, or in some cases un-tested, 
capacity to identify high-risk premalignant oral lesions. Suprisingly, none of these 
devices capitalize upon the diagnostic potential of emerging cancer biomarkers which 
may be detected during early stages of tumorigenesis and offer opportunities for 
increased sensitivity and specificity, particularly when used in multi-marker panels. The 
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high cost and complexity of many biomarker assay formats, along with the need for 
highly skilled technicians and long assay times, may deter their widespread application in 
cancer diagnostics and screening. Thus, new approaches toward OSCC biomarker 
detection are needed.  
The membrane-based LOC sensor approach to early detection of oral cancer 
utilizes a combination of molecular and morphological markers of malignancy in non-
invasive exfoliative cytology specimens. While morphological changes may occur 
relatively late during tumorigenesis, they form the basis for traditional cytopathologic 
examination which have long been established. This may allow potentially cancerous 
cells to be identified using standard morphological features and directly correlated with 
biomarker expression on a single-cell basis for discriminate analysis in a heterogeneous 
mixture. Further, this dual molecular and morphological approach encompasses a wide 
range of tumor phenotypes, potentially increasing sensitivity and specificity over 
conventional methods. As such, this dissertation strives to test the hypothesis that the 
membrane-based LOC sensor system can provide a suitable platform for detection of 
OSCC and high-risk oral pre-malignant lesions using well-established features of 
dysplasia, including increased nuclear size and nuclear-to-cytoplasm ratio, alone or in 
combination with the EGFR biomarker. The research objective here is not for discovery 
of new OSCC biomarkers, but to utilize previously characterized biomarkers in the LOC 
sensor as a validation tool that may facilitate clinical translation into effective 
diagnostics. Likewise, the overall aims of the work are two-fold: (1) to develop a general 
system for biomarker analysis that allows us to begin asking questions regarding the use 
of individual and multiple biomarkers to enhance early tumor detection and (2) to provide 
proof-of-concept support for the clinical application of the LOC sensor system in oral 
cancer diagnostics. With the development of a new diagnostic technique, a number of 
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questions must be addressed regarding the structure and design of the sensor, selection of 
biomarker inputs, detection modality, accuracy of detection by comparison with currently 
available techniques, and potential role in clinical practice. Points of focus for the 
dissertation include the following: 
 Can microsensor systems be used to acquire useful information about the 
clinical status of oral cancer patients? 
 What are the structure and design elements of cell capture systems that can 
be included in a microchip sensor systems targeted for oral cancer 
screening and diagnosis? 
 What are the best modes to introduce the samples into the microchip? 
 What are the best assay conditions to provide optimal sample 
visualization? 
 What are the challenges and opportunities that are presented in the 
microchip cell analysis as applied to oral cancer diagnosis? 
 Is it possible to include both morphological and molecular diagnostic 
information into the microchip cell analysis as applied to oral cancer 
diagnosis? 
 What are the best biomarkers to be included in the microchip cell analysis 
as applied to oral cancer diagnosis? 
 How do the microchip sensors systems compare to macro systems, like 
flow cytometry, for cell analysis? 
 How do the microchip sensors systems compare to standard 
histopathology and cytopathology methods? 
 What is the diagnostic accuracy of microchip cell assays as applied to oral 
cancer diagnosis? 
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 Can the microchip cell be used to screen for early signs of malignant 
transformation and cancer? 
 Can these noninvasive devices be used to provide information about 
cancer field growth? 
This research aims to contribute toward the science base that will enable the 
development of molecular diagnostic tools for early detection of oral cancer and other 
malignancies. The following chapter details the design and instrumentation employed for 
cellular analysis in the LOC sensor. In addition, the development and optimization of a 
proof-of-principle assay for the EGFR biomarker is described using in vitro tumor-
derived cell lines as models of malignant transformation. Conventional assay techniques 
served as a standard for LOC assay development with respect to intensity, homogeneity, 
and cellular localization. The efficacy of the LOC sensor for characterization of EGFR 
overexpression in three oral cancer cell lines is examined and directly compared with the 
“gold standard” technique for protein expression analysis, flow cytometry. Quantitative 
flow cytometry further served to ascertain the absolute number of EGFR receptors per 
cell in each cell line, providing a basis for relating significant differences between oral 
cell lines identified using the LOC sensor. 
Once it was established that the microchip sensor serves as a suitable platform for 
rapid, highly sensitive biomarker assays, the examination of cells from more clinically 
relevant sources was necessary. Chapter 3 serves to probe the conditions and adaptations 
necessary for the integration of exfoliative cytology specimens into the microchip sensor. 
The methods for obtaining and validating the quality of exfoliative cytology specimens 
were explored with particular considerations toward each phase of sample collection, 
processing, dissociation, and fixation in order to maintain compatibility with the 
previously established EGFR biomarker assay. In addition, factors affecting the capture 
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and dispersal of adherent epithelial cells across the membrane in the LOC sensor were 
investigated and optimized until a relatively homogeneous distribution was obtained.  
The supplemental use of Phalloidin and DAPI fluorescent stains as cytoplasmic and 
nuclear markers, respectively, served to expand the capacity of the LOC sensor for 
morphometric examination of cell and nuclear area, as well as nuclear to cytoplasmic 
ratio. These new markers presented additional requirements for multi-spectral imaging 
using X, Y, and Z-scan patterns which were further explored along with automated image 
analysis routines to obtain quantitiative measurements of biomarker expression and 
cytomorphometry. This work served to establish and refine the methods for cell-based 
assays in the microchip sensor using clinically relevant cytology specimens for the 
analysis of molecular and morphological parameters which could then be applied toward 
characterization of malignancy. 
Chapter 4 presents the initial results of a collaborative pilot study to examine the 
clinical utility of the LOC sensor for identification of oral cancer and high-risk 
premalignant lesions. The differences in EGFR expression and cytomorophometry were 
examined in normal healthy mucosa, non-dysplastic benign lesions, pre-malignant lesions 
exhibiting mild/moderate/severe dysplasia, and in SCC tumors. Particular attention was 
focused upon the value of EGFR biomarker expression, as well as the nuclear area and 
distribution, in discriminating normal epithelium from dysplasia and SCC, either alone or 
in combination using logistic regression and ROC curve analysis. When contralateral or 
“mirror-image” brush biopsies were available, they served to provide insight regarding 
the presence of field changes in the mucosal epithelium and their relevance toward early 
detection and/or monitoring. The overall performance characteristics of the microchip 
sensor were evaluated, including sensitivity and specificity, for comparison with 
conventional oral examination and other diagnostic adjunctive devices to define the 
 33
clinical role of the LOC sensor assays described herein and the necessity for additional 
biomarker validation.  
Collectively, the body of work in this dissertation lends itself to addressing the 
clinical need for new diagnostic methods targeting early OSCC tumor progression 
through the molecular evaluation of tumor biomarkers using a microchip sensor. Such 
biosensor systems may then be utilized as a clinical or translational tool to assess the 
strength of particular biomarkers, alone or in multi-marker panels, for detection of 
disease and possibly prediction of tumor behavior. Ultimately, this research aims to 
contribute toward the growing field of in vitro diagnostics using lab-on-a-chip and 
microfluidic techniques which may impact human healthcare by increasing the 
availability and access to diagnostic tests enhancing patient care and survival. 
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Chapter 2:  Development of LOC Sensor Assay for Analysis of EGFR 
Biomarker Expression in OSCC Cell Lines1
2.1 INTRODUCTION 
In the current chapter the development and optimization of an immunoassay for 
the epidermal growth factor receptor (EGFR) using LOC sensor techniques is presented. 
The purpose of this chapter is to evaluate and define the appropriate sensor design 
elements, as well as the assay and imaging parameters, relevant to the cellular analysis 
capability of the LOC sensor system. Toward this goal, in vitro tumor-derived cell lines 
are employed as models of malignant transformation in which EGFR expression can be 
characterized using standard immunophenotyping techniques for methods comparison 
and correlation with the microchip sensor. This chapter is organized in the following 
manner, beginning with background information on the function of the EGFR and its role 
in tumorigenesis. The LOC sensor platform is described along with the “on-membrane” 
EGFR assay development and optimization methods. The homogeneity, localization, and 
labeling times in the microchip sensor will be explored and directly compared with 
conventional immunolabeling techniques. The capacity of the LOC sensor for 
characterization of biomarker expression in OSCC tumor-derived cell lines will be 
evaluated by direct comparison and correlation with flow cytometry.  
The epidermal growth factor receptor has emerged as a prominent biomarker 
whose overexpression has been characterized in a number of epithelial malignancies 
occurring in the lung, breast, head and neck, glioma, colon, bladder, and ovary.106, 107 
EGFR (also known as erbB-1 or HER1) is a 170-kDa transmembrane protein belonging 
 
1 Portions of this chaper have been published previously in Weigum, S.E., Floirano, P.N., Christodoulides, 
N., and McDevitt, J.T. 2007. Cell-based Sensor for Analysis of EGFR Biomarker Expression in Oral 
Cancer. LabChip. 7(8), 995-1003. 
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to the erbB/HER family of receptor tyrosine kinases. Structurally, EGFR consists of an 
extracellular N-terminal ligand-binding domain with two cysteine rich regions, a 
membrane spanning domain, a juxtamembrane regulatory domain, and an intracellular C-
terminal domain containing protein kinase activity and multiple phosphorylation sites.108 
A variety of ligands can bind EGFR receptors including epidermal growth factor (EGF), 
transforming growth factor-α (TGF-α), amphiregulin, heparin-binding EGF-like growth 
factor, betacellulin, and epiregulin.109, 110 Upon ligand binding, the EGFR receptor 
dimerizes, forming either homo- or hetero-dimers with other erbB/HER family members, 
which in turn stimulates autocatalytic tyrosine kinase activity. Activated EGFR 
subsequently recruits and trans-activates cytoplasmic signaling complexes that initiate 
downstream signal transduction pathways, such as the ras-mitogen activated protein 
kinase (MAPK) pathway, signal transducers and activators of transcription (JAK/STAT) 
pathway, phosphatidylinositol-3-kinase (PI3K)-Akt pathway, and phospholipase C 
gamma (PLC-γ) pathway. These pathways regulate transcription of powerful oncogenes 
involved in cell proliferation, differentiation, survival (protection from apoptosis), 
angiogenesis, adhesion, and migration (Figure 2-1).106, 108  
 
 
Figure 2-1. General schematic of EGFR signal transduction following ligand binding 
and receptor dimerization. Pathways involved include Ras/MEK/MAPK pathway 
(purple), JAK/STAT pathway (green), PI3K-Akt pathway (red), and PLC-γ pathway 
(blue) resulting in transcriptional activation of oncogenes promoting tumor cell growth 
and proliferation, angiogenesis, survival (anti-apoptosis), invasion, and metastasis.  
Alterations in EGFR and its signaling pathways have been directly linked with 
malignant transformation and uncontrolled cell growth in a variety of epithelial and non-
epithelial cancers.106 Mechanisms include genetic mutation, over-expression of the 
receptor and/or ligands, structural rearrangement, or loss of inhibition and regulatory 
constraints. The oncogenic effect of these alterations is attributable to excessive EGFR 
activity in either a ligand dependent or independent manner. For example, a truncated 
EGFR mutant (EGFRvIII) containing a 268 amino acid deletion in the extracellular 
domain has been identified in up to 40% of glioblastomas, as well as cancers of the 
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breast, lung, ovary, and prostate.111, 112 This EGFRvIII mutant exhibits constitutive 
activity functioning in the absence of ligand binding and has been associated with 
enhanced pathogenicity and chemotherapeutic resistance.111, 112 
2.1.1 EGFR in Oral Cancer: Diagnostic and Prognostic Significance   
EGFR has been extensively studied in the pathogenesis of oral cancer with 
significant implications toward diagnosis, prognosis, and treatment selection. 
Overexpression of both EGFR and its ligand, TGF-α, are common in head and neck 
squamous cell carcinomas (HNSCC) as demonstrated by elevated mRNA levels in 92% 
and 87% of tumors, respectively.70 EGFR protein overexpression has also been reported 
in 34-80% of HNSCC tumors detected using immunohistochemistry (IHC).58, 70 This 
overexpression is primarily due to epigenetic mechanisms where transcriptional 
activation becomes dysregulated resulting in increased mRNA synthesis and decreased 
downregulation.70, 110 EGFR gene amplification appears to play only a minimal role in 
EGFR overexpression in HNSCC.113 Site-specific differences in EGFR expression occur 
within the general category of head and neck SCC where laryngeal tumors demonstrate 
reduced EGFR expression compared to those in the pharynx and oral cavity.108  
Two lines of evidence suggest that EGFR overexpression occurs early during 
tumorigenesis: (i) presence in pre-malignant or dysplastic lesions and (ii) presence in 
clinically normal tissue adjacent to SCC tumors. Shin et al. demonstrated a two-step 
increase in EGFR protein expression where EGFR was elevated 2-fold in dysplastic, 
hyperplastic and normal tissue adjacent to SCC tumors above healthy control tissue.114 A 
second significant increase was observed at the transition from dysplasia to SCC.114  In 
agreement with this finding, Grandis et al. reported 29-fold increase in EGFR mRNA in 
histologically normal tissue from SCC patients and up to 69-fold increase in SCC tumors 
compared to normal control mucosa. Here, EGFR expression increased according to the 
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degree of epithelial dysplasia and distance from the primary tumor site suggesting that 
EGFR may be a useful diagnostic marker of early tumor progression. These findings also 
provide support for field cancerization where tobacco and alcohol “pre-condition” the 
epithelium toward hyperproliferation or high-risk reactive changes mediated via EGFR 
activity. 
Due to the central role of EGFR in promoting cell growth, it is reasonable to think 
that elevated EGFR activity could be related to aggressive tumor growth and repopulation 
following treatment. Therefore, EGFR has also been investigated as a prognostic marker 
for identification of OSCC patients with a high-risk of disease relapse and death, as well 
as therapeutic resistance. Indeed, several studies have associated EGFR overexpression 
with a reduction in disease-free survival and overall survival, suggesting utility as 
negative prognostic indicators either alone or in combination with additional markers.71, 
115-118 However, other studies have not found EGFR expression to be correlated with 
clinicopathological features or survival leaving the prognostic utility of EGFR unclear.119, 
120  
Interestingly, upregulation of EGFR activity has also been shown to occur in 
response to ionizing radiation such that tumors overexpressing EGFR may demonstrate 
increased resistance to chemotherapeutic agents and radiotherapy. This implies that 
EGFR status may aid in the selection of the optimum treatment and radiation scheduling. 
In HNSCC patients with high EGFR expression, Bentzen et al. reported a significant 
benefit in locoregional control from accelerated hyperfractionated radiotherapy, which in 
theory allows less time between treatments for tumor repopulation, over conventional 
fractionated therapy.121 Thus, as a biomarker EGFR may not only provide useful 
diagnostic information but enhance prognostic evaluation and treatment selection in 
patients with SCC, particularly for new EGFR molecular therapeutics in development. 
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2.1.2 EGFR-Targeted Treatment  
The pivotal role of EGFR in promoting tumor growth and malignant 
transformation make EGFR an excellent target for therapeutic intervention. EGFR 
targeted cancer therapies currently under investigation utilize immunotoxins, monoclonal 
antibodies, tyrosine kinase inhibitors, and antisense oligonucleotides to inhibit EGFR 
activation and signaling.69, 106, 122 In fact, the monoclonal antibody cetuximab (Erbitux, 
ImClone Systems Inc., New York, NY) is the first new drug to receive FDA approval for 
treatment of OSCC in over 45 years.123 Cetuximab is a chimeric mouse and human IgG1 
antibody that attaches to the extracellular domain of EGFR, thereby inhibiting ligand 
binding and receptor activation. In combination with radiotherapy, cetuximab increased 
the duration of locoregional control by 11 months and improved overall survival by 20 
months, thereby increasing the 2-3 year survival rates in patients with locoregionally 
advanced HNSCC without significantly increasing the incidence of severe (grade 3-5) 
toxicities.124, 125 Although this treatment appears promising, efficacy of cetuximab plus 
radiation as compared to standard chemoradiotherapy (CRT) remains to be 
determined.125, 126 Further, challenges remain to identify patients who may benefit most 
from this targeted therapy (i.e. patients with tumors that overexpress EGFR). 
2.1.3 Clinical Role for EGFR Biomarker Detection 
EGFR is one of the most well characterized biomarkers in OSCC that holds 
enormous diagnostic potential for early tumor detection and characterization of high-risk 
pre-malignant lesions. In addition, its association with poor prognosis suggests that 
EGFR characterization at the time of diagnosis may help to identify patients with high 
risk of recurrence and metastasis who may benefit from more aggressive treatment. Thus, 
EGFR biomarker detection in OSCC may fill multiple roles in cancer diagnostics, not 
only for early detection but at the time of diagnosis for prognostic evaluation and 
 40
treatment selection. The research presented herein describes the development of a lab-on-
a-chip sensor assay for EGFR biomarker detection using a novel membrane-based 
immunoassay technique and quantitative fluorescent image microscopy/analysis. Using 
EGFR as a proof-of-principle biomarker, general methods will be established that may be 
applied toward detection of additional clinically relevant OSCC biomarkers. Ultimately, 
this research program aims to impact human healthcare by providing a rapid, cost-
effective molecular diagnostic tool for early detection, assessment of risk, and prediction 
of therapeutic response in OSCC tumors which may improve patient prognosis and 
survival. 
2.2 EXPERIMENTAL METHODS 
2.2.1 Sensor Design and Instrumentation 
The cell-based LOC sensor is a multi-layered structure built upon a 22 x 30 x 8.6 
mm poly-methyl methacrylate (PMMA) base containing a 1mm diameter, round fluid 
inlet and outlet port (Figure 2-2a) (design and machining specifications are provided in 
Appendix A). A polycarbonate track-etched membrane, or screen filter, with 0.4µm pores 
(#HTBP01300, Isopore™ Millipore, Billerica, MA) (Figure 2-2c) and underlying support 
were embedded within the base, sealed with laminate adhesives containing a precision 
cut fluid delivery channel and topped with a glass coverslip. Laminate cut-out structures 
were created using SolidWorks® 3D CAD software and cut at 25 µm resolution using a 
SummaCut D-60 vinyl plotter cutter. Dimensions of the fluidic channel are 1 mm wide 
by 125 µm high by 8.2 mm long generating a channel volume of 1.1 µl. The circular 
membrane capture area and imaging window is 5 mm in diameter by 200 µm high 
resulting in a reaction volume of 3.9 µl above the membrane surface. Fluid and sample 
delivery was facilitated by a peristaltic pump with 6-port injection valve at flow rates 
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between 250µl/min-725µL/min. Cells retained on the surface of the membrane using this 
straightforward filtration mechanism were analyzed for protein and/or nucleic acids using 
assay-specific fluorescent labeling techniques as described below. Efficiency of 
membrane capture is dependent upon the ratio of particle size, or in this instance cell size 
(typically 10 µm), to membrane pore size (0.4 µm). According to the manufacturer, 
greater than 99% capture efficiency is obtained for particles exceeding the membrane 
pore size of 0.4 µm. 
Digital micrographs were obtained in an (X, Y) membrane scan using a 20X (0.4 
NA) or 10X (0.3 NA) objective, on an automated Olympus BX-61 modified 
epifluorescent microscope with motorized X,Y,Z stage (Prior, Rockland, MA), and 12-bit 
monochrome CCD camera (Q-Imaging, British Columbia) controlled via Simple PCI 
software (Compix Inc., Sewickley, PA).  Automated image analysis was performed using 
ImageJ (v1.38e)127  open-source software with custom written macros for quantitative 
intensity standardization and cell contouring to identify and define the boundaries of 
individual cells for measurement. As field illumination with Hg light sources is often 
non-uniform, the field uniformity was measured using FITC/GFP Fluor-Ref reference 
slide (Microscopy Education, Allen, TX) with homogeneous intensity. Typically the 
variation in field uniformity was 5.5% (mean intensity 145.4 ± 8.34) with the brightest 
intensity located at the center of the field and slightly dimmer at the edges. Thus, all 
fluorescent images were shade corrected to eliminate these variations according to Varga 
et al.128 using the equation:  
  I'x,y = Ix,y * Wmean/Wx,y  
where I' and I are the corrected image and the original image respectively; W is the bright 
(or white) reference image and x,y denotes the pixel location in each image. Relevant 
objects in each field were then identified using a basic screen according to size and 
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intensity to generate individual 8-bit single-object images. Next, auto-segmentation with 
an Otsu thresholding algorithm was performed to define the intensity contour and area-
of-interest (AOI) of each object followed by local background subtraction and watershed 
algorithms to separate touching objects. Measurement parameters included AOI area, 
perimeter, circularity, minimum and maximum intensity, mean, standard deviation, 
mode, and integrated intensity. For statistical analysis, data was exported to Microsoft® 
EXCEL® with Analyse-It® (Analyse-It Software Ltd., Leeds, UK) software and 
SigmaPlot 9.0 (Systat Software Inc., San Jose, CA) for graphical representation.  
2.2.2 In vitro cell culture 
Three human oral tumor-derived cell lines were utilized in this study including 
A253 adenocarcinoma from the submaxillary saliva gland, obtained from the American 
Type Culture Collection (ATCC); SqCC/Y1 from the bucal mucosa; and UMSCC-22A 
from the hypopharynx, both squamous cell carcinomas generously provided by Dr. 
Rebecca Richards-Kortum at Rice University. Cells were maintained in recommended 
culture media (McCoy’s 5A, DMEM-F12, and EMEM respectively) containing 1.5 mM – 
2.5 mM L-glutamine, 10% fetal bovine serum and 50µg/mL penicillin/streptomycin at 
37OC with 5% CO2 in a humidified environment. Two breast adenocarcinoma cell lines, 
MDA-MB-468 and MDA-MB-435S (ATCC), were maintained in Leibovitz’s L-15 
media, supplemented as above, at 37OC under atmospheric conditions. All cells were 
seeded at 0.5-1x104cells/cm2 in T-75 flasks and allowed to grow for 3-5 days until cells 
reached ~80% confluency. Adherent cells were harvested using 0.25% Trypsin/EDTA 
solution, washed twice in 3mL PBS (BupH™ Modified Dulbecco’s Phosphate Buffered 
Saline, #28374, Pierce/Thermo Fisher Scientific, Rockford, IL) by centrifugation at 150g 
for 5 minutes and fixed in 1mL Histochoice™MB fixative (Electron Microscopy 
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Sciences, Hatfield, PA) for 20 minutes at room temperature then stored at 4OC for up to 
two weeks.  
2.2.3 Flow cytometry and pre-labeling EGFR protocol 
EGFR labeling was performed using an indirect flow cytometry protocol for cell 
surface antigens as previously described by Hsu et al.129 Briefly, 1-2x106 cells were 
incubated in anti-EGFR mouse monoclonal antibody (10µg/ml in PBS with 0.1% BSA, 
LabVision/Thermo Fisher Scientific Inc., Waltham, MA) for 1 hr. at room temp. 
followed by goat anti-mouse IgG F(ab’)2 conjugated to AlexaFluor®488 (20µg/ml in 
PBSA, Molecular Probes, Eugene, OR) for 45 minutes. Intermediate washing was carried 
out twice in 2 mL PBSA by centrifugation at 150xg for 5 minutes. Negative controls 
replaced anti-EGFR with an irrelevant antibody of the same isotype (10µg/ml Mouse 
IgG1 in PBSA, Sigma, St. Louis, MO). Optimal primary and secondary antibody 
concentrations for use in flow cytometry and LOC assays were determined by titration. 
All labeled cell samples were analyzed on a Beckman Coulter FC500 flow cytometer or 
delivered directly to the LOC sensor serving as “pre-labeled” samples for comparison of 
immunoassay techniques.  
2.2.4 Assay development in LOC sensor 
In order to determine the optimal assay parameters for “on-membrane” labeling 
within the LOC sensor, an intensity curve was generated using A253 cells incubated for 
various time periods (0.2-2 minutes) in primary and secondary antibodies with a 2 minute 
intermediate buffer wash. Incubation time was manipulated by increasing the antibody 
sample loop size from 50-500µl while maintaining a constant flow rate of 250µl/min to 
avoid introducing variations in flow dynamics within the microfluidic channels and 
membrane chamber. Mean EGFR intensity was expressed as a percentage of the intensity 
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obtained from pre-labeled A253 cells imaged and analyzed in LOC sensor under the 
same conditions. All assays were performed in triplicate with matched isotype controls. 
In order to ensure homogeneous labeling across the membrane surface, the sample 
distribution and variation in integrated intensity of bead standards labeled in LOC sensor 
versus those pre-labeled in centrifuge tube was examined. Bead standards were obtained 
from QIFI quantitative flow cytometry kit (see below) set solution. Data acquisition and 
analysis was performed as described using a 10X objective with a 4x4 raster pattern scan 
of 11.4 mm2 of the membrane surface area. Events were gated according to ROI area and 
max pixel intensity followed by single-parameter histogram analysis of log-transformed 
integrated intensity values to obtain the geometric mean and CV of each population.  
2.2.5 EGFR in tumor cell lines 
Capacity of the LOC sensor to detect EGFR overexpression was examined in oral 
tumor cell lines using the membrane-based sensor immunoassay protocol above. The 
MDA-MB-486 cells known to overexpress EGFR at approximately 1x106 
receptors/cell129, 130 served as a positive immunolabeling control while MDA-MB-435S 
cells which express no or low levels of EGFR served as a negative control.130-132 Data 
acquisition and analysis was performed as described using a 20X objective with a 5x10 
scan pattern covering 9.12 mm2 membrane area. Integrated intensity data was not 
normally distributed; therefore, log transformation was applied to data prior to statistical 
analysis and presented in original scale for convenience. Mean integrated intensity values 
of triplicate biomarker assays were reported and 1-way pairwise ANOVA performed to 
determine statistically significant (p < 0.05) differences among cell populations. Parallel 
cell samples were labeled and analyzed via standard flow cytometry. Correlation of mean 
fluorescent intensity (MFI) obtained from flow cytometry and LOC sensor (calculated as 
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the mean of all integrated intensity values for a single cell population in LOC data) was 
assessed using linear regression with 95% confidence interval.  
2.2.6 Quantitative flow cytometry 
Quantitative flow cytometry using QIFIKIT® (#K0078, Dako Cytomation, 
Denmark) was performed on all cell lines to determine how many receptors per cell were 
being labeled. The QIFIKIT® consists of a series of bead standards with defined amounts 
of anti-CD5 monoclonal antibody immobilized on the surface to mimic cells labeled with 
primary antibody to surface antigens. Binding of fluorescently labeled secondary 
antibodies generated an intensity calibration curve from which the number of receptors 
per cell was interpolated. Bead standards and cell samples were labeled in parallel under 
the same conditions according to the flow cytometry protocol above. Data acquisition and 
analysis, including linear regression of calibration curve and calculation of antigen 
density, was completed according to manufacturer’s instructions.  
2.3 RESULTS 
2.3.1 Membrane Cell Capture  
The LOC sensor utilized an embedded size-selective membrane, functioning as a 
microsieve, to capture and screen epithelial cells from culture suspensions (Figure 2-2a). 
The flow-through design allowed cell samples and reagents to enter through the side inlet 
in the PMMA base; from here, fluid traveled up to the adhesive layers where a narrow 
channel directed fluid over the membrane then out using a bottom drain (Figure 2-2b). 
Cell capture was verified by scanning electron microscopy (SEM) of the membrane 
surface (Figure 2-2c). Once captured, cells retained on the membrane were available for 
protein expression analysis using assay-specific fluorescent labeling. This simple yet 
elegant integrated microfluidic system is shown to be functional for both cell collection 
and cell staining steps as described below. 
 
 
Figure 2-2.   Structure of membrane-based LOC sensor. (a) Schematic diagram of layered 
LOC device with embedded track-etched membrane designed for cellular capture, 
imaging and analysis. (b) Cross-section view shows continuous fluid flow path 
supporting cell capture and delivery of reagents for “on-membrane” assays. (c) SEM 
micrograph of a LOC sensor 0.4µm track-etched membrane section before (left) and after 
(right) cell capture. 
2.3.2 EGFR Biomarker Assay in LOC Sensor 
Mean fluorescence intensity of oral cancer cells immunolabeled in the LOC 
sensor for EGFR biomarker at increasing antibody incubation times under saturating 
conditions is demonstrated in Figure 2-3a. At a constant flow rate of 250µl/min, 2 
minutes of sequential primary and secondary antibody incubation resulted in an EGFR 
labeling intensity of 110 ± 10 percent of pre-labeled EGFR intensity. Thus, these 
conditions were established as the optimal sensor immunolabeling parameters 
comparable to standard protocols. Ultimately, the EGFR assay was established in the 
LOC sensor as follows: (1) cell capture of 5,000-10,000 cells at 725µl/min for 1 min.; (2) 
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PBS wash for 2 min.; (3) 10µg/ml anti-EGFR at 250µl/min for 2 min.; (4) PBS wash for 
2 min.; (5) 20µl/ml AlexaFluor-488 conjugate at 250µl/min for 2 min. immediately 
followed by automated imaging and analysis.  
A surface plot of cell subsets from the LOC sensor assay at 2 min. and pre-labeled 
cells further demonstrates equivalent EGFR intensity obtained using the “on-membrane” 
sensor immunolabeling technique (Figure 2-3b). In addition, the surface contour reveals 
cellular localization of EGFR primarily at the cell surface, as expected for a membrane-
bound receptor, using both methods. Direct comparison of immunolabeling schemes 
exhibits a greater than 10-fold reduction in assay labeling time using the integrated 
microfluidic cell collector-detector methodology. Here EGFR biomarker detection was 
completed in 9 minutes, which accounts for cell capture, antibody incubation, and brief 
buffer washes between reagents, whereas the pre-labeling/flow cytometry protocol 
required 2 hrs and 5 min (Figure 2-3c).   
 
Figure 2-3.  Optimization of EGFR immunoassay in LOC sensor. (a) Line graph of 
EGFR fluorescent labeling intensity obtained using LOC sensor “on-membrane” staining 
of A253 cells at various antibody incubation times from 10-120 seconds. Results are 
expressed as a percentage of the EGFR intensity found when cells were pre-labeled 
according to a standard flow cytometry protocol. (b) A surface intensity plot of select 
cells from the LOC sensor assay at 120 seconds (top) and pre-labeled cells (bottom) 
shows relative EGFR intensity and membrane localization. (c)  Bar graph comparing 
stepwise immunolabeling time in LOC sensor and pre-label protocol. 
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2.3.3 Homogeneous Labeling in Sensor 
With the “on-membrane” sensor immunoassay technique it is important that all 
cells are adequately labeled regardless of their spatial location on the membrane. In order 
to assess labeling spatial homogeneity, single-parameter intensity histograms of EGFR 
pre-labeled bead standards versus those labeled within LOC sensor were examined 
(Figure 2-4). A gating scheme, similar to those utilized in flow cytometry, was 
implemented according to visual observation of a 2-D scatter plot using area and 
maximun pixel intensity parameters as demonstrated in Figure 3 inset. Here, a large 
cluster of measured objects are clearly seen near an area of 200 pixels with a smaller 
cluster found at 400 pixels, approximately double, suggesting the presence of bead 
doublets that were not separated during image processing. This finding was confirmed by 
tracing individual measurements in each of these two populations back to the original 
LOC images as shown. Thus, data was filtered according to user-established area and 
max pixel intensity thresholds in order to exclude these doublets and higher level 
aggregates along with debris, from each data set for further calculations. Comparison of 
the histogram CVs, which provide a measure of variation within each sample population, 
shows narrow peak distributions with a slightly lower CV found for the LOC sensor 
labeled beads (1.7%) versus beads pre-labeled in centrifuge tube (2.1%) (not analyzed for 
statistical significance). Hence, the LOC sensor provided homogeneous immunolabeling 
of the bead population across the membrane surface comparable to current in-tube 
labeling methods.  
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Figure 2-4.  Frequency histograms of bead standards labeled “on-membrane” in LOC 
sensor (green) and pre-labeled in centrifuge tube (black overlay) for comparison of 
immunolabeling homogeneity in the microchip sensor versus conventional methods. A 
rectangular gate according to object area and max pixel intensity (inset) was utilized in 
order to eliminate debris and bead doublets from histogram analysis and statistics which 
was verified using raw images of events, or in this case beads. The geometric mean and 
CV are reported for each population containing approximately 1000 events each. 
2.3.4 EGFR in OSCC Cell Lines 
Fluorescent micrographs of EGFR detected in tumor cell lines using the LOC 
sensor are presented in Figure 2-5a. Visually, EGFR expression was demonstrated in all 
oral cancer cell lines (ii-iv) and in MDA-MB-468 cells (i) known to overexpress EGFR. 
The MDA-MB-435S cells, previously reported to express no or very low levels of EGFR, 
demonstrated slight staining intensity (v) while isotype controls were indistinguishable 
from background fluorescence (vi). Subsequent automated image analysis revealed 
quantitative differences in EGFR intensity with significantly elevated levels found in 
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MDA-MB-468, A253, SqCC/Y1, and UMSCC-22A cells compared to MDA-MB-435S 
negative control cells (Figure 2-5b). The three oral cancer cell lines appeared to cluster at 
similar EGFR expression levels, although A253 cells exhibited a significant increase 1.5-
fold over UMSCC-22A cells. In order to validate the LOC sensor assay methodology, 
parallel cell samples were stained and analyzed using flow cytometry, the gold standard 
in cellular protein expression analysis. The lab-on-a-chip sensor EGFR immunassay 
results displayed a high degree of correlation (r2 = 0.98) with 95% confidence interval to 
conventional flow cytometry (Figure 2-5c). 
 
Figure 2-5.  Detection of EGFR overexpression using LOC sensor. (a) Fluorescent 
micrographs of EGFR sensor immunoassays in cancer cell lines (i) MDA-MB-468; (ii) 
A253; (iii) SqCC/Y1; (iv) UMSCC-22A; (v) MDA-MB-435S; and (vi) isotype control. 
(b) Examination of EGFR expression using automated image analysis macros shows 
mean integrated intensity ± SD of triplicate EGFR assays with statistical differences 
found between all cell lines and MDA-MB-435S negative control (p < 0.05). Among the 
oral cancer cell lines, A253 and UMSCC-22A also exhibited statistical differences in 
EGFR expression (p < 0.01) denoted with *. (c) Correlation of mean fluorescent intensity 
(MFI) obtained from LOC expression analysis with standard flow cytometry shows a 
high degree of correlation (r2 = 0.98) at the 95% confidence interval (dashed lines). 
 
2.3.5 Quantitative Flow Cytometry 
In order to further understand the cellular differences detected by the LOC sensor, 
the number of EGFR receptors per cell was determined in all cell lines by quantitative 
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flow cytometry using QIFIKIT® analysis (Figure 2-6). In agreement with the results 
achieved on the LOC system, MDA-MB-486 cells exhibited the highest EGFR 
expression at a density of 8.1x105 receptors per cell, followed by A253 (2.7x105 
EGFR/cell), SqCC/Y1 (2.5x105 EGFR/cell), UMSCC-22A (2.3x105 EGFR/cell), and 
MDA-MB-435S cells with less than 0.2x105 EGFR/cell. Although normal oral epithelium 
was not examined in this study, previous investigators have reported ~0.3x105 EGFR 
binding sites per cell in normal cervical squamous epithelium131 similar to MDA-MB-
435S cells presented here. Thus, MDA-MB-435S cells more closely model a “normal” 
control rather than a true EGFR negative control as does the isotype. Attempts at EGFR 
quantitation in the LOC sensor using QIFI standards was unsuccessful as presented in 
Appendix C. 
 
Figure 2-6.  Quantitative flow cytometry. Standard curve generated from flow 
cytometric analysis of QIFI bead standards for interpolation and quantification of EGFR 




In the present study, we describe the development of a cellular biomarker assay 
for EGFR towards the establishment of a lab-on-a-chip sensor for early detection of oral 
cancer. Current methods for detection of cellular biomarkers, such as slide-based 
immunohistochemistry and flow cytometry, require extensive sample preparation, long 
incubation periods and repeated washing steps which may result in sample loss. In 
contrast, the optimized LOC sensor assay was completed in less than 10 minutes using a 
constant flow “on-membrane” staining technique while maintaining labeling intensity 
and homogeneity comparable to standard protocols. These results support the use of the 
LOC sensor platform for rapid cellular immunoassays, in less than one-tenth the labeling 
time of conventional techniques, which is highly desirable for diagnostic testing devices 
and point-of-care applications. 
Using in vitro tumor cell lines to serve as a model for the biomarker expression 
levels found in healthy and diseased patients, we have demonstrated successful 
characterization of EGFR overexpression in OSCC cells. As shown in Figure 2-5, MDA-
MB-468, A253, SqCC/Y1 and UMSCC-22A, with a mean EGFR range from 36.3x103 to 
169.6x103, exhibited EGFR intensities significantly above control MDA-MB-435S cells 
with a mean of 5x103 and EGFR expression similar to normal squamous epithelium.131 
Thus, there is roughly a 7- to 10- fold difference between MDA-MB-453S cell intensity 
and the three oral cancer cell lines, UMSCC-22A, SqCC/Y1, and A253. With respect to 
the MDA-MB-468 cell line, known to strongly over-express EGFR, this factor goes up to 
as high as 33. For each of these cell lines, an analysis of the sample distribution of cell 
fluorescence intensities shows a log-normal distribution with the coefficient of variation 
(CV) values in the range of 3% to 5%. Since the differences in the mean intensity values 
far exceed the population differences as manifested in their modest CV values, the 
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prospect for differentiating the various cell phenotypes based upon EGFR expression is 
quite good for the method herein described. 
Furthermore, if a threshold for normal EGFR expression is established based upon 
the sample distribution and variance for the MDA-MB-435S cell line located 2 standard 
deviations above the mean EGFR intensity (8.84x103), then all cells intensities above this 
threshold could be classified as EGFR over-expressed. Using this criteria, the oral cancer 
cell lines A253, SqCC/Y1 and UMSCC-22A in addition to MDA-MB-468 are 
characterized as over-expressing the EGFR biomarker.   
The LOC sensor assays were well correlated to flow cytometry, the current 
clinical standard in cell-based protein expression analysis with r2 = 0.98. Corresponding 
quantitative flow cytometry revealed a mean EGFR/cell of 2.5x105 among the OSCC cell 
lines, far exceeding the expression level found in MDA-MB-435S cells (0.2x105 
EGFR/cell) similar to normal squamous epithelium, but below MDA-MB-468 cells 
(8.1x105 EGFR/cell) known to strongly over-express EGFR. In agreement with LOC 
results, quantitative flow cytometry suggests that EGFR is over-expressed in these OSCC 
cell lines, although to a lesser extent than MDA-MB-468 cells. Taken together, these 
results support the lab-on-a-chip sensor system as a suitable platform for analysis of 
EGFR cellular biomarker expression. Further validation via a small pilot study examining 
OSCC patients versus normal healthy controls is warranted and necessary to establish the 
sensitivity and specificity of this EGFR biomarker assay in clinical applications. 
Although tumor cell lines make excellent models for assay development, there are 
fundamental differences likely to be encountered in clinical samples from cancer patients. 
In particular, heterogeneous cell populations containing both normal and cancerous cells 
are expected, compared to the relatively homogeneous cell line populations utilized in the 
current study. Should this be the case, future clinical measurements may rely on the 
 56
identification of cell sub-populations and percentage of cells over-expressing EGFR. In 
addition, the presence of EGFR negative cells may necessitate the use of secondary 
cellular fluorophores labeling cytoplasmic and/or nuclear structures independent of 
EGFR expression in order to identify cells for measurement. This multi-spectral labeling 
strategy could further exploit the image cytometry capabilities of the sensor system to 
incorporate cytomorphological analyses such as cell size and nuclear-to-cytoplasm ratio 
which are often altered during tumorigenesis. Thus, potentially cancerous cells could be 
identified using traditional pathological features and directly correlated with specific 
biomarker expression on a single-cell basis.  
Ability of the LOC sensor to characterize cell samples based upon intrinsic EGFR 
biomarker expression, or in combination with other cytomorphological markers, is 
governed by the quality of cell labeling and fluorescent imaging. Each of these areas 
must be considered carefully and optimized in a systematic manner in order to extract 
meaningful information regarding cellular phenotype during image analysis procedures. 
While it is beyond the scope of this manuscript to provide an exhaustive discussion of 
these areas, some of the more key issues related to the LOC sensor are discussed briefly 
here.  
The flatness of the membrane and the associated support is one of the most 
important variables affecting cell imaging. If the membrane deflects under the influence 
of the fluid flow, some of the cells will move out of the plane of focus. In order to 
minimize this effect the LOC sensor utilizes a planar track-etched membrane with a 
smooth glass-like surface which maintains captured cells on the surface of the membrane 
at similar heights as compared to the uneven fiber matrices found in depth-type filters. In 
addition, application of microscope-based autofocusing on each field of view further 
compensates for focal variations due to minute fluctuations in membrane flatness. 
 57
Alternatively, acquisition of multiple Z-plane images for selection of the best focused 
image or deconvolution may be utilized for similar purposes in future analyses.  
The amount of acceptable deviation from the ideal planar geometry depends on 
the depth of field and the numerical aperture of the optical objective used. While higher 
NA affords better light collection, the lower NA values provide increased depth of field 
enabling all cells within the field of view to be imaged in a single focal plane. The 
microscope objective utilized in these studies had a 10X magnification with a low 
numerical aperture of 0.3 yielding a depth of field of 5.8 µm. Although this depth of field 
is less than the typical cell size of 10 µm, in practice the LOC sensor appears to 
adequately represent fluorescent intensities obtained from the entire cell as demonstrated 
by the excellent correlation of LOC EGFR analysis with flow cytometry. Further use of 
deconvolution and extended-depth-of-field algorithms may enable more quantitative 
image analysis applications in future analyses. 
Background fluorescence intensity is another factor that is important to successful 
cellular analysis. Here the choice of materials to construct the imaging chamber and 
membrane support is essential. Low fluorescence plastics like PMMA and glass slides are 
used for the current studies and found to be adequate for this purpose. For the cell line 
with the lowest EGFR expression level (i.e. MDA-MB-453S), an estimate of the number 
of copies of EGFR per cell for this protein is 20,000. Even with this cell system having 
the lowest number of fluorophores thereon, a signal (on cell) to background (off cell) 
ratio of 0.6 and a signal-to-noise ratio of 10.5 was obtained. For the other cancer cell 
lines, signal-to-background (S/B) ratios in the range of 4 to 20 were obtained. These 
values serve to establish a contrast level that is readily exploited for the recognition of the 
cellular objects from the digital images.  
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2.5 CONCLUSIONS 
This body of work demonstrated the design and development of a cell-based lab-
on-a-chip sensor supporting rapid immunoassays for biomarker expression. Using EGFR 
as a proof-of-principle biomarker, the sensor demonstrated capacity to characterize 
EGFR overexpression in less than one-tenth the time of traditional methods and to 
discriminate between closely related sample populations. As a clinical tool, such assays 
may fill multi-functional roles in cancer diagnostics (i) as an early detection device 
screening pre-malignant oral lesions and (ii) as an adjunct to surgical pathology providing 
a molecular basis for prognostic evaluation and therapeutic selection. 
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Chapter 3:  Integration of Exfoliative Cytology in LOC Sensor Assays 
3.1 INTRODUCTION 
In the previous chapter, the membrane-based lab-on-a-chip sensor was shown to 
support cellular biomarker assays which may aid in the early detection of oral cancer 
using in vitro tumor-derived cell lines. While these cell lines serve as an excellent model 
for tumorigenesis, further development of the LOC sensor system for diagnostic and 
translational purposes must employ cells from more clinically relevant sources. The use 
of exfoliative cytology offers a rapid, non-invasive method to obtain a sampling of 
epithelial cells from mucosal membranes which may be subjected to microscopic or 
molecular examination for signs of malignancy. This chapter strives to develop the 
practical methods for analysis of exfoliative cytology using the LOC microchip 
technique. The chapter is organized in the following manner beginning with background 
information regarding the current methods and applications of exfoliative cytology 
followed by the specific challenges existing in the imaging and analysis of once adherent 
epithelium in the LOC sensor. The optimal cell sampling and processing methods, 
including the necessity for cell dissociation, fixation, and permeabilization, will be 
critically evaluated along with the appropriate conditions for sample introduction and 
capture on the sensor membrane. A variety of cytoplasmic and nuclear markers will be 
examined, as well as the requisite z-scan imaging parameters. In addition, a detailed 
description of the data extraction and analysis approach employed with this new 
automated cytology technique will be provided. Implications of such techniques in 
disease diagnostics will be discussed with the overall goal of establishing the precedent 
for Chapter 4 in which the clinical utility of these new automated cellular analysis 
methods will be explored. 
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Cytopathology has been successfully utilized for cervical cancer screening for 
over 50 years and has also been applied toward detection of malignancies in the lung and 
respiratory tract, breast, female genital tract, digestive tract, oral cavity, urinary tract and 
the prostate.133 However, traditional cytopathology for early detection of oral cancer has 
long been viewed unfavorably with limited diagnostic ability and low sensitivity. This 
has frequently been attributed to poor or inadequate cell sampling and subjectivity 
associated with cytologic interpretation and diagnosis.134 Recent improvements in 
specimen collection and quantitative image analysis techniques, including 
cytomorphometry and DNA aneuploidy, have helped to overcome these past limitations 
stimulating a renewed interest in cytology for detection of oral malignancies.135 In 
addition, exfoliative cytology has emerged as an excellent, non-invasive method to obtain 
cellular material for DNA-, RNA-, and protein-based analysis of tumor biomarkers 
shifting the clinical impact of oral cytology toward molecular diagnostic techniques.135 
Bringing these two approaches together on a single microchip platform for molecular and 
morphological analysis in oral cytology may further enhance their role and utility in 
clinical diagnostics.  
3.1.1 Exfoliative Cytology Sample Collection Techniques  
Exfoliative cytology cells may be found naturally in biological fluids, such as 
sputum and saliva, or collected by brushing, scraping, or rinsing of the tissue surface. A 
cytobrush, such as the OralCDx® brush biopsy instrument (OralScan Laboratories Inc., 
Suffern, NY), is used most frequently and appears to provide an full trans-epithelial 
sampling of cells from the basal, intermediate and superficial layers.76 Sampling through 
the entire thickness of epithelium, particularly the basal cells, is crucial for early 
detection of oral cancer because dysplasia or other signs of malignancy are first apparent 
in the basal epithelium while morphology of the upper layers may appear cytologically 
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normal. Poor or inadequate cell sampling limited to the superficial cell layers is 
frequently associated with the low sensitivity originally found with oral cytopathology.136  
Characterization of oral cytology is typically based upon available features of 
dysplasia including variations in cell size and shape, presence of enlarged and irregular 
nuclei, increased nuclear-to-cytoplasm ratio, hyperchromatism, presence of mitotic 
figures, and irregular keratinization (Table1-2).133, 134 Thus, cytopathology suffers similar 
limitations as histology where subjectivity exists in determining the extent of abnormality 
present and the significance of individual dysplastic features, particularly in pre-
malignant stages, which has restricted the clinical value of oral cytology in the past. 
Attempts to reduce subjectivity of cytopathologic diagnosis have implemented computer-
assisted image analysis techniques, quantitative measurement of cellular and nuclear 
morphometry, DNA cytometry, and/or tumor biomarkers. 76, 137, 138 
3.1.2 Exfoliative Cytology Applications 
3.1.2.1 OralCDx® with Computer-assisted Analysis 
As described previously, the OralCDx® system is a slide-based cytopathology test 
with computer-assisted analysis utilized for screening and detection of high-risk oral 
lesions. According to Sciubba et al., the OralCDx® test employs a neural network-based 
image-processing system to identify epithelial cells with abnormal cellular morphology 
and keratinization, indicative of malignancy.76 As few as two abnormal epithelial cells 
are reported to be detectable among thousands of cells in a brush biopsy specimen.76 
These “abnormal” cells are then reviewed by a trained pathologist who interprets 
cytologic images and makes a final diagnosis.76 Although the OralCDx® system shows 
promise, numerous discrepancies have been described regarding the true sensitivity and 
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specificity of this technique for identification of high-risk pre-malignant lesions with a 
number of false-negative and false-positive test results having been reported.83 
3.1.2.2 Cytomorphometry and DNA Aneuploidy 
Application of other quantitative techniques, such as cytomorphometry and 
image-based DNA cytometry, have also shown efficacy for characterization of malignant 
change in exfoliative cytology specimens. Morphometric features examined often include 
nuclear and cytoplasmic area, diameter, or perimeter, and the nuclear-to-cytoplasmic 
ratio (N/C ratio). Using image-based cytomorphometry to assess cellular and nuclear 
diameter, Ramaesh et al. demonstrated a progressive decrease in mean cell diameter, 
from 51.8 µm in normal epithelia to 38.6 µm in SCC lesions.137 This coincided with an 
increase in nuclear diameter, found to be highest in SCC and dysplasia (10.1 µm and 9.0 
µm, respectively) compared to non-dysplastic lesions and normal epithelia (8.3 µm).137 
These studies suggest that a reduction in cellular size and increase in nuclear size are 
valuable indicators of malignant transformation. However, using cytomorphometry alone 
a rather low sensitivity of 77% was reported for identification of pre-malignant 
leukoplakia lesions. It remains unclear if this low sensitivity is truly representative of the 
technique or a result of the absense of basal cells when using a wooden spatula for 
cytology collection, frequently seen in these earlier studies.139  
Additional research further suggests that a combination of cellular/nuclear 
morphometry and DNA ploidy profiles can help to discriminated malignant and pre-
malignant lesions from normal cytology specimens with a low rate of false negatives, 
which has plagued oral cytology in the past.138, 140 Change in DNA content or 
chromosome number, also known as aneuploidy, results from unbalanced chromosomal 
segregation during mitosis and is thought to be the most prevalent genetic alteration 
reported in over 20,000 solid tumors analyzed to date.141 High sensitivity and specificity 
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have been reported using DNA image cytometry for tumor characterization with strong 
implications toward early identification of lesions with a high-risk of malignant 
progression.142-144 While there is a very solid research based for the use of DNA ploidy as 
an indicator of malignancy, much of the literature focused upon DNA cytometry in oral 
cancer authored by J. Sudbo is not considered to be reliable, leaving the role of DNA 
ploidy in oral cancer uncertain and in need of further validation.145 
3.1.2.3 Immunohistochemistry  
The identification of tumor biomarkers in exfoliative cytology has generated 
considerable interest toward early detection of oral cancer.146 In particular, the profile of 
cytokeratin expression, which provides useful information on cell differentiation status, 
has been widely examined, but with limited diagnostic success due to the complexity of 
cytokeratin expression patterns and presence in normal epithelia.146 Nonetheless, Ogden 
et al. have shown cytokeratin-8 and -19 to be useful indicators of malignancy, 
particularly when assessed in conjuction with DNA content or ploidy status.146, 147 The 
p53 immunoreactivity has also shown diagnostic value in oral cytology, although, 
immunoreactivity is not necessarily indicative of p53 mutation which has been reported 
in approximately 50% of OSCC tumors. Further, p53 expression may be associated with 
advanced stage disease restricting its utility for early detection and diagnosis.148 Other 
tumor-related proteins detectable by immunohistochemistry in exfoliative cytology with 
varying degrees of success include laminin-5,74 tenascin-C,149 and minichromosome 
maintenance proteins (Mcm-2/Mcm-5).150 While immunohistochemistry is a very useful 
technique, many of the markers present in oral tumors are also present at various 
expression levels in normal mucosa and/or benign conditions necessitating the use of 
more quantitative biomarker approaches and advanced image analysis techniques.146  
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3.1.2.4  Molecular Analysis 
Over the past 20 years, a shift from histopathology toward molecular methods has 
occurred in disease diagnostics, and exfoliative cytology has emerged as a rapid, non-
invasive method to obtain cellular material for such analyses.146 Molecular techniques 
applied toward exfoliated cytology have included fluorescent in situ hybridization 
(FISH),78 analysis of genomic instability via loss of heterozygosity (LOH) and 
microsatellite markers,73 gene expression,77 and proteomic profiling.75 There appears to 
be a high correlation between the molecular changes present in tumor biopsy tissue and 
those found in exfoliated cells.6 In one study by Rosin et al. LOH, or allelic loss, was 
evaluated in brush cytology specimens with a nearly identical pattern of loss seen in 
corresponding biopsy tissue at the same site.6, 151 As stated earlier, molecular-level 
changes can occur prior to the appearance of microscopically or clinically apparent 
abnormalities. Thus, examination of exfoliated cells for molecular or protein biomarkers 
opens new opportunities for early detection and diagnosis, as well as monitoring the 
progress of lesions during treatment and follow-up.6 
The purpose of this chapter is to develop the practical methods for analysis of 
exfoliative cytology using the LOC microchip technique. The integration of exfoliative 
cytology into the microchip sensor presents a number of opportunities as well as a 
number of significant new challenges for sample processing and imaging of these 
naturally adherent cells. Relative to the simple non-adherent cell suspensions examined in 
the previous chapter, it is clear that additional cytoplasmic and nuclear markers are 
required for the microchip analysis of the cytology samples as demonstrated in Figure 3-
1. This example highlights the approach described in this chapter for transitioning sensor 
assays and methods from tumor cell lines to more complex epithelial cytology specimens. 
The origin of this challenge can be seen in Figure 3-1(a) and (b), i, where cultured cells 
are readily apparent based soley upon EGFR labeling intensity (Figure 3-1(a), i) while 
cytology cells are not (Figure 3-1(b), i). With the addition of a cytoplasmic marker (red) 
(Figure 3-1,(b), ii), cells present in the cytology specimen materialize allowing digital 
recognition of individual cells. However, when cells are touching, as is often found in 
these cytology specimens, the cytoplasmic marker alone poorly delineates the appropriate 
divisions between cells due to the irregular cell shape and borders. Thus, the nuclear 
marker serves to identify the number of cells present, which provides additional 
information from which to define the divisions between adherent cells. These new modes 
of data collection, made necessary with the more difficult sampling and imaging 
challenges, provide an opportunity to explore morphological features of malignancy 
which have been well established in cytopathology for decades.  
 
 
Figure 3-1. Representative cells from in vitro tumor-derived cell line SqCC/Y1 (a) and 
healthy exfoliated brush cytology specimen (b) for analysis of EGFR expression (panel i) 
and cytomorphometry, using dual cytoplasmic (phalloidin, panel ii) and nuclear (DAPI, 
panel iii) markers. The combination of nuclear and cytoplasmic markers (RGB, panel iv) 
allows identification and separation of each epithelial cell for measurement.  
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3.2 EXPERIMENTAL METHODS  
3.2.1 Exfoliative Cytology Sample Collection, Dissociation and Fixation 
Exfoliative cytology specimens were collected using the OralCDx® biopsy brush 
according to manufacturer’s protocol. Briefly, the nylon brush was placed firmly against 
the buccal mucosa of healthy volunteers and rotated 10-15 times while applying moderate 
pressure. The appearance of pinpoint bleeding signified breach of the basement 
membrane and biopsy depth through the full-thickness of the epithelium. Cells were 
released from the biopsy brush and suspended in 5 mL cold Eagle’s Minimum Essential 
Media (EMEM) culture media supplemented with 2 mM L-glutamine and 10% fetal 
bovine serum using vigorous agitation for 15-30 seconds. Culture media was removed by 
centrifugation at 1200 rpm for 5 minutes. Cells were then washed twice in 3 mL PBS 
buffer (BupH™ Modified Dulbecco’s Phosphate Buffered Saline Packs #28374, 
Pierce/Thermo Fisher Scientific, St. Louis, MO) by centrifugation at 1200 rpm for 5 
minutes.  
Cell dissociation was investigated using a variety of mechanical and enzymatic 
methods. Mechanical methods included vortexing (Vortex-Genie 2, setting 7.0) for 5 
minutes, shear stress with a 27 ½ gauge needle (approximately 10 aspirations), and 
straining through 35 µm mesh built into the cap of a 12 x 75 mm flow cytometry tube 
(BD Falcon #352235). Enzymatic treatments included 0.025%-0.25% trypsin-EDTA 
(Gibco #25200-056), Versene™ (Gibco #15040), 50 U/mL – 100 U/mL Collagenase 
Type-1 (Gibco #17100-017), and 0.5 U/mL – 1.0 U/mL Dispase (Gibco #17105-041) at 
durations ranging from five minutes to one hour. Following dissociation, cells were 
stained with 0.4% Trypan blue solution (#T8154, Sigma-Aldrich, St. Louis, MO), using a 
1:1 mixture of staining solution and cell suspension, for evaluation of viability and 
dissociation efficiency using a bright field hemacytometer. The relative ranking of each 
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method was based upon the presence of intact squamous cells, moderate clustering (<10 
cells each), extra-cellular debris, isolated nuclei, and extent of membrane folding using 
an arbitrary scale of (+) poor, (++) fair, (+++) good, and (++++) excellent. The effect of 
fixation on EGFR biomarker immunolabeling was examined by flow cytometry in the 
OSCC cell line, SqCC/Y1, cultured in vitro and labeled for EGFR biomarker according 
to previously established protocols.152 Fixation was typically carried out prior to 
immunolabeling in 1 mL of 0.5% - 4% formaldehyde in PBS buffer at 40C for 20 minutes 
to 1 hour or in commercially available fixatives according to manufacturer’s instructions. 
These included Histochoice™-MB fixative (#64115) from Electron Microscopy Science, 
Hatfield, PA; Cyto-Chex® Cell Preservative (#213350) from Streck, Omaha, NE; and 
Cytofix/Cytoperm™ (#554714) from BD Biosciences, San Diego, CA. Following 
fixation, cells were washed twice in PBS buffer, immunolabeled with anti-EGFR mAB 
followed by AlexaFluor®-488 fluorescent secondary antibody as described using in-tube 
flow cytometry protocol, and analyzed on an FC500 Beckman Coulter flow cytometer.152 
Negative controls replaced anti-EGFR antibody with an irrelevant antibody of the same 
IgG1 isotype. Flow cytometry data was collected in the FS (linear), SS (linear) and FL-1 
(log) channels then exported to WinMDI2.9 software, available from the Scripps 
Research Institute (http://facs.scrips.edu), for analysis. Events were gated upon forward 
and side scatter parameters and analyzed via single-parameter EGFR intensity histograms 
with user-defined region markers roughly centered on each peak allowing statistical 
evaluation of the mean intensity and coefficient of variation. Signal to background (S/B) 
ratios were calculated by subtracting the mean of the isotype, or background, from the 
mean EGFR signal, divided by the background also represented as [(mean M2 – mean 
M1)/mean M1]. Fixed cells were stored in PBS with 0.1% BSA (PBSA) at 40C for up to 
1 week. 
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3.2.2 Labeling of Basal Cells  
Brush cytology specimens were collected and processed as described above then 
labeled in the LOC sensor using either 10 µg/mL AE1 (#ab3117, Abcam Inc., 
Cambridge, MA) in PBSAT followed by a secondary fluorescent staining cocktail 
containing 20 µg/mL goat anti-mouse/AlexaFluor®-488 conjugate in PBSAT or 1:30 
dilution of cytokeratin-14 Ab (#2001-1, Epitomics Inc., Burlingame, CA) in PBSAT 
followed by 20 µg/mL goat anti-rabbit/AlexaFluor®-488 secondary antibody conjugate 
in PBSAT. Counter-stains were added to the secondary antibody solution at a final 
concentration of 0.33 µM Phalloidin/AlexaFluor®-647 and 5 µM DAPI in PBSAT. The 
use of phalloidin and DAPI as cytoplasmic and nuclear markers is discussed in further 
detail below. Negative controls for AE1 and cytokeratin-14 labeling replaced primary 
antibodies with an irrelevant antibody of the same isotype or normal rabbit serum, 
respectively.  
3.2.3 Cell Capture and Dispersal in LOC Sensor  
Cell capture and dispersal on the membrane surface were optimized through a 
series of experiments altering the flow rate, from 250 µL/min – 2 mL/min, and viscosity 
of the cell suspension fluid with the addition of 0%, 20%, 40%, 50% and 60% glycerol in 
PBSA. The sample volume delivered to the membrane remained constant at 500 µL with 
a concentration of 1x103 – 1x104 cells/mL, capturing approximately 2,500 – 5,000 cells 
total. Visual assessment of cell dispersal was facilitated by the addition of DAPI (5 µM in 
PBSAT) directly to cell suspensions and manual 2 x 2 epifluorescent imaging of the 
entire membrane surface at 2.5X magnification. Alignment of images for full membrane 
representation was performed in Adobe® Photoshop®CS8.0.  
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3.2.4 Z-Scan Imaging 
A z-scan image sequence of DAPI stained nuclei (see below for details) was 
collected over a range of 50 µm at 1.0 µm intervals above and below the ideal focal 
plane, determined using autofocus routines in SimplePCI microscope software (z = 0 
with z-scan ±25 µm). Ten well-focused nuclei were selected at random and regions of 
interest (ROI) were manually drawn to encircle each nucleus for mean intensity 
measurement in the full z-sequence of 51 images. Images at 5 µm intervals (z = 0, +5, 
+10, +15, and +20 µm) were extracted from this z-scan sequence and recombined, using 
a stack focusing algorithm in ImageJ, in progressive cycles generating a single “focused” 
image consisting of one to five focal planes. Using a simple intensity thresholding and 
segmentation procedure, the total number of nuclei detectable in each focused image was 
calculated and superimposed onto the corresponding focused image in a cell subset.  
3.2.5 DAPI Nuclear Staining  
DAPI (4',6-diamidino-2-phenylindole) (#D3571, Molecular Probes Invitrogen) 
(Ex/Em 358/461 nm) stock solutions were prepared in 2 mL deionized water yielding a 
stock concentration of 5 mg/ml or 10.9 mM. DAPI staining was performed 
simultaneously with the EGFR assay, such that DAPI was directly added to the EGFR 
secondary antibody labeling solution at a final concentration of 5 µM in PBSA with 0.1% 
Tween-20 (PBSAT) and delivered to the microchip sensor at 250 µL/min for 2.5 minutes 
followed by a brief buffer wash as outlined below. DAPI filter set (#31000v2, Chroma 
Technology, Rockingham, VT) was used for imaging. 
3.2.6 Staining/Labeling with Cytoplasmic Markers 
Cell samples were collected according to the brush biopsy protocol above and 
fixed in either Histochoice-MB® or 0.5% formaldehyde fixative, or left unfixed. When 
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possible, cytoplasmic staining was performed in conjunction with the established EGFR 
assay using brush biopsy cells as detailed below. Briefly, cell capture of ~2,500 cells was 
accomplished at 2 mL/min (50% glycerol in PBSA) followed by primary anti-EGFR 
antibody labeling, and fluorescent secondary antibody labeling with intermittent buffer 
washes. Secondary antibody solution contained 5 µM DAPI for identification of nuclei. 
Imaging was carried out in a four by four X, Y raster scan of the membrane surface 
collecting three consecutive 12-bit monochrome images of the red/green/blue (RGB) 
fluorescent channels with the corresponding filter sets. 
3.2.6.1 Sulforhodamine 101 
Sulforhodamine 101 (SR101, #S359 Invitrogen Corp., Carlsbad, CA) is a 
rhodamine derivative (Ex/Em 576/593 nm) that has been reported to bind ionically and 
non-specifically to proteins enabling measurement of total cellular protein in flow 
cytometry applications.153-155 A 1 mg/mL SR101 stock solution was prepared in PBS with 
sodium azide and stored at 40C protected from light for up to six months. In the LOC 
sensor assay, the SR101 stain was directly added to the goat anti-mouse/AlexaFluor®-
488 secondary antibody solution at a final concentration of 20 µg/mL in PBSAT, in the 
presence of 5 µM DAPI forming a three-color fluorescent staining cocktail. The Texas 
Red® (#41004, Chroma) filter set was utilized for epifluorescent imaging of SR101. 
3.2.6.2 FM®4-64 Lipophilic Dye 
The FM®4-64 (#T13320, Invitrogen Corp.) reagent is a lipophilic styryl dye 
(Ex/Em 565/744 nm) that becomes strongly fluorescent upon insertion into plasma 
membranes. The FM®4-64 stock solutions were prepared in 1 mL deionized water at a 
concentration of ~100 µg/mL and stored at -200C for up to two weeks. Similar to SR101, 
FM®4-64 was directly added to the AlexaFluor®-488 secondary antibody solutions 
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during the EGFR assay, at a final concentration of 10 µg/mL in PBSAT. Filter set 
#11007v2 (Chroma) containing a 535/50 nm excitation filter, 565 nm dichroic filter, and 
590 nm long pass filter was used for imaging of FM®4-64. 
3.2.6.3 Pan Cytokeratin 
For cytokeratin immunolabeling, a rabbit anti-human pan cytokeratin antibody 
(#C9097-48D, US Biological, Swampscott, MA) was selected for indirect labeling which 
could be performed simultaneously with the EGFR assay due to the difference in 
antibody species of origin and no known cross-reactivities. As such, 10 µg/mL of anti-
cytokeratin was added to the primary anti-EGFR antibody solution in PBSAT followed 
by 20 µg/mL of goat anti-rabbit IgG secondary antibody conjugated to AlexaFluor®-594 
(#A110037, Invitrogen, Ex/Em 590/617 nm) to the secondary antibody solution in 
PBSAT. Texas Red® filter set was utilized for imaging. 
3.2.6.4 β-Actin 
As one of the most abundant and universally expressed proteins in eukaryotic 
cells, β-actin, serves as an attractive cytoplasmic marker for use in the LOC sensor assay. 
Here, a rabbit monoclonal antibody to β-actin (#NB110-55433, Novus Biologicals, 
Littleton, CO) was used in parallel with EGFR labeling similar to cytokeratin, at a 
dilution of 1:50 (concentration unreported) in PBSAT. Goat anti-rabbit 
IgG/AlexaFluor®-594 (#A110037, Invitrogen, Ex/Em 590/617 nm) was added at a final 
concentration of 20 µg/mL to the secondary staining cocktail in PBSAT. Texas Red® 
filter set was utilized for imaging. 
3.2.6.5 Phalloidin 
Phalloidin is a naturally occuring toxin isolated from the Amanita phalloides 
mushroom that binds to F-actin in the cell cytoskeleton. Two fluorescent conjugates of 
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phalloidin were tested including AlexaFluor®-594 (#A12381, Invitrogen, Ex/Em 
581/609 nm) and AlexaFluor®-647 (#A22287, Invitrogen, Ex/Em 650/668 nm). 
Phalloidin stock solutions were prepared in 1.5 mL methanol at a concentration of 
approximately 6.6 µM and stored in single-use aliquots at -200C for up to one year. Since 
phalloidin is directly conjugated to a fluorophore, it could also be mixed into a cocktail 
with the secondary antibody/DAPI solution in PBSAT during the microchip assay 
sequence. Concentrations ranging from 0.165 µM to 1 µM were examined in order to 
determine the optimal dilution. 
3.2.7 Image Analysis and Data Extraction using Custom Macros 
Two open-source software programs were utilized for oral cytology image 
analysis and data extraction, ImageJ (version 1.38e)127 and Cell Profiler™ (version 
1.0.4684).156 Programming for custom macros/modules were written in JavaScript and 
MATLAB®, respectively, in order to identify and discriminate individual cells from the 
background, as well as each other in adherent cell clusters. The overall image processing 
steps and sequences were implemented as described in Figure 3-2. Ultimately, two 
regions of interest (ROIs) were created for each cell, the whole cell ROI and the nuclear 
ROI, which serve to define the cellular regions for measurement. Measurement 
parameters related to morphometry include ROI area, Feret’s diameter, perimeter, and 
circularity for both the whole cell and nucleus generating eight measurements (4 
parameters in 2 ROIs, whole cell and nucleus), plus the calculated nuclear-to-cytoplasm 
ratio for a total of nine morphological parameters examined in each cell. An additional 
seven intensity parameters, including the mean intensity, standard deviation, mode, 
minimum, maximum, median, and integrated density are also measured for each ROI pair 
from the three separate red (phalloidin), green (EGFR), and blue (DAPI) images, yielding 
a 42 total intensity parameters related to the individual cell’s physiological staining 
pattern. For statistical analysis, data was exported to Microsoft® EXCEL® with Analyse-
It® software and SigmaPlot 9.0 for graphical representation. 
 
 
Figure 3-2. Flow diagram demonstrating the overall image analysis sequence using 
custom macros and processing routines optimized for cytologic analysis in the LOC 
sensor assays.  
3.3 RESULTS 
3.3.1 Specimen Collection and Adequacy of Basal Cell Sampling  
In the current study, the OralCDx® cytobrush was selected for collection of oral 
cytology specimens based upon literature support for trans-epithelial sampling from the 
basal, intermediate, and superficial layers of epithelium, as well as from the suggestion of 
clinical collaborators.76 Further, the design of the OralCDx® brush enabled sampling 
using either the brush tip or the side surface for added comfort in the oral cavity. In order 
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to integrate this technique into the LOC sensor system, two important criteria must be 
met; (1) a sufficient number of cells for the microchip assay must be collected, and (2) 
cells from all layers of epithelium must be present. Using the OralCDx® brush technique 
in ten isolated instances, an average of 1.4 x 105 total cells (range 2.0 x 104 – 3.0 x 105) 
were collected from a brush sample of the buccal mucosa of healthy volunteers. 
However, this measurement provides only a rough estimate of total cell number due to 
the inherent inaccuracy of cell counting with a hemacytometer, particularly in the 
presence of clumped cells. Nevertheless, given that each microchip sensor assay requires 
only 2,500 – 5,000 cells, the volume of sample obtained with the brush cytology method 
was more than enough for multiple sensor assays. 
Next, the ability to obtain trans-epithelial sampling of cells was examined. 
Adequate cell sampling through the full thickness of epithelium is crucial if cytology is to 
provide representative diagnostic findings, particularly in pre-malignant cases exhibiting 
mild or moderate dysplasia. This is evidenced by the low sensitivity associated with past 
cytopathology efforts where sampling was typically limited to the superficial layers of 
epithelia. Here, two cytokeratin makers, AE1 and cytokeratin-14, were utilized to identify 
the presence of basal/suprabasal cells in brush cytology specimens (Figure 3-3). 
Immunolabeling with the AE1 monoclonal antibody resulted in positive staining in a 
fraction of the cells as shown in Figure 3-3(a) (green), with a diffuse labeling pattern in 
the cell cytoplasm counterstained with phalloidin (red) and DAPI (blue). The AE1 
negative cells exhibited phalloidin and DAPI staining only. A similar labeling pattern 
was seen with cytokeratin-14 (Figure 3-3(b), green), where a combination of positively 
and negatively stained cells was observed throughout the specimen. While AE1 and 
cytokeratin-14 have been utilized as basal cell markers in a number of prior studies, these  
markers have also been identified in suprabasal layers, albeit to a lesser extent.157, 158 
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Thus, the results presented herein cannot definitively identify basal cells, but rather 
suggest the presence of basal and/or suprabasal cells in these brush cytology specimens.  
Further examination of brush cytology used slide-based cytospin preparations and 
Papanicolaou (Pap) staining, as shown in Figure 3-3(c), where mature epithelial cells 
from superficial layers were stained pink, intermediate cells were stained green, and 
immature basal/parabasal cells exhibited a blue-green color. In such preparations, basal 
cells may also be identified by a difference in morphology when compared to mature 
squames due to their smaller size, slightly larger nuclei, and somewhat cuboidal shape.  
While certain cellular features may be recognizable in cytology smears by an untrained 
eye, true interpretation requires a highly trained specialist in the field of cytopathology or 
oral diagnostics. Therefore, the final assessment of the quality of cytological sampling 
was made through consultation with clinical pathologists from the University of Texas 
Health Science Centers in Houston and San Antonio. Using standard cytopathology 
criterion and the AE1 and cytokeratin-14 staining methods above, the presence of basal 
cells were confirmed in OralCDx biopsy specimens by these experts in the field of 
cytopathology and oral diagnostics, verifying the adequacy of cell sampling using the 






Figure 3-3. Identification of basal/parabasal cells in healthy brush cytology specimen. 
Cells were immunolabeled in the LOC sensor using two basal cell markers, (a) AE1 
monoclonal antibody/AlexaFluor-488 (green) or (b) cytokeratin-14/AlexaFluor-488 
(green), and counterstained with phalloidin (red) and DAPI (blue), cytoplasmic and 
nuclear markers, respectively. Basal/parabasal cells with positive AE1/cytokeratin-14 
labeling are marked with arrows. (c)* Slide-based cytospin preparations stained with 
Papanicolaou further confirm the presence of mature squamous cells (pink), intermediate 
cells (green), and immature basal/parabasal cells (blue-green). *Image provided by 
courtesy of N. Vigneswaran at UTHSC Houston. 
3.3.2 Mechanical and Enzymatic Dissociation of Adherent Cells 
One of the main challenges associated with cellular analysis in exfoliative 
cytology is the use of naturally adherent cells, which, when significantly clustered, may 
obstruct visualization and imaging of rare or subtle signs of disease that are particularly 
important for detecting early cancerous or pre-cancerous conditions. Therefore, a variety 
of mechanical and enzymatic methods were evaluated in an attempt to dissociate large 
cell clusters in exfoliative cytology specimens, as listed in Table 3-1. Each method was 
compared to untreated cells which exhibited a high degree of cell clustering with 
approximately 50-60% of all cells touching at least one other cell estimated using a 
hemacytometer. Unfortunately, none of the enzymatic methods or conditions tested 
provided adequate or even acceptable results. For example, treatment with Trypsin-
EDTA resulted in fewer cell clusters, but also generated a large amount of debris and 
isolated nuclei indicative of cell lysis. While treatment with collagenase or dispase either 
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had no effect on cell dissociation or again resulted in extensive cell lysis. Interestingly, 
nearly all of the treated and untreated cells stained positive with Trypan blue indicating 
disruption or perforation of the cell membrane, which likely occurred during the 
collection process when cell-cell and cell-ECM contacts were disrupted. Thus, it is 
possible that these enzymatic treatments were ineffective because the epithelial cell 
membranes did not remain intact following the brush biopsy procedure. This surprising 
occurrence provided a significant advantage in later microchip assay development, 
enabling intracellular staining/labeling in the absence of additional cell permeabilizing 
agents. 
The only method with somewhat reasonable outcome was the 35 µm cell strainer 
which generated a very nice distribution of individual cells and small clusters, typically 
with less than five cells per cluster. This method was utilized for a brief period during the 
initial testing of normal and diseased cytology specimens, but was later discounted due to 
unacceptable levels of cell loss. In fact, it was pointed out by our collaborators in oral 
pathology that these clusters may contain the majority of basal cells and be the most 
relevant for assessment of malignancy. Therefore, no dissociation treatment was 
ultimately adopted and rather than eliminating the cell clusters, a multi-Z-plane imaging 








Table 3-1. Comparison of mechanical and enzymatic methods used for dissociation of 
exfoliative cytology specimens. 
Treatment % Cells Touching Comments 
Relative 
Performance
Untreated  59% All cells trypan blue positive; 
few isolated nuclei; clear 
background with no debris 
 
Mechanical    
       Vortex, 5 min. NC Severe clumping and cell debris 
prevented counting 
Poor (+) 
        Shear stress – 27½ gauge  
            needle 
13% Significant cell loss (~½) Fair (++) 
        Mesh filter – 35 µm 24% Majority of cells appear as intact 
squames; significant cell loss 
Good (+++) 
Enzymatic    
       Trypsin-EDTA 0.25% 18% Significant fibrous debris; and 
large number of isolated nuclei 
Poor (+) 
       Versene (EDTA) 52% Cell debris and isolated nuclei 
seen after 10 min. 
Poor (+) 
       Collagenase 100U/mL NC Significant cell debris, 
fragments and isolated nuclei 
Poor (+) 
       Collagenase 50U/mL NC Large clumps still present Fair (++) 
       Dispase 1U/mL NC Minimal cell damage, but only 
moderate effect on dispersal 
Fair (++) 
      Dispase 0.5U/mL NC No effect  
      Dispase 0.5U/mL and   
          collagenase 100U/mL 
NC Extensive cell lysis and debris Poor (+) 
3.3.3 Effect of Fixation on EGFR Immunolabeling 
Cell fixation, while unwanted in a true point-of-care LOC sensor assay intended 
for clinical practice, is preferred during development due to decreased biohazard risk and 
prolonged sample utility. However, aldehyde-based fixatives are known to disrupt 
secondary alpha helical protein structure, which may in turn affect antibody binding at 
certain epitopes, particularly in membrane-bound receptors such as EGFR.159 For this 
reason, the selection of fixative is very important to overall sensor performance and 
immunolabeling sensitivity. In this experiment, a variety of fixatives were tested to 
determine their effect on EGFR immunolabeling intensity as shown in Figure 3-4. Here, 
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unfixed cells demonstrated a mean EGFR intensity of 790, while the mean isotype 
control was 6.8 yielding a S/B ratio of 115, which served as the standard by which other 
methods were compared (Figure 3-4(a)). Fixation in 0.5% formaldehyde resulted in peak 
channels for EGFR and isotype of 880 and 7.8, respectively, with a S/B ratio of 110 
(Figure 3-4(c)) while 4% formaldehyde fixation exhibited slightly higher EGFR and 
isotype means (1150 and 20, respectively), but with significantly lower S/B ratio of 57 
(Figure 3-4e). The three commercially available fixatives yielded S/B ratios of 53 for 
Cytofix/Cytoperm®, 102 for CytoChex® and 465 for Histochoice-MB® (Figure 3-4(b, d, 
and f)). Although the exact chemical composition of the commercially available fixatives 
is proprietary, Cytofix/Cytoperm® is reported to contain 4% paraformaldehyde and 
demonstrated very consistent S/B ratio as the 4% formaldehyde solution prepared in-
house. Suprisingly, the Histochoice-MB® fixative exhibited nearly 4 times greater S/B 
ratio over any other method. The manufacturer reports that the use of Histochoice-MB® 
fixative often enhances signal intensity, yet the mechanism for this phenomenon is 
unknown. These results initially directed attention toward the use of Histochoice-MB® 
for EGFR assays in the LOC sensor. However, it was later discovered that this fixative is 
incompatible with one of the cytoplasmic markers investigated, which raised doubts 
regarding the overall compatibility of Histochoice-MB® fixative in the development of 
future sensor assays. In the end, fixation using a low percentage of formaldehyde (0.5%) 
was selected due to the high similarity to unfixed cells. 
 
Figure 3-4. Effect of fixation of EGFR immunolabeling. Single-parameter EGFR 
intensity histograms, obtained by flow cytometry, of SqCC/Y1 tumor cells (a) unfixed, 
(b) fixed in Cytofix/Cytoperm, (c) 0.5% formaldehyde, (d) CytoChex, (e) 4% 
formaldehyde, and (f) Histochoice-MB. Matched isotype controls are overlayed as black 
outline histograms and are typically located in the first decade along the X-axis. User-
established region markers centered on each peak generated statistics for calculation of 
the signal to background ratio using the equation [(mean M2 – mean M1)/ mean M1]. 
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3.3.4 Optimization of Cell Capture and Dispersal in Microchip Sensor 
Another important factor affecting cellular analysis in the LOC sensor is the 
dispersal of cells across the membrane surface. Under ideal conditions, cells would be 
distributed homogeneously throughout the membrane forming a dispersed monolayer, 
such that no excessive cell accumulation occurred in any one membrane region 
compounding the challenges associated with imaging and analysis of aggregated or 
clumped cells. Influencing this dispersal is the size and shape of the cells, the viscosity of 
the fluid, the dimensions of the fluidic channels, and the flow rate. In the current 
experiment, the size and shape of the cells, as well as the fluidic channels, remain 
relatively fixed, while the flow rate and viscosity of the fluid were adjusted to find the 
optimal parameters for cell capture and dispersal. Starting at an initial flow rate of 725 
µL/min, previously optimized for tumor cell lines, brush biopsy cells suspended in PBSA 
buffer tended to gather at the left border of the membrane near the fluidic channel 
entrance with very few cells reaching the center and/or right edge, suggesting the need 
for higher flow rates (data not shown). Subsequent cell capture trials at 1.0, 1.5, 2.0, and 
2.5 mL/min demonstrated that a flow rate of 2 mL/min provided the best improvement in 
cell dispersal with cells found throughout the membrane, albeit at a higher density near 
the exterior edges and somewhat sparse in the center of the membrane (Figure 3-5(a)).  
Further improvement in cell dispersal was obtained by increasing the viscosity of 
the cell suspension fluid with the addition of glycerol as shown in Figure 3-5. At a 
constant flow rate of 2 mL/min, low percentage glycerol solutions resulted in the same 
general pattern of accumulation near the edges of the membrane with sparse patches 
located in the interior (Figure 3-5(a-c)). However, at 60% glycerol cell dispersal appeared 
much more even across the entire membrane surface with no overt regions of high or low 
cell density (Figure 3-5(d)). Further experiments revealed that 50% glycerol provided 
similar dispersal patterns as 60% glycerol, but with greater reproducibility and less risk of 
sensor failure under high pressure (data not shown); therefore, cell capture at 2 mL/min 
in 50% glycerol/PBSA was implemented in all subsequent LOC cytology assays.  
 
 
Figure 3-5. Evaluation of optimal conditions for cytology dispersal. Pseudo-color image 
montages of healthy brush biopsy cells stained with DAPI captured on the LOC 
membrane surface at a flow rate of 2 mL/min. in (a) 0% glycerol, (b) 20% glycerol, (c) 
40% glycerol, and (d) 60% glycerol in PBSA solutions. 
3.3.5 Parameters for Z-Scan Imaging of Cell Clusters 
In order to circumvent the challenges, and ultimately failures, associated with cell 
dissociation, a z-scan imaging approach was adopted to collect multiple focal planes 
which could be recombined into a single “focused” image using convolution algorithms. 
With this methodology, two parameters must be defined including the z-axis step size and 
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the total number of z-planes necessary to image cell clusters. The appropriate step size 
was determined by examining the distribution in mean intensity values of ten randomly 
selected nuclei as a function of z-position in a 50 µm z-scan sequence as shown in Figure 
3-6(a). The maximum intensity was seen at the z = 0 position, which was the “ideal” 
focal plane selected using autofocusing algorithms built into the microscope software. A 
sharp decrease in intensity was apparent as the z-position moved ±25 µm above or below 
the ideal focal plane. Using this intensity curve, the full width at half maximum intensity 
of approximately 12 µm was measured indicating that ±6 µm from the ideally focused z-
plane resulted in a 50% decrease in intensity, beyond which intensity losses were 
unacceptable. This value closely approximates the size of a typical nucleus (~5 µm) and 
the calculated depth of field for the microscope objective (5.8 µm). Thus, as an 
underestimate, a step size of 5 µm was selected for z-scan imaging. 
Next, the minimum number of focal planes necessary to image through a typical 
cluster of 20 or more cells was explored. Here, a total of five z-planes were extracted 
from the full 50 µm z-sequence at 5 µm intervals above the autofocus plane, generating a 
stack of z-images which were recombined sequentially using an ImageJ stack focusing 
algorithm. Figure 3-6(b) presents a subset of cells found in an adherent cluster at z = 0 in 
a single focal plane (i), followed by the combined image of two focal planes, z = 0 and 5 
µm (ii), three focal planes, z = 0, 5, and 10 µm (iii), four focal planes, z = 0, 5, 10, and 15 
µm (iv), and all five focal planes, z = 0, 5, 10, 15, and 20 (v). Using these combined 
images, a simple image threshold and segmentation macro was established to count the 
number of individual cells/nuclei which could be identified in each processed image as 
presented in Figure 3-6(c). Here, a total cell count of 129 was obtained for the single z = 
0 focal plane identified via autofocus routine, while 142 cells could be identified using 
two focal planes, 152 cells in three focal planes, and 153 cells in four or five focal planes. 
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These differences were further demonstrated by overlaying the outline of individually 
identified nuclei in the cell cluster found in Figure 3-6(b). Obviously, a number of nuclei 
present in this cluster were poorly focused in the z = 0 focal plane which prevented their 
clear identification and subsequent measurement (Figure 3-6(b), i). The combination of 
two focal planes enabled identification of several more nuclei which were undetectable in 
the previous single image (Figure 3-6(b), ii). This trend continued with the addition of a 
third focal plane, but leveled off thereafter with the extra fourth and fifth focal planes 
(Figure 3-6(b), iii-v). Thus, in this instance three focal planes were sufficient to provide 
the maximum number of cells/nuclei that could be identified in the cluster, as well as the 
full field of view.  
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Figure 3-6. Examination of z-scan imaging parameters in DAPI-stained healthy 
cytology specimen with (a) nuclear intensity plotted as a function of distance along the Z-
axis at 1 µm intervals exhibiting a 50% decrease in intensity approximately 6 µm above 
and below the ideal focal plane. (b) Using stack focusing algorithms, multiple image 
planes were recombined with the ideal focal plane, 0 µm (panel i) in progressive 
sequence at 5 µm intervals consisting of two focal planes, 0 and 5 µm, (panel ii); three 
focal planes, 0, 5, and 10 µm (panel iii); four focal planes, 0, 5, 10, 15 µm, (panel iv); and 
5 focal planes, 0, 5, 10, 15, and 20 µm (panel v). “Focused” images of a typical cell 
cluster are shown at left with contours of nuclei detectable using automated image 
segmentation overlayed at right. (c) Graphical representation of the number of nuclei 
identified in progressive stacks of multiple Z-focal planes demonstrates that three focal 
planes are sufficient for maximum detection of nearly all nuclei. 
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3.3.6 Selection of Nuclear and Cytoplasmic Markers for Cytomorphometry 
In order to measure biomarker expression on a single-cell basis, the entire cell 
must be recognizable and distinguishable from the background by the image analysis 
software. This was easily achieved with the EGFR biomarker alone in the tumor derived 
cell lines, even at very low levels in the MDA-MB-435S cells.152 However, it was 
apparent very early that this was not the case for oral brush biopsies, particularly from 
healthy mucosa. Here, low EGFR expression and diffuse cytoplasmic/membrane labeling 
was insufficient to define the cellular area for measurement. This necessitated the 
investigation of cytoplasmic and nuclear counter-stains for identification of oral epithelial 
cells regardless of EGFR expression level and disease state. Ideally, these stains would be 
found in all cells with a relatively homogeneous intensity throughout the cell, and would 
be compatible with previously established cell processing techniques and EGFR assay.  
Representative images of the five cytoplasmic markers examined in conjunction 
with the EGFR immunoassay (green) and DAPI staining (blue) in brush biopsy 
specimens are presented in Figure 3-7. Sulforhodamine 101, FM®4-64, and cytokeratin 
(Figure 3-7(a-c), red) all exhibited positive cytoplasmic labeling, but with rather 
heterogeneous or punctate staining patterns and poorly defined cell boundaries. 
Furthermore, FM®4-64 lipophilic dye was found to be incompatible with Histochoice-
MB® fixation and generated a high fluorescence background emanating from the frit 
support underlying the membrane as a result of interaction with the black frit coating 
(data not shown). Immunolabeling with β-actin/AlexaFluor®-594 resulted in relatively 
low cytoplasmic intensity (Figure 3-7(d), red), but with somewhat higher EGFR (green) 
signal intensity. It appears as if non-specific binding or fluorescence bleed through may 
contribute to the higher EGFR intensity seen here as a result of overlapping emission 
spectra between AlexaFluor®-488 and AlexaFluor-®594. Phalloidin yielded positive 
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cytoplasmic staining in nearly all of the cells present with a moderately homogeneous 
labeling pattern that distinguishes individual cells from each other and the background 
(Figure 3-7(e), red). Based upon these results, phalloidin/AlexaFluor®-647 was chosen 
as a suitable cytoplasmic marker and subsequent dilution studies established an 
appropriate concentration of 0.33 µM for future assays (data not shown). 
In all of the samples tested, DAPI exhibited excellent nuclear staining (Figure 3-7, 
blue). The presence of several small, faintly stained nuclei in Figure 3-7(a) and (b) may 
be indicative of superficial surface cells found in non-keratinized epithelium, whose 
nuclei often appear pyknotic. Interestingly, DAPI was also found to interact with the 
black coating applied to the frit support underlying the membrane (data not shown). This 
generated a relatively high background in the absence of the membrane or in combination 
with certain membranes which were not dyed black and/or possessed large pore sizes (~ 3 
µm). The influence of this background fluorescence toward DAPI signals is not 
appreciable with the 0.4 µm black membranes utilized in the current study as evidenced 
by the extremely low background found in DAPI channel (mean 3.0 ± 1.0, range 1 - 33 in 
8-bit scale). This is likely due to the increased thickness and surface area of the blackened 
0.4 µm membranes and the low exposure times. 
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Figure 3-7. Comparison of cytoplasmic staining/labeling employing (a) sulforhodamine 
101 total protein stain (0.2 s. exposure and 1.0 camera gain); (b) FM®4-64 lipophilic dye 
(0.2 sec, 1.0 gain); (c) pan cytokeratin/AlexaFluor®-594 antibody (0.5 sec., 2.0 gain); (d) 
β-actin/AlexaFluor®-594 antibody (0.5 sec., 1.0 gain); and (e) phalloidin/AlexaFluor®-
647 (1.0 sec., 10.0 gain). Staining was perfomed in conjunction with EGFR assay (green) 
and DAPI staining (blue) in 0.5% formaldehyde fixed specimens. Brightness and contrast 
settings have been adjusted for visualization and printing purposes. 
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3.3.7 Digital Image Analysis 
With the integration of exfoliative cytology specimens, the necessity for multiple 
z-focal planes and multi-spectral detection of EGFR/phalloidin/DAPI required 
development of a new, more complex image analysis strategy than previously described 
for tumor cell lines. In addition, the irregular shape of the epithelial cells and their 
adherent nature further complicated the image analysis process. Using a variety of image 
analysis tools, custom routines were developed to automatically detect individual cells 
and define the regions of interest (ROI) for EGFR biomarker measurement.  This was 
achieved by strategic nuclear and cytoplasmic dye selection based upon the assumption 
that each cell must possess a nucleus and a surrounding cytoplasm. As such, when cells 
are closely clustered or adherent, their nuclei are less likely to overlap than the 
surrounding cytoplasm, thus, the DAPI stained nuclei serve to identify the presence of 
each cell regardless of clustering, while cytoplasmic phalloidin staining serves to identify 
the boundary of the cell surrounding each nucleus. Therefore, both dyes are necessary to 
identify the whole cell ROI for measurement of EGFR biomarker intensity. Early in the 
development of these methods, it became very apparent that the techniques necessary for 
measurement of biomarker expression in cytology cells could be used in parallel for 
cytomorphometric analysis, offering additional parameters in which to characterize 
malignancy.  
An example image sequence is presented in Figure 3-8 showing the digital inputs 
and outputs at each stage of this process. Here, illumination corrected digital micrographs 
consisting of three z-focal planes were convolved using ImageJ stack focusing algorithms 
as shown in Figure 3-8(a), i-iv. These focused images were then utilized to define the 
nuclear and cytoplasmic outlines based upon intensity threshold and segmentation in 
DAPI and phalloidin images, respectively (Figure 3-8(b), v-xi). Touching cells were 
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separated based upon weighted parameters of intensity and distance from adjacent nuclei. 
Binary masks of primary (nuclei) and secondary (whole cell) objects were generated from 
which the regions of interest (ROI) outlining each paired cell and nucleus were drawn for 
measurement on the original focused image. All together nine morphological parameters 
and seven intensity parameters were extracted from three separate RGB channels for a 
total of 30 measurement parameters and one calculated parameter, nuclear-to-cytoplasm 
ratio (N/C ratio), per sample.  
Examination of the Cell Profiler™ output image (Figure 3-8, xi) with outlines 
overlayed onto the original focused images demonstrates successful discrimination of the 
cell cytoplasm and borders between overlapping or adjacent cells. Although, this is by no 
means perfect and discrepancies between automated separation borders and visual 
interpretation may exist, but this method exhibits the best capability for cytologic 
analysis examined so far. As such, cytomorphometric measurements obtained from 
fifteen random cells in Figure 3-8, iv were as follows: mean cellular area, 2261 µm2; 
mean cellular diameter, 70.9 µm; mean nuclear area, 55.2 µm2; mean nuclear diameter, 
11.1 µm; and mean nuclear-to-cytoplasm ratio, 0.027. Thus, using this combination of 
cellular dyes and image analysis sequence, we have identified an automated method for 
cellular examination and in the processes expanded the capacity of the LOC sensor assay 
for analysis of cytomorphometry, which has widely been demonstrated as a useful 
indicator of malignancy. 
 
 
Figure 3-8. Digital image analysis was performed in ImageJ using custom macros and 
sequences for combining three z-focal planes, collected at 5 µm intervals, into a single 
convoluted or “focused” image (a, panels i-iv). This focused image served as the input for 
Cell Profiler (b) in separate RGB channels where the blue or DAPI channel (panel v) was 
utilized for primary identification of a cell followed by secondary identification of the 
cell cytoplasm surrounding each nucleus according to phalloidin staining intensity (panel 
vi). Binary masks of these objects are shown in panel viii and ix, respectively, and in a 
combined mask, panel x. The outlines of individual nuclei and cell boundaries generated 
from these masks (panel xi) were exported back to ImageJ for measurement and digital 
filtering to eliminate debris and non-cellular material. Scale bar is 100 µm. 
3.4 DISCUSSION 
The integration of exfoliative cytology into the LOC sensor methodology offers a 
number of opportunities as well as challenges for oral diagnostics. Advantages include 
the quick, non-invasive nature of cell sampling which could enable examination of 
lesions which do not call for surgical biopsy or in cases where surgical biopsy is not 
feasible. In addition, the relatively painless procedure could allow for repeated sampling 
 91
 92
for monitoring purposes in high-risk individuals, response to treatment, and follow-up in 
OSCC patients. Challenges related to oral exfoliative cytology stem from the direct 
relationship between diagnostic capacity and the quality of the specimen collection and 
preparation, such that individual cell and nuclear characteristics should be visible in a 
monolayer of cells from all epithelial layers.  
While the adequacy of sampling with the OralCDx brush technique has 
previously been reported, in the current application further verification was sought using 
the modified suspension-based protocol described herein.76 Two basal cell markers, the 
AE1 monoclonal antibody and cytokeratin-14, were utilized for this purpose with positive 
cellular staining seen in both instances as demonstrated in Figure 3-2. The AE1 
monoclonal antibody recognizes shared epitopes on all acidic (Type 1) cytokeratins 
including cytokeratin-10, -14, -15, -16, and -19, and has previously been shown to 
localize in basal/suprabasal cells in complex mucosal epithelium, such as the oral 
mucosa.157, 158 In clinical applications, AE1 has also been employed in an antibody 
cocktail, in combination with AE3 mAB recognizing the basic (Type 2) keratins, to 
identify metastatic tumors of epithelial origin. Due to the multiple proteins recognized by 
AE1, an antibody specific to cytokeratin-14 only was further used to assess the presence 
of basal cells in cytology specimens (Figure 3-2b). All basal cells in stratified squamous 
epithelia have been shown to express cytokeratin-14, though expression may persist in 
upper stratified layers where differentiation-specific keratins are also expressed.157 
Despite the fact that cytokeratin-14 is not restricted to the basal epithelium, it may still 
serve as a useful basal cell marker due to higher intensity seen in basal versus suprabasal 
layers.157  
While AE1 and cytokeratin-14 may be useful indicators of basal/parabasal cells, 
the cells with positive staining in Figure 3-2 do not all appear as small cuboidal cells with 
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slightly larger nuclei, characteristic of true basal cells. Therefore, the final classification 
was completed using the standard procedures employed by trained pathologists using 
H&E stains of paraffin tissue sections.160 Based upon standard cytology techniques, as 
well as the AE1 and cytokeratin-14 staining profile, basal cells were confirmed in 
OralCDx brush specimens collected with the current protocol (Figure 3-2(c)). In addition, 
it was pointed out that the proportion of basal cells expected in a cytology sample, in 
relation to the intermediate and superficial cells, is rather low such that basal cells may 
not be visible in every 20X field of view. Taken together, the evidence and expert 
opinions support the use of brush cytology to provide an adequate sampling of cells 
representative from the basal, intermediate, and superficial layers of oral epithelium for 
application in the microchip sensor system. 
Besides obtaining an adequate sampling of cells, one of the intrinsic challenges 
associated with exfoliative cytology is the examination of naturally adherent cells, which, 
when significantly clustered, may prevent clear visualization and imaging of infrequent 
or subtle signs of disease that are particularly important for detecting early malignancies. 
Of the methods investigated for cell dissociation, including both mechanical and 
enzymatic treatments, none provided satisfactory results (Table 3-1). For example, 
methods which successfully dissociated the cell clusters, such as 35 µm mesh filter or 
trypsin, were also accompanied by unacceptable levels of cell loss and/or cell lysis 
generating cellular fragments and isolated nuclei. As an alternative to these harsh cell 
dissociation techniques, capability of Z-scan imaging to enhance the detection and 
measurement of clustered cells was examined. Here, digital convolution or de-blurring of 
three z-focal planes at 5 µm intervals enabled detection of 19 additional nuclei present in 
a typical adherent cell cluster (Figure 3-6(b)) and 23 additional nuclei in the full field of 
view (Figure 3-6(c)). The subsequent convolution of an additional fourth or fifth focal 
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plane yielded only one more detectable nucleus in the full field of view (Figure 3-6(c)). 
Based upon these results, the acquisition of three focal planes at a z-step size of 5 µm 
served as the most appropriate parameters for z-scan imaging in exfoliative oral cytology 
specimens. Of course, the size of cell clusters encountered in oral cytology varies by 
specimen and may be larger or smaller than the one examined here. However, there is an 
important trade-off between the potential benefits of acquiring additional z-focal planes 
with sample photobleaching which must be considered. With this in mind, the minimum 
number of focal planes applicable to the majority of cell clusters was sought. As such, it 
is likely that a fraction of cells in clusters larger than the one in Figure 3-6 may remain 
undetectable. The effects of photobleaching were also minimized with the use of 
relatively stable fluorophores such as the Alexa series of molecular dyes.  
During development of the LOC microchip assay using oral exfoliative cytology, 
cell fixation was performed in order to decrease the biohazard risk associated with human 
tissue and preserve sample integrity for delayed analysis. This is likely an unnecessary 
and unwanted step in a true point-of-care LOC sensor assay due to the additional time 
required and potential for sample loss during centrifugation and washing. Nevertheless, 
fixation serves a useful purpose during development of this new sensor technique, 
unfortunately, not all fixatives are suitable for immunocytochemistry. Therefore, the 
effect of various fixatives on EGFR immunolabeling intensity was examined in order to 
identify an appropriate method for LOC sensor assays as demonstrated in Figure 3-4. 
Based upon S/B ratio, Histochoice-MB® appears to be the best fixative with a S/B ratio 
nearly 4 times greater than any other method, including unfixed cells. This effect was 
also seen in the LOC sensor where tumor cell lines fixed in Histochoice-MB® exhibited 
appreciably stronger EGFR intensity (data not shown). While this phenomenon has been 
reported elsewhere and by the manufacturer, the mechanism remains unexplained and the 
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formula proprietary, leaving a number of variables essentially unknown. In addition, it 
was later discovered that this fixative is incompatible with FM®4-64 membrane staining, 
which raised doubts regarding the cellular effect and overall compatibility of 
Histochoice-MB® fixative in the development of future sensor assays. Thus, rather than 
the highest S/B ratio, the fixation method which was most similar to unfixed cells, 0.5% 
formaldehyde, was identified as the least disruptive method and most appropriate for 
LOC sensor assays, now and in future applications in the absence of fixation. Fixation in 
0.5% formaldehyde exhibited mean EGFR intensity and signal to background ratio values 
closest to unfixed cells (112.8 and 114.6, respectively), followed by CytoChex® fixative 
(102.2). Other fixatives with a higher percentage of formaldehyde, particularly 4% and 
Cytofix/Cytopem® known to contain 4% formaldehyde, resulted in a slight shift of both 
the isotype and EGFR histogram peaks to the right with appreciably reduced S/B ratios 
(approximately 50). The affect is primarily seen on the isotype control indicating 
increased background fluorescence. Typically, fixation in 4% formaldehyde is performed 
after labeling of surface antigens and the higher level of cross-linking generated with 4% 
formaldehyde, versus 0.5% formaldehyde, may account for an elevation in non-specific 
antibody binding.159 Although a variety of fixatives were examined, it is by no means 
exhaustive and additional fixatives and/or cell storage solutions may serve the purposes 
of the microchip sensor equally or better than 0.5% formaldehyde. 
Another important factor to consider in the integration of exfoliative cytology into 
the LOC sensor is the dispersal of cells across the membrane surface. Under ideal 
conditions, cells would be distributed homogeneously throughout the membrane forming 
a well-dispersed monolayer. Under sub-optimal conditions, regional accumulation of 
cells may compound the challenges associated with imaging and analysis of aggregated 
or clumped cells, while regions devoid of cells prevent effective utilization of the full 
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membrane area. During the transition from cultured cell lines toward exfoliated cells, the 
change is cell size and shape significantly affected membrane dispersal such that re-
optimization of the cell capture conditions was necessary. Here, a high flow rate of 2 
mL/min and high viscosity of the cell suspension fluid (>50% glycerol/PBSA) improved 
cell dispersal over other methods generating a relatively even density of cells across then 
entire membrane capture area (Figure 3-5). The influences of flow rate and viscosity on 
cell dispersal may be elucidated by tracing the path of fluid flow through the LOC sensor 
and the forces acting upon suspended cells. Naturally, fluid will travel the path of least 
resistance, so as soon as the fluid enters the membrane chamber it exits through the first 
available membrane pores leaving behind the suspended cells. At high viscosity, the path 
of least resistance may result in fluid filling the entire membrane chamber before it is 
pushed through the membrane pores allowing cell capture in all regions of the membrane 
equally. Similar influences of viscosity have previously been seen in the membrane-based 
LOC sensor system for enumeration of CD3+CD4+ lymphocytes. In this instance, whole 
blood, with a viscosity of 4 mPa·s at 200C and 2.7 mPa·s at 370C, enhanced the dispersal 
of white blood cells enabling assay and sampling of the entire membrane area.1 
Interestingly, a 50% glycerol solution in water is reported to possess a viscosity of 6.0 
mPa·s at 200C and 3.1 mPa·s at 400C, somewhat similar to whole blood.161 While 
viscosity obviously has a strong affect on cell dispersal, sensor to sensor variations in 
fluidic channels created by mis-alignment of laminate adhesives during assembly may 
also contribute to altered dispersal patterns. Further development toward a clinical device 
should explore additional techniques to generate well-dispersed monolayers, such as 
liquid-based preparation and thin-prep techniques employed in slide-based 
cytopathology, and their applicability in the microchip sensor.162 
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Next, the incorporation of cytoplasmic and nuclear markers into the LOC sensor 
assay was explored. The need for these markers stems from the poor identification of 
cellular boundaries in exfoliative cells using the EGFR signal intensity alone, particularly 
in normal healthy mucosa. Five putative cytoplasmic markers were identified targeting 
diverse cellular structures or physiology, including one total protein stain, one lipophilic 
dye, and three cytoskeletal proteins as represented in Figure 3-7. Not suprisingly, all 
markers analyzed exhibited positive cytoplasmic or membrane staining to a certain 
extent. Although, only phalloidin staining appeared relatively homogeneous throughout 
the cytoplasm with well defined cell boundaries important toward identification of 
individual cells, and particularly separation of touching cells, during automated image 
analysis routines. Thus, phalloidin was selected as the cytoplasmic marker to be 
implemented in subsequent LOC sensor assays. In addition, DAPI provided superb 
staining of nuclei in all samples tested (Figure 3-7) thus serving as an excellent nuclear 
marker in microchip sensor assays. Overall, the integration of these cytoplasmic and 
nuclear markers into the LOC sensor system served to enhance cell identification and 
discrimination independently of biomarker expression level, analogous to the 
forward/side scatter parameters available in flow and image cytometry. Unlike traditional 
flow cytometry, these markers enable direct measurement of cellular morphology, 
including cell and nuclear size, area, perimeter, and nuclear to cytoplasm ratio which may 
provide additional information regarding the presence and progression of disease. 
The extra complexity of z-scan imaging and cytomorphometry in irregularly 
shapped and adherent cells presented a number of unique challenges for image analysis. 
Foremost, among these was the difficulty associated with the separation of adherent or 
touching cells. While the z-stack focusing plugin in ImageJ sufficed for detection of 
nuclei in clustered cells, the focused cytoplasms remain overlapped due to their larger 
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size and direct cell-cell contacts as seen in Figure 3-8(a). Typical methods for separation, 
such as watershed technique, often resulted in over or under segmentation in larger cell 
clusters where the borders of cells were not very well defined, even with the use of 
phalloidin staining. Therefore, a combined approach was taken where each cell could first 
be identified by its nucleus and then by the cytoplasm surrounding each nucleus. In other 
words, the number of nuclei present in a cell cluster served to define the number of cells 
into which the cluster was expected to be divided. Cell Profiler™ routines were well 
suited for this type of approach with the dual identification of primary and secondary 
objects based upon DAPI and phalloidin intensity, respectively. During identification of 
secondary objects, separation of overlapping or adjacent cells was based upon a 
propagation algorithm according to weighted factors of intensity of phalloidin staining 
and distance to primary objects (Figure 3-8(b)). This method provided suitable 
identification and separation in the majority of cells as judged by visual examination 
(Figure 3-8(b), xi) which further enabled cytomorphometric measurement of cell and 
nuclear area, diameter, and nuclear-to-cytoplasm ratio. Unfortunately, this method 
requires the assumption that there exists one nucleus for each cell which may not always 
be the case, particularly in malignancies where bi-nucleated cells may occur. In addition, 
instances where individual nuclei are overlapping would improperly result in 
identification of a single cell cytoplasm suggesting the need for verification of proper 
segmentation and filtering of unwanted events in the final measurement data.   
While Cell Profiler™ software was particularly useful for identification of 
individual cells; the program is relatively new, released in 2006, and a number of 
problems with its functionality were encountered during analysis which prevented its 
utility throughout the image analysis process. Therefore, initial image processing was 
performed in ImageJ prior to Cell Profiler™ analysis, such as illumination correction and 
z-stack focusing, and image masks generated from Cell Profiler™ were exported back to 
ImageJ for final measurement. Through these image analysis tools, it was possible to 
achieve the objective of an integrated lab-on-a-chip analysis of cellular morphology and 
biomarker expression associated with oral cancer brush biopsy samples.  
Taken as a whole, the studies presented in this Chapter have successfully defined 
new methods for examination of exfoliative cytology using the lab-on-a-chip sensor 
technique. The complete microchip assay sequence, with integrated cell capture, staining, 
and imaging/analysis routines, has been established as illustrated in Figure 3-9. In this 
overall process, each step builds upon the one before it, such that suboptimal conditions 
in any one step have significant implications toward the overall sensor analysis capability 
and output. This cumulative effect underscores the importance of the studies presented 
herein to characterized and isolate the key influences and requirements for cytologic 
analysis at each step, establishing the framework for diagnostically relevant assays 
applied in Chapter 4. As such, the major accomplishments in assay development and 
optimization of LOC sensor methods are further outlined in Table 3-3. 
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Figure 3-9. Schematic diagram of the full LOC sensor assay as described for EGFR 
biomarker detection and cytomorphometry from cell collection and processing, through 
cell capture on the sensor membrane, immunolabeling and staining with 
EGFR/Phalloidin/DAPI, fluorescent imaging and analysis. 
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Table 3-3.    Accomplishments toward LOC cellular analysis methods   
 Identified appropriate nuclear and cytoplasmic markers 
 Developed compatible three color EGFR/Phalloidin/DAPI labeling protocols 
 Optimized cell capture and dispersal conditions 
 Established z-scan imaging approach for imaging of adherent cell clusters 
 Developed custom image analysis routines for EGFR biomarker expression 
 Incorporated cytomorphometry into LOC sensor analysis  
 Determined the cell dissociation is unnecessary  
 Demostrated intracellular staining without need for additional cell permeabilization 




In this Chapter, the dynamic influences and issues associated with LOC sensor 
assays integrating exfoliative cytology were examined and defined for the first time. Here 
the OralCDx brush cytology protocol was shown to provide an adequate sample of cells 
from the oral mucosa that can be introduced directly into the LOC device. The need for 
cell dissociation was discounted and overcome using a z-scan imaging approach. The 
parameters for sample introduction and capture on the sensor membrane were 
characterized, yielding a relatively homogeneous distribution of cells across the 
membrane surface critical for imaging and analysis. Cytoplasmic and nuclear markers 
were shown to be compatible with the EGFR assay and aid identification of individual 
cells for measurement; while new image analysis techniques and sequences were 
developed for examination of cytomorphometry in exfoliative cytology cells within the 
LOC sensor. Taken together, this research demonstrates capability of the LOC sensor 
system for dual molecular and morphological examination of clinically relevant 
exfoliative cytology tissue. Such biosensor systems may then be utilized to assess the 
strength of particular biomarkers, such as EGFR and/or cytomorphometry, for detection 
of disease and possibly prediction of tumor behavior. 
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Chapter 4:  Preliminary Results of Pilot Study to Identify Clinical 
Utility of LOC Sensor Assay and Technique for Detection of OSCC 
4.1 INTRODUCTION 
In the preceding chapter, the important influences and imaging methods for 
expansion of LOC sensor assays integrating exfoliative cytology were defined. The next 
step toward development of a clinically relevant device was to initiate a pilot study 
whereby the sensor methods could be challenged with diseased and non-diseased samples 
to determine efficacy in characterizing oral malignancy. In the current chapter, the 
capacity of the LOC sensor system, with dual molecular and morphological assays, to 
serve as a suitable diagnostic platform for detection of OSCC and high-risk pre-
malignancies is tested. Toward this goal, two overall objectives may be delineated; (1) 
examination of the sensor methodology itself in order to establish clinical viability and 
value of such lab-on-a-chip sensor devices, and (2) assessment of the established assay 
for detection of OSCC using a combination of EGFR biomarker expression and 
cytomorphometry.  
Although oral cancer is a pressing medical issue, it is less prevalent than many 
other cancers occuring in the breast, ovary, prostate, or colon. Thus, the availability and 
access to oral cancer patients and tissue is far more limited. For this pilot study, an initial 
sample size of 25 – 30 participants, including healthy controls, was targeted in an effort 
to balance the number of OSCC patients which could be identified within a reasonable 
time-frame (~ 1 yr.) and the requirements for statistical inference. Patients were enrolled 
in the study by clinical collaborators at the University of Texas Health Science Center 
(UTHSC) at San Antonio and Houston Dental Branch and colleagues at M.D. Anderson 
Cancer Center. Eligibility criteria for inclusion in the study included presentation of a 
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clinically suspicious oral lesion in patients undergoing surgical biopsy. These lesions 
included leukoplakia or erythroplakia pre-malignancies, or overt lesions with signs and 
symptoms of suspected carcinoma within the oral cavity, with or without prior history of 
oral cancer. All oral lesions underwent surgical biopsy for histopathological diagnosis, 
which served as the “gold standard” for comparison with the microchip sensor technique. 
Tissue sections and/or cytospin preparations from these patients were submitted for 
immunohistochemical analysis for the epidermal growth factor receptor in order to 
provide comparison and possibly correlation between standard staining methods and the 
LOC sensor assay. When available, contralateral control brush cytology specimens taken 
from the “mirror image” of the lesion site served for assessement of wether or not the 
microchip sensor could provide useful information regarding cancer field growth. 
4.2 EXPERIMENTAL METHODS  
4.2.1 Study Participants and Demographics 
A total of 31 participants were enrolled in this study from May 2007 to June 2008. 
Eleven of these volunteers were healthy individuals with no known oral diseases or signs 
of epithelial abnormality within the oral cavity. Nine of these healthy subjects were 
recruited from the student population at UT Austin, while two were from the laboratory 
of Dr. N. Vigneswaran from the Dental Branch at the University of Texas Health Science 
Center, Houston. An additional 20 clinical participants were identified by collaborating 
physicians located at UTHSC at San Antonio (n = 9) and Houston (n = 11). Eligibility 
criteria included patients presenting with a visible oral lesion(s) with suspicion of 
carcinoma who would be undergoing surgical biopsy or removal. Informed consent was 
obtained from all participants and the study guidelines were approved by the Institutional 
Review Board at each institution.  
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The demographic data and pathological diagnosis available from clinical 
participants is provided in Table 4-1. Of the 20 cases, 75% were male, 85% had a history 
of tobacco use, 42% also reported moderate to heavy alcohol consumption, and 70% 
were ethnically Caucasian. The average age in this clinical group was 57 (40 – 75 years). 
The majority of lesions occurred in the tongue or floor of the mouth (12 of 20, 60%), 
with two cases from the soft palate, two from the hard palate, one alveolar ridge, one 
retromolar trigone region, and one from the gingiva. Diagnosis was established for each 
patient by surgical biopsy of the lesion site and standard histopathology by board 
certified oral and maxillofacial pathologists at their respective institutions. These 
included fourteen squamous cell carcinomas, one lymphoma, three dysplasias (mild, 
moderate, or severe), and one benign hyperkeratosis. Ten of the SCCs were moderately 
differentiated and one was poorly differentiated, while the remaining were undetermined. 
The group of eleven healthy participants consisted of 55% males, 64% of which were 
ethnically Caucasian, with an average age of 33 (21 – 53 years). Only one of the healthy 
participants reported a history of smoking. 
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Table 4-1. Demographic data and pathological diagnosis for study participants enrolled 
at UTHSC San Antonio and Houston clinics. 
Patient ID Age Sex Ethnicity 
Smoking 
History Lesion Location Pathological Diagnosis 




UTSA-002 56 M Caucasian 37 pack years  Base of tongue 
(R)  
Poorly differentiated SCC 
UTSA-003 57 M Caucasian 45 pack years Soft palate Mild-moderate dysplasia 




UTSA-005 40 M Caucasian 30 pack years Lateral tongue SCC 
UTSA-006 48 M Asian No Hard palate (R) Benign hyperkeratosis and 
submucosal fibrosis  
UTSA-007 45 F Hispanic No  Ventral tongue SCCA 
UTSA-008 44 M Hispanic Yes Alveolar ridge Lymphoma 
UTSA-009 64 M Caucasian Yes Retromolar 
trigone 
SCCA 
UTH-001 56 M Caucasian 30 pack/yrs. Hard palate Invasive SCC, moderately 
differentiated, ulcerated 
UTH-002 68 M Indian ½ pack/day; 
betel nut use 
Hard palate Invasive SCC, moderately 
differentiated, ulcerated 
UTH-003 53 M Caucasian 31 pack/yrs. Tongue Invasive SCC, moderately 
differentiated, ulcerated 
UTH-004 52 M Caucasian 1 ½ x 30 yrs Tongue, floor of 
mouth 
Invasive SCC, moderately 
differentiated, ulcerated 
UTH-005 74 F Caucasian Quit > 40yrs. 
ago 
Tongue Residual SCC - ulcerated 
UTH-006 47 M Asian 10-15/day for 
25 yrs. 
Tongue, floor of 
mouth 
Invasive SCC, moderately 
differentiated, ulcerated 
UTH-007 75 F Caucasian 40 pack/yrs. Tongue Moderate dysplasia 
UTH-008 50 M Caucasian 30 pack/yrs. Tongue Invasive SCC, moderately 
differentiated, ulcerated 
UTH-009 79 F Caucasian No Tongue Invasive SCC, moderately 
differentiated, ulcerated 
UTH-010 69 M Caucasian 1 ½ pk/day 
for 55 yrs. 
Tongue Focal superficially invasive 
SCC, moderately 
differentiated, ulcerated 
UTH-011 62 F Caucasian 40 pack/yrs. Gingiva Leukoplakia – severe 
dysplasia 
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4.2.2 Sample Collection and Processing 
Exfoliative cytology specimens were collected using the OralCDx® biopsy brush 
by placing the nylon brush firmly against the epithelial surface and rotating 10-15 times, 
while applying moderate pressure, till pinpoint bleeding was attained. Cells were then 
released from the biopsy brush and suspended in 5 mL cold EMEM culture media in a 15 
mL centrifuge tube using vigorous agitation for 15-30 seconds. Culture media was 
removed by centrifugation at 1200 rpm for 5 minutes. Cells were then washed twice in 3 
mL PBS buffer (BupH™ Modified Dulbecco’s Phosphate Buffered Saline Packs #28374, 
Pierce/Thermo Fisher Scientific, St. Louis, MO) by centrifugation at 1200 rpm for 5 
minutes. Following the final wash, the supernatant was discarded and the cell pellet was 
resuspended in cryopreservative, consisting of fetal bovine serum with 10% dimethyl 
sulfoxide (DMSO), and frozen at -800C in order to allow for long-term storage and 
transport to Austin for LOC sensor analysis. In preparation for analysis, frozen samples 
were thawed rapidly in a 370C water bath, fixed in 0.5% formaldehyde in PBS for 20 
minutes at 40C as described and then stored at 40C for up to two weeks. All pre-
processing was carried out in a certified biosafety level-2 facility as necessary for 
working with human tissue and/or blood bourne pathogens. 
 Healthy brush biopsy samples were all collected from the buccal mucosa, while 
clinical samples were collected from the lesion site or surgically excised tissue using 
similar protocols. When possible, a “mirror image” brush specimen was collected from 
the contralateral oral cavity site relative to the lesion. In addition, when multi-focal 
regions of irregularity were present, multiple brush biopsies from the same lesions were 
taken sampling clinically distinct lesion areas.  
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4.2.3 LOC Cellular Assay and Data Extraction 
Based upon the combined influences and results presented in chapter 3, the 
overall LOC sensor assay for EGFR biomarker detection and cytomorphometry in 
exfoliative brush cytology specimens was instituted as outlined in Figure 3-9. Here, 
approximately 2,500 – 5,000 fixed/processed cells suspended in 50% glycerol/PBSA 
were delivered and captured in the LOC sensor membrane at a flow rate of 2 mL/min for 
30 seconds followed by a 2.5 minute PBS buffer wash at 1 mL/min flow rate. Next, 
immunolabeling was carried out through sequential delivery of immunoreagents, 
consisting of primary (10 µg/mL anti-EGFR in PBSAT) and secondary (20 µg/mL goat 
anti-mouse/AlexaFluor®-488, 33 µM phalloidin/AlexaFluor®-647, and 5 µM DAPI in 
PBSAT) staining cocktails, delivered to the membrane-captured cells at 250 µL/min for 
2.5 minutes with intermittent buffer washes at 1 mL/min for 2.5 minutes. Following the 
final wash, an automated fluorescent imaging sequence was initiated for collection of 
three-color RGB micrographs from sixteen fields of view (4x, 4y membrane scan), at 
three 5 µm z-focal planes each, for a total of 54 images. Exported images were then 
analyzed in ImageJ and Cell Profiler as described using custom macros for identification 
and measurement of cellular and nuclear morphology and EGFR expression. A minimum 
of fifty cells were measured in each biopsy sample. All together, fifty-one parameters, 
nine morphological and forty-two intensity parameters, were extracted or calculated for 
each cell based upon the identified whole cell and nuclear ROIs. Particular attention was 
focused on the cellular area and diameter, nuclear area and diameter, N/C ratio and mean 
cellular EGFR intensity as these features have been previously reported to be early 
indicators of malignancy.70, 139, 140  
 107
4.2.4 Statistical Analysis of Data 
A Student’s t-test (Analyze-It® for MSExcel®) was utilized to assess statistically 
significant differences in the measured cellular parameters within each study group, 
including benign lesions, dysplasia, and invasive SCC, when compared to the healthy 
controls (p < 0.05). In order to identify which parameters, alone or in combination, were 
most predictive of disease, a logistic regression model was generated using MedCalc® 
(MedCalc Software, Mariakerke, Belgium) statistical software. This method requires the 
input of parameter values measured for each sample (i.e. EGFR intensity, nuclear and 
cellular area, etc.) according to a binary classification of disease status where non-
diseased samples received a value of zero and diseased samples one (“Non-diseased” = 0; 
“Diseased” = 1). The logistic function, with general equation of f(z) = 1/(1+exp(-z)) 
serves to predict the probability of an outcome (disease occurrence) between 0 and 1 
based upon one or more of these input parameters or factors. The variable (z), is a 
measure of the total contribution of all the factors used in the model, according to the 
logit equation (z = a0+ a1xBM1+a2xBM2+.....anxBMn) where a0 is the intercept and 
(a1....an) are the regression coefficients for each biomarker (BM1....BMn). Predicted values 
using the linear regression model were utilized to build receiver operating characteristics 
(ROC) curves plotting the projected true positive and false positive rates (sensitivity vs. 1 
– specificity) for disease classification based upon the model. 
4.3 RESULTS 
A total of 34 oral brush cytology samples from healthy and disease participants 
were examined using the LOC sensor method. Eleven specimens were obtained from 
healthy individuals while twenty-three were from clinically suspicious lesions identified 
in twenty patients. Histopathological diagnosis confirmed one case of benign 
hyperkeratosis and submucosal fibrosis, three lesions exhibited dysplasia, fifteen invasive 
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carcinomas, and one malignant lymphoma (Table 4-1). Two of the SCC samples were 
exhausted during the initial assay development stages, while another two specimens were 
found to be inadequate due to poor cell sampling (2 out of 32, 6.2%), including one SCC 
and one dysplasia specimen from the tongue. Table 4-2 summarizes the LOC sensor 
results obtained from the remaining 30 brush cytology specimens analyzed for 
cytomorphometry and EGFR expression.  
Since this data was pooled from multiple patient sources and populations, 
statistical differences in sensor data and results according to facility were examined for 
validation purposes.  No significant differences were identified between patient samples 
collected at UTHSC at San Antonio (n = 9) and Houston (n = 11) for any of the 
parameters listed is Table 4-2 (p > 0.2). However, healthy control specimens collected at 
UTHSC Houston (n = 2) and UT Austin (n = 9) did exhibit a significant difference in 
their respective nuclear area measurements (p = 0.026). This discrepancy may be linked 
to an elevation in nuclear size with advancing age as there was a significant difference 
between the average age of these groups.163 This reflects a minor flaw in the study design 
where healthy participants were recruited from a younger student population than the 
typical OSCC patient, 50 years and older. This age difference evolved due to practical 
considerations associated with the collection of normal controls and the difficulty in the 
early stages of this program to secure age-matched samples from the clinical 
collaborators. Age matched healthy individuals would have been more appropriate and 
should be incorporated in futher studies. Given the promising results here obtained in the 
initial pilot study, it is clear that the additional effort to collect such age-matched patients 
is warranted. Nevertheless, overall the specimens from all institutions were quite similar 
and could reasonably be pooled for added value in determining the efficacy of the 
microchip sensor system. 
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4.3.1 Cytomorphometry  
A significant reduction in cellular area was revealed in invasive SCC and a B-cell 
lymphoma malignancy (586 µm2 and 524 µm2, respectively) versus healthy control 
mucosa (1038 µm2) (p < 0.0001). A slight decrease in cellular area was also seen in cases 
of dysplasia, although this difference was not significant. A similar pattern occurred with 
the cellular diameter in which there was a significant decrease found in both 
malignancies, but not in dysplasia. On the other hand, the nuclear area and diameter 
where shown to increase with malignancy and, in this instance, dysplastic cells exhibited 
significant nuclear enlargement over healthy controls as did SCC and lymphoma (Table 
4-2). Interestingly, this rise in nuclear area appeared to be progressive from healthy 
mucosa through dysplasia and SCC (63.4 µm2, 122 µm2, and 143.5 µm2, respectively), 
though the difference in nuclear area between dysplasia and SCC was not found to be 
significant. In line with the inverse relationship demonstrated between nuclear and 
cellular size, the nuclear-to-cytoplasm (N/C) ratio was also found to be significantly 
higher in dysplasia, SCC, and lymphoma over healthy controls, suggesting that all of 










Table 4-2. Results of LOC sensor assay and analysis of cytomorphometry and EGFR 




n = 11 
Benign†
n = 1 
Dysplasia 
n = 2 
Invasive SCC 
n = 14 
Other 
Malignancy 
n = 2 
Cellular Area 
(µm2) 
1040 ± 160 1670 ± 960 914 ± 200 586 ± 210* 
p < 0.0001 
524 ± 120* 
p < 0.0001 
Cellular 
Diameter (µm) 
37.8 ± 3.2 46.9 ± 12 34.2 ± 2.0 27.7 ± 4.9* 
p < 0.0001 
25.6 ± 3.9* 
p < 0.0001 
Nuclear Area 
(µm2) 
63.4 ± 11 62.4 ± 59 122 ± 4.7* 
p < 0.0001 
144 ± 47* 
p < 0.0001 
116 ± 13* 
p < 0.0001 
Nuclear 
Diameter (µm)  
8.47 ± 0.5 8.49 ± 3.9 11.3 ± 1.0* 
p < 0.0001 
12.3 ± 2.0* 
p < 0.0001 
11.0 ± 0.8* 
p < 0.0001 
N/C Ratio 0.063 ± 0.015 0.055 ± 0.062 0.138 ± 0.035* 
p < 0.0002 
0.282 ± 0.14* 
p < 0.001 
0.230 ± 0.079* 
p < 0.0001 
Mean EGFR 
Intensity (au) 
5.99 ± 1.4 5.23 ± 2.9 8.50 ± 1.3* 
p < 0.04 
9.72 ± 6.1** 
p < 0.035 
5.10 ± 0.75 
* denotes statistical significance relative to healthy controls using paired t-test (p < 0.05) 
† single case of benign submucosal fibrosis could not be statistically compared due to lack of replicates 
** statistically significant with the removal of one outlier, sample UTSA-005 
au – arbitrary units 
 
Further examination of the nuclear area distribution within each sample 
population revealed additional features which could potentially be exploited for disease 
characterization. Box and whisker plots presented in Figure 4-1 depict the median, inter-
quartile range and data outliers in the distribution of nuclear area measurements from 
each sample population analyzed using the LOC sensor. Here, the median nuclear area 
for healthy control samples ranged from 47 µm2 to 63 µm2, while the SCC samples 
exhibited median values from 66 µm2 to 141 µm2. Quite interestingly, it is the spread of 
outliers that appeared to be the most distinguishing characteristic in which to differentiate 
normal cytology specimens from dysplasia and SCC. As such, none of the healthy 
controls specimens exhibited outliers over 500 µm2 while all of the SCC specimens 
possessed numerous outliers over 500 µm2. Indeed, the two cases of dysplasia also 
showed a shift toward increased nuclear area within the outlier subset of cells suggesting 
that the outlier population and/or the range in nuclear area distribution may be useful for 
early disease characterization.  
 
 
Figure 4-1. Box and whisker plot of the median, interquartile range, and the distribution 
of outliers in the nuclear area data for each cell population according to disease status. 
Two representative cells from a healthy participant and SCC patient are shown (inset).  
4.3.2 EGFR Biomarker Expression 
In addition to changes in cytomorphometry, the mean EGFR intensity was also 
demonstrated to be higher in lesions with diagnosed dysplasia and OSCC relative to 
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healthy epithelium (8.5 au, 9.7 au, and 6.0 au, respectively) (Table 4-2). While EGFR 
intensity increased with disease, the fraction of cells which express EGFR may also be 
indicative of malignancy. Therefore, an EGFR labeling index was calculated as the 
percentage of cells with positive staining above normal and isotype controls (6.0 au) as 
plotted in Figure 4-2. Among the healthy controls, a wide range of EGFR labeling indices 
was found; with two specimens in particular exhibiting indices nearly double that of their 
nearest neighbors. Within the clinical specimen group, over-expression of EGFR was 
identified using a rough threshold established from the mean EGFR labeling index for the 
healthy control subjects plus two standard deviations (0.028 ± 0.05). According to this 
criteria, nine out of fourteen SCC tumors (64%) and 50% of dysplastic lesions over-
expressed EGFR. A representative image from one of these EGFR over-expressing 
carcinomas is shown in Figure 4-2 with strong EGFR staining apparent in the cell 
membranes of this adherent epithelial cluster. The one benign lesion displayed a low 
EGFR labeling index within the range for most healthy controls, while the non-epithelial 
malignancy, diagnosed as B-cell lymphoma, was similar to healty control tissue as well. 
Although this threshold serves only as a rough estimate to compare EGFR expression 
levels, it does not necessarily correspond to the optimal threshold with diagnostic 
decision making capacity which will be examined in further detail below. 
Contralateral controls were available from six participants as shown in Figure 4-2 
denoted with an (*) and lighter bar shade located adjacent to their matched lesion site. 
Over 80% of the contralateral controls demonstrated EGFR labeling indices that were 
lower than their respective lesions and well within the ranges of healthy mucosa.  One 
contralateral control did exhibit elevated EGFR labeling index, although this occurred in 
a SCC which itself was not shown to over-express EGFR. With the limited dataset and 
contralateral control specimens available, the presence or absence of field changes 
remains unclear. Further studies are required to explore this issue. 
 
 
Figure 4-2. EGFR labeling index in all LOC specimens grouped according to disease 
status. A representative cluster of epithelial cells with strong EGFR staining is shown 
from a SCC specimen while available contralateral controls (*) taken from healthy 
appearing mucosa in clinical subjects serve to assess the extent of field changes in a 
subset of diseased patients. 
4.3.3 Case Study: Comparison with Histopathology and Immunohistochemistry 
While histopathology and EGFR immunohistochemistry was performed for all 
surgically biopsied oral tissue, two cases were selected to demonstrate the similarities and 
differences in the type or range of cellular features examined in traditional diagnostic 
methods versus the microchip sensor system using brush cytology (Figure 4-3). One case 
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was diagnosed as mild to moderate dysplasia in the soft palate (Figure 4-3(a)) and the 
other an invasive squamous cell carcinoma located on the ventral tongue (Figure 4-3(b)). 
In the hematoxylin and eosin (H&E) stained tissue shown in Figure 4-3(a), panel i, a thin 
keratin layer is seen at the surface of the epithelium with the various stratified layers 
beneath, relatively normal for mucosa at this oral cavity site. Upon higher magnification 
(Figure 4-3(a), panel iii), several dysplastic features are seen including enlarged, irregular 
and/or mitotic nuclei found above the basal cell layer, with possible loss of basal cell 
polarity. Corresponding EGFR immunohistochemistry (IHC) revealed EGFR staining in 
the lower layers of epithelium, including the basal cells, which dissipated in the more 
superficial layers and in the surface epithelium (Figure 4-3(a), panel v). Cytologic 
analysis using the LOC sensor assay from this patient displayed a combination of both 
positive and negative EGFR-labeled cells (Figure 4-3(a), panel vii) presumably derived 
from the differential EGFR-expressing epithelial layers apparent in IHC. This behavior 
suggests that the sensor method and cytology effectively reflected molecular changes in 
tumor tissue, even at these early pre-malignant stages.  
Similar pathological features were also seen in the SCC case, albeit more 
pronounced, where hyperkeratinization and a number of irregular or mitotic nuclei were 
visible in H&E histopathology sections (Figure 4-3(b), panels ii and iv) and IHC 
demonstrated strong EGFR staining throughout the tumor (Figure 4-3(b), panel vi). In the 
LOC sensor cytology assay, extremely high EGFR labeling intensity was evident in the 
cell membranes of adherent epithelial cell clusters and in some individual cells (Figure 4-
3(b), panel viii). In the particular cluster shown in Figure 4-3(b), panel viii, a number of 
the nuclei present also appear irregular and/or enlarged, suggesting that these cells exhibit 




Figure 4-3. Comparison of histopathology, EGFR immunohistochemistry, and LOC 
sensor immunoassays in case studies of two patients, one with mild to moderate dysplasia 
(a) and one invasive SCC (b). Surgical biopsy tissue sections stained with hematoxylin 
and eosin are shown in panels i-ii and iii-iv at low and high magnification, respectively. 
Corresponding EGFR immunohistochemistry using peroxidase-DAB staining, panels v 
and vi. Representative images from LOC sensor assay using EGFR/phalloidin/DAPI 
staining, panels vii and viii, with inset of individual cells over-expressing EGFR. 
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4.3.4 Logistic Regression Model for Prediction of OSCC Disease 
While these studies provide initial evidence supporting the value of 
cytomorphometry and EGFR expression in SCC detection, further exploration into which 
of these markers, and in what combinations, could be most effective toward diagnosis of 
oral cancer was necessary. Each individual biomarker was evaluated by a receiver 
operating characteristic (ROC) curve, as shown in Figure 4-4 for EGFR, N/C ratio, and 
nuclear area. The ROC curve is a plot of a diagnostic test’s sensitivity, or true positive 
rate (TPR) versus 1-specificity, or the false positive rate (FPR) at various discrimination 
thresholds depicting the trade-offs between the true positives (benefits) and the false 
positives (costs) in diagnostic accuracy. All of the markers tested exhibited significant 
capacity for disease classification and discrimination between patients with OSCC or 
severe dysplasia, versus healthy controls or patients with mild-moderate dysplasia, as 
demonstrated by the area under the curve (AUC) values greater than 0.5. Of these 
markers, the N/C ratio exhibited the best performance characteristics with AUC of 0.99, 
followed by the nuclear area (0.97) and EGFR biomarker (0.67) (Figure 4-4). While the 
N/C ratio alone is an excellent diagnostic marker, the added value of these markers in a 
combined panel was further examined using logistic regression. Here, the ROC curve 
generated from the predicted values in the combined biomarker panel, exhibited AUC of 
1.0 with a projected 100% sensitivity and 100% specificity for disease classification. 
Thus, the combined cytomorphometry and EGFR panel likely holds the greatest potential 
for cancer detection and diagnosis. Obviously, additional studies incorporating a larger 
patient sample size are needed to test and validate this model in order to define the true 
sensitivity and true specificity of the LOC sensor method in oral cancer diagnostics for 
external blind studies. Nonetheless, these initial findings en route to devising a new 
method for cancer screening and diagnosis look promising.  
 
 
Figure 4-4. Receiver operating characteristic (ROC) curves were used to evaluate the 
performance characteristics of cytomorphometry and EGFR biomarker, alone and in a 
combined biomarker panel, for detection and diagnosis of oral cancer. Area under the 
curve (AUC) for single parameter measurements (a) EGFR biomarker is 0.67 and (c) 
nuclear area is 0.97; while two parameter ratiometric measurement of (c) the nuclear-to-
cytoplasm ratio is 0.99. Using a logistic regression model the combined EGFR and 





4.4 DISCUSSION  
In this small pilot study, the capacity of the LOC sensor assay and technique to 
detect oral cancer and pre-cancerous lesions was examined. Five morphological 
parameters were found to be significantly different in SCC versus healthy controls 
including: (1) cellular area, (2) cellular diameter, (3) nuclear area, (4) nuclear diameter, 
and (5) the nuclear-to-cytoplasm ratio (Table 4-2). The nuclear area, diameter, and N/C 
ratio were also found to be significantly different in cases exhibiting dysplasia, 
suggesting that these markers may serve as indicators of early pre-malignancy. The data 
presented here is very much in-line with earlier reports indicating significant 
morphological changes in cell and nuclear size, and N/C ratio associated with 
malignancy, while providing a new method for automated cytomorphometry that is rapid 
and highly amenable to point-of-care diagnostics.137 In addition to cytomorphometry, the 
EGFR biomarker was also found to be significantly elevated in cases of epithelial 
dysplasia and SCC, supporting a role for EGFR in clinical diagnosis of malignant and 
pre-malignant lesions as well. 
While examination of the mean values obtained for each cytology sample 
provides valuable information regarding the cell population as a whole, it is important to 
note that these samples represent a heterogeneous mixture of cell types. As such, healthy 
cytology specimens are expected to consist of combinations of basal, intermediate, and 
superficial cells with varying morphological characteristics and protein expression 
patterns. In the presence of disease, a mixture of normal and abnormal cells overlayed 
upon this inherent cellular diversity would be expected as well. Thus, examination of the 
population distribution, with particular attention toward the outliers in the data, may 
provide additional insight regarding the cellular phenotypes present and reveal any 
characteristic shifts within the population which may be related to the onset of disease. 
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These data outliers may represent the “rare events” important for disease detection which 
may be obscured or masked in mean measurements over the entire population. As shown 
in Figure 4-1, the spread of outliers in the nuclear area measurements can clearly 
distinguish healthy controls from dysplasia and SCC. A new parameter, such as a 
“polymorphic index”, representing the range or spread in this distribution may provide an 
addition handle from which to classify disease with enhanced accuracy over mean values 
in future assays.   
Along these same lines, the intensity of EGFR staining was shown to increase 
with disease, yet this may not represent the full extent of EGFR alterations associated 
with malignancy. For example, shifting patterns of EGFR expression, even at low levels, 
extending into the more superficial layers of epithelium may also be found in 
tumorigenesis.116 How this translates from intact tissue to dissociated cytology specimens 
is likely to be related to the number of cells sampled which express EGFR. Thus, a 
labeling index calculated as the percentage of cells with EGFR intensity exceeding that of 
normal healthy controls was utilized for examination of the EGFR-positive cell subset 
(Figure 4-2). Here, most of the healthy controls exhibited relatively low labeling indices 
with a small fraction of EGFR-stained cells, possibly the basal cells known to express 
EGFR. Two healthy controls did show elevated EGFR labeling indices. The role of 
EGFR in non-malignant conditions, such as inflammation and wound healing, may 
account for the elevated EGFR expression found in these healthy individuals. Within the 
clinical group, EGFR over-expression was defined by a rough cut-off established from 
the mean labeling index of the healthy controls plus two standard deviations. Using this 
criterion, 64% of SCC tumors and 50% of lesions exhibiting dysplasia were identified to 
over-express the EGFR biomarker, congruent with previous literature reporting EGFR 
protein overexpression in 34-80% of OSCC tumors.58, 70 These findings support EGFR as 
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an indicator of malignancy with diagnostic value, but allude to the need for a combined 
biomarker panel for cancer diagnostics, since EGFR alone is not likely to be sufficient for 
detection and characterization of malignancy due to its involvement in non-malignant 
conditions and the fact that not all OSCC or pre-malignant lesions express EGFR. 
The EGFR expression was also used to explore potential field changes related to 
the field cancerization effect found in oral tumorigenesis. Here, 80% of the contralateral 
control sites exhibited EGFR labeling indices similar to normal healthy controls, and the 
one which did show elevated EGFR was in a patient whose SCC lesion itself did not 
over-express EGFR (Figure 4-2). While it appears that field changes were not evident in 
this study using the EGFR biomarker, the limited number of matched lesion and control 
samples restricts any firm conclusions. In this process though, the LOC sensor approach, 
with non-invasive cytology sampling, did demonstrate capacity for the ethical 
examination of normal appearing mucosa. As such, the sensor technique could be applied 
to probe the cancer field environment for molecular alterations beyond EGFR expression 
in the future.   
Comparison of the LOC cellular analysis methods with standard histopathology 
and immunohistochemistry, as shown in Figure 4-3, offers insight into the types of 
cancerous features available with each method and their associated benefits and trade-
offs. Based upon histopathology, panel (a) was diagnosed with mild to moderate 
dysplasia with several abnormal/enlarged nuclei and a loss of basal cell polarity seen in 
H&E histology stained tissue sections, but with the overall epithelial structure and 
stratification maintained (Figure 4-3(a), panels i and iii). IHC results revealed EGFR 
expression restricted to the lower layers of epithelium (Figure 4-3(a), panel v). These 
alterations in nuclear morphology and EGFR expression were successfully detected and 
quantitated in the LOC sensor assay using automated cell analysis techniques (Figure 4-
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3(a), panel vii), suggesting that the sensor method adequately reflects cellular alterations 
in tumor tissue, even at early premalignant stages. A similar comparison could be seen in 
a patient with invasive SCC (Figure 4-3(b)). A trade-off does exist with the loss of 
information regarding cellular architecture and cell-cell or cell-matrix interactions while 
gaining the capacity to obtain statistical sampling of cells for automated cellular analysis 
successfully shown here for characterization of morphological and EGFR biomarkers in 
malignancy. 
While these studies provide the initial evidence supporting the value of 
cytomorphometry and EGFR expression in SCC detection, identification of which 
markers, alone or in combination, could be most effective toward diagnosis of oral cancer 
was undertaken in a more quantitative manner using logistic regression and ROC curves 
analysis. Logistic regression serves as a model to predict the outcome of disease, based 
upon input of one or more variables, such as the N/C ratio, nuclear area, and EGFR 
biomarker measurements obtained in LOC sensor assays. The predicted values generated 
from logistic regression were used to build ROC curves. A ROC curve is a graphical 
representation of a diagnostic test’s sensitivity, or true positive rate (TPR) versus 1-
specificity, or the false positive rate (FPR) at various discrimination thresholds. An ideal 
diagnostic test would perfectly classify individuals with and without disease, yielding a 
point in the upper left corner or coordinate (0,1) of the ROC space, representing 100% 
sensitivity (all true positives are found) and 100% specificity (no false positives are 
found). Alternatively, a completely random guess would give a point along a diagonal 
line (the so-called line of no-discrimination) from the bottom left to the top right corners. 
Thus, the diagonal line determines the areas of good or poor classification with points 
above the diagonal line indicating good classification results, while points below the line 
indicate poor classification ability. Values of the area under the curve (AUC), or C 
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statistic are computed, as well as the standard error (SE), and applied using a two-tailed 
p-value at the 95% confidence level, providing a measure of a diagnostic test’s 
performance to accurately discriminate diseased from non-diseased individuals. In Figure 
4-4, the ROC curves for the EGFR biomarker, nuclear area, and N/C ratio are presented. 
According to the prediction model, the EGFR biomarker exhibited only moderate disease 
discrimination capability with an AUC value of 0.67 and a curve located somewhat close 
to the diagonal.  The ROC curves for the nuclear area and N/C ratio, on the other hand, 
were located very close to the top left corner with AUC values 0.97 and 0.99, 
respectively, indicating excellent disease classification performance. Thus, the two 
morphological parameters out performed the EGFR biomarker and hold the greatest 
potential for detection of OSCC in the current LOC sensor assay with a projected 
sensitivity and specificity of 100% and 92%, respectively for nuclear area and 94% and 
100% for N/C ratio (Figure 4-4). In a combined panel with all three markers, ROC curve 
and AUC of 1.0 reveal a predicted 100% sensitivity and 100% specificity for diagnosis of 
OSCC and dysplasia based upon the current model and dataset. Validation of this model 
requires testing of additional samples from a larger patient population, with particular 
emphasis on pre-malignancies, but holds strong promise as a new tool for oral cancer 
diagnostics. 
Evolving issues regarding the best approach toward early detection of oral cancer 
must consider advantages and disadvantages of the three competing methodologies using 
cellular, mRNA, or protein-based analyses. Previous studies by Li et. al., demonstrated 
the use of seven salivary mRNA transcripts for discrimination of OSCC from healthy 
controls with a calculated area under the ROC curve of 0.95, yielding 91% sensitivity and 
91% specificity.72 However, practical concerns exist regarding the stability of mRNA in 
this unproven diagnostic approach. In addition, mRNA is not currently implemented in 
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cancer diagnostics or as widely accepted by the medical community when compared to 
cellular approaches, such as cervical cytology, or protein-based methods using 
biomarkers such as prostate specific antigen (PSA) and CA-125. Using a single protein, 
interleukin-8 (IL-8), Tan et. al. recently demonstrated an optical procedure for oral 
cancer diagnosis with an AUC value of 0.83.164 As in many biomarker studies, single 
biomarkers alone often fall short of the necessary performance characteristics indicating 
the need for multiple diagnostic markers in order to achieve high sensitivity and 
specificity. In the current study, the capacity of a new cell-based imaging sensor for dual 
molecular and morphological analysis was explored for the first time. Area under the 
curve values for single parameter measurement of nuclear area were 0.97, while two 
parameter ratiometric measurement of the N/C ratio was 0.99. Either of these 
morphometric markers provides enhanced diagnostic performance over emerging mRNA 
or protein-based biomarkers. In addition, a logistic regression model of the combined 
EGFR and cytomorphometry marker panel was predicted to exhibit an AUC of 1.0 near 
diagnostic perfection. Of course, further validation of these diagnostic approaches is 
necessary in order to evaluate which method and markers are optimal for early detection 
of oral cancer in clinical practice. 
4.5 CONCLUSIONS AND FUTURE DIRECTIONS 
This dissertation has demonstrated a successful automated cellular analysis 
procedure using a lab-on-a-chip approach which integrates cell capture, staining, and 
measurement of both molecular and morphological biomarkers. This new method has 
been applied in a small pilot study isolating the important assay and imaging variables in 
order to secure an initial understanding of the diagnostic accuracy of such biosensor 
systems in clinical settings. While the method described herein projected 100% 
sensitivity and 100% specificity based upon a linear regression model, it is important to 
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note that this has been done only with a limited internal data set and LOC assays in 
additional samples are needed to test this model. Nonetheless, the rapid approach for 
cytopathological diagnosis of oral cancer on a chip shows strong promise. The next steps 
toward the development of a clinical device are to complete larger clinical studies, with 
particular emphasis on early OSCC and dysplasia, in order to validate the microchip 
sensor approach. Plans are currently underway for such studies. 
APPENDIX A:  CAD DRAWING OF THE LAB-ON-A-CHIP SENSOR 
 
 
Figure A-1. Materials, design and machining specifications for the lab-on-a-chip sensor 
base utilized in the oral cancer studies. 
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Appendix B:  Microscope Standardization and Monitoring 
Since it was not feasible to complete all LOC assays within a single day, it was 
important to monitor and minimize the day to day fluctuations in microscope 
performance to enable reasonable comparison of all assays. The daily output of the 
mercury lamp and overall microscope functioning was monitored using a fluorescence 
reference slide (Fluor-Ref™ Green Intensity Slide Standard, Microscopy Sciences, Ltd.) 
prior to LOC sensor assays. Following Hg lamp warm-up period of at least 30 minutes, 
two images were collected of the Fluor-Ref™ slide, a brightfield and a darkfield image at 
0.05 second exposure time with five-frame averaging for noise reduction. A neutral 
density filter (5.0) was utilized to attenuate the light source and bring exposure times into 
ranges relevant for immunoassays. Images were obtained at a z-position of -20 µm below 
the surface of the slide to minimize intensity variations due to surface imperfections. The 
darkfield image, which provided a measure of the dark current background, was 
subtracted from the brightfield image. Measurement of the mean intensity and standard 
deviation in the resulting image was plotted over time as shown in Figure B-1. Over an 
initial period of 2 months, the average intensity ±10% was utilized to establish the upper 
and lower boundaries for acceptable levels of microscope variation. Deviation from this 
intensity range signified need for microscope adjustment or maintenance, including 
replacement of the Hg bulb (Figure B-1, arrows). The Fluor-Ref™ slide also served as 
the homogeneous standard for measurement of field uniformity and field illumination 
correction as described above. 
 
 
Figure B-1. The mean ± SD of a homogeneous fluorescent slide standard (Fluor-Ref™) 
was utilized to monitor microscope performance and Hg lamp output prior to each assay. 
Progressive decrease beyond the acceptable 10% deviation range typically signaled need 
for microscope adjustment and/or replacement of Hg bulb, shown at arrows. 
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Appendix C:  EGFR Antibody Titration 
The optimal antibody concentrations for LOC sensor assays were determined by 
titration of primary and secondary antibodies using a standard flow cytometry protocol 
and the A253 squamous cell carcinoma cell line. Here, cells were labeled with primary 
anti-EGFR antibody at concentrations ranging from 1 µg/mL– 20 µg/mL and a secondary 
goat anti-mouse IgG antibody conjugated to FITC fluorophore, packaged with the QIFI 
kit, which was reported to be at saturating concentrations. EGFR intensity was measured 
via flow cytometry with the resulting primary titration curve shown in Figure C-1, left. 
The optimal concentration of 10 µg/mL anti-EGFR was selected as the lowest 
concentration reaching saturation which was then applied in all subsequent EGFR assays. 
Secondary antibody titration was performed using 10 µg/mL primary antibody at 
increasing concentrations of goat anti-mouse IgG F(ab’)2 secondary antibody conjugated 
to AlexaFluor®-488 (Figure C-1, right). A concentration of 20 µg/mL was identified as 
the ideal secondary concentration with less than 10% increase in intensity when the 
antibody concentration was doubled, designated as saturation.  
 
 
Figure C-1. Primary and secondary antibody titration curves to determine the optimal 
EGFR assay concentrations with 10 µg/mL primary and 20 µg/mL secondary antibody. 
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Appendix D:  QIFIKIT® Quantitation in LOC Sensor 
While the QIFIKIT® standards were designed for use in flow cytometry, their 
application in the LOC sensor for absolute quantification of EGFR biomarker expression 
was explored. Here, the set of five bead standards were labeled in the microchip sensor 
using the same protocol as for tumor derived cell lines with imaging performed in a 5 x 
10 (x, y) membrane scan, 20X objective (0.4NA). Data extracted using established 
automated image analysis routines is presented as log transformed intensity histograms in 
Figure C-1. The QIFIKIT® standards (Figure C-1(a)) exhibited five visible intensity 
peaks from which the standard curve relating mean fluorescence intensity with the 
antibody binding capacity (ABC) of each bead was generated. Parallel EGFR assay and 
analysis performed on the tumor derived cell lines is shown in Figure D-1(b) with 
reported geometric mean and coefficient of variation for each population. Extrapolation 
from the standard curve identified the number of EGF receptors per cell (EGFR/cell) in 
each cell line as follows: 1.2 x 104 EGFR/cell in MDA-MB-435S cell line, 5.6 x105 
EGFR/cell in MDA-MB-468, 1.1 x 105 in UMSCC-22A, 1.2 x 105 in SqCC/Y1, and 1.4 x 
105 in A253 cells. When compared with EGFR/cell measured via flow cytometry, the two 
methods appeared to be well correlated with an r2 value of 0.98 (Figure D-1(c)). 
However, upon closer examination the position of the cell lines relative to the bead 
standards was altered. For example, the OSCC cell lines in the sensor system were 
located between the third and fourth bead standards (Figure D-1(a), left panel), but in 
flow cytometry these same cells exhibited intensity ranges between the fourth and fifth 
bead standards (Figure 2-6) significantly affecting the extrapolated values. Calculation of 
the percent difference between the EGFR/cell for each cell line using flow cytometry and 
LOC sensor method revealed up to 52% difference (range 31% - 52%) between these two 
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methods, with the LOC sensor consistently exhibiting lower EGFR/cell values. This data 
indicated that while a nice correlation may exist, the agreement between the absolute 
EGFR values obtained using these two methods is poor and inappropriate for integration 
into the LOC sensor system.  
There are a number of factors which may have contributed to this result. Foremost 
is the limited depth of field of the microscope optics (3.25 µm) which was below the 
average size of the QIFI beads (6.0 µm in diameter). Under these conditions, the full bead 
was not in focus within a single z-focal plane and therefore, light above and below may 
not be fully collected. This was even more pronounced in the measurement of cultured 
epithelial cells with a typical diameter of 20 µm or more. As such, measurable intensity 
from the beads/cells was only a fraction of the total intensity present and a 
disproportional fraction at that when intensity was compared from the beads to the cells 
due to the difference in size. Accounting for the consistently lower intensity measured in 
cells, where less than one-sixth of the cellular intensity was sampled, relative to the QIFI 
beads with over half of the bead found in one field depth. While in the current situation 
absolute quantitation using the QIFI standards in the microchip sensor was unsuccessful, 
use of a microscope objective with a lower numerical aperture, such as a 10X objective 
(0.3 NA) with calculated depth of field of 5.8 µm, and incorporation of z-scan imaging 
approach may help to overcome these limitations.  
 
 
Figure D-1. Results of QIFIKIT® labeling and analysis as performed in the membrane-
based LOC sensor system. (a) The LOC sensor successfully detected all five of the 
standard bead populations generating a standard curve relating the fluorescence intensity 
to antibody binding capacity (ABC) or EGF receptors per cell. (b) Parallel assays in five 
tumor-derived cell lines. (c) Correlation between the standard quantitative flow 
cytometry technique and LOC microchip system, with 95% confidence interval, yielded 
an r2 value of 0.98 indicating good correlation between these methods. 
 131
 132
Appendix E:  Materials and Suppliers 
Buffers and Reagents 
 Phosphate buffered saline (PBS) (#28374 BupH™ Modified Dulbecco’s Phosphate 
Buffered Saline, Pierce/Thermo Fisher Scientific, Rockford, IL) containing 0.008 M 
sodium phosphate, 0.002 M potassium phosphate, 0.14 M sodium chloride, 0.01 M 
potassium chloride, and 0.05% sodium azide was prepared in 500 mL deionized water 
(diH2O) at final pH of 7.4. 
 PBSA, consisting of PBS with 0.1% bovine serum albumin (BSA, #A3059, Sigma-
Aldrich, St. Louis, MO), was used as a blocking agent and for storage of all cell 
suspensions at 40C. 
 PBSAT, PBSA with 0.1% Tween-20 (#BP337, Thermo Fisher Scientific, Rockford, 
IL), was used for all antibody solutions unless otherwise stated. 
 Formaldehyde fixative solutions, 0.5% - 4.0%, were prepared fresh for each assay by 
diluting 16% stock solution (#18814 Polysciences Inc., Warrington, PA) in PBS 
buffer.  
Cell Culture Media and Supplements 
 All cell culture media was obtained from American Type Culture Collection (ATCC 
Manassas, VA) including McCoy’s 5A culture media (#30-2007) containing 1.5 mM 
L-glutamine and 2200 mg/L sodium bicarbonate; DMEM: F-12 medium (#30-2006) 
containing 2.5 mM L-glutamine, 0.5 mM sodium pyruvate, 15 mM HEPES, and 1200 
mg/L sodium bicarbonate; Eagle’s Minimum Essential Medium (EMEM, #30-2003) 
containing non-essential amino acids, 1 mM sodium pyruvate, 2 mM L-glutamine, 
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and 1500 mg/L sodium bicarbonate; and Liebovitz’s L-15 medium (#30-2008) 
containing 2 mM L-glutamine with no added sodium bicarbonate. 
 Fetal bovine serum (10% FBS, #10082 Gibco/Invitrogen, Carlsbad, CA) was 
supplemented to all media along with penicillin/streptomycin antibiotic solution (#30-
2300 ATCC) at a final concentration of 50 IU and 50 µg/mL, respectively. 
 Supplemental L-glutamine (GlutaMAX™, #35050-061 Gibco/Invitrogen, Carlsbad, 
CA) was added to media formulations as necessary to extend shelf-life of media. 
 Trypsin/EDTA (0.25%) solution (#25200-56 Gibco/Invitrogen) dissociated in vitro 
cells from adherent culture flasks and/or brush cytology suspenstions. 
 Trypan blue (0.4%) solution (#T8154 Sigma-Aldrich, St. Louis, MO) served to count 
and/or assess the cell viability at a 1:1 dilution with culture suspension in PBS or 
PBSA. 
Antibodies and Fluorescent Dyes/Stains 
Table E-1. Supplier and concentration information for all antibodies and fluorescent 
dyes/stains utilized in oral cancer studies. 
 











#MS-378-P 200µg/ml in PBS 




AE1  Abcam Inc. #ab31117 0.2 mg/ml in PBS 




Cytokeratin-14 Epitomics Inc. #2001-1 undefined in Tris-
glycine buffer with 
BSA and azide 
1:30 dilution  in 
PBSAT 
Pan cytokeratin US Biological #C9097 0.68 mg/ml in PBS 




β-Actin Novus Biologicals #NB110-55433 undefined in Tris-
glycine buffer with 
1:50 dilution  in 
PBSAT 
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BSA and azide 
Mouse IgG1 
(Isotype) 







#JNZ000001 60 mg/ml in PBS 
with azide 









#A11017 2mg/ml in buffer 









#A21246 2mg/ml in buffer 





















#A22287  6.6 µM in 
methanol 










#T13320 100 µg/ml in 
diH2O 
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